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Abstract 
Fibromyalgia syndrome (FMS) is a disorder characterised by chronic widespread pain, 
non-restorative sleep, fatigue and daytime dysfunction. Occurring in 2-5% of the 
population, the aetiology is largely unknown. Sleep dysfunction occurs in over 90% of 
FMS patients. While research has shown that both the macrostructure and microstructure 
of sleep may be altered, there remain inconsistencies in the polysomnographic (PSG) 
findings, and wide variations in methodological approaches. Few studies have controlled 
for symptom duration or the time elapsed between diagnosis and PSG sleep assessments. 
In addition, while psychometric analyses have suggested a distinctive FMS psychological 
profile (which includes higher levels of depressive symptoms, anxiety and fatigue) few 
studies have simultaneously, and thoroughly examined sleep and psychological status in 
the same participants. A frequently reported alteration found in the sleep microstructure 
of FMS patients is the alpha-delta sleep anomaly, characterised by an increase in alpha 
wave activity during slow wave sleep.  Originally considered a possible neurological 
contribution to FMS, whether the alpha-delta sleep anomaly is fundamental to the 
development of fibromyalgia syndrome, or results mainly from the pain experience of 
FMS patients remains unknown. No previous study has directly compared the sleep of 
FMS and other (non-FMS) patients experiencing similar levels of chronic pain and sleep 
dysfunction.   
The present study was designed to examine sleep macrostructure and 
microstructure in FMS patients, and evaluate the role of the alpha-delta sleep anomaly as 
either a possible contributor to fibromyalgia syndrome, or a likely consequence of pain 
experience. In order to explore these relationships, detailed sleep, activity and 
psychological profiles were compared in 3 groups: 1) FMS patients (n = 19); 2) 
osteoarthritis patients with sleep disturbance (n = 17); and non-clinical (normal healthy) 
adults (n = 10).  In order to standardise diagnostic reliability and symptom chronicity, the 
FMS group was recruited from a single rheumatology facility immediately following 
diagnosis.   
Guided by a series of formal research questions, analyses compared sleep 
macrostructure (using American Academy of Sleep Medicine criteria), sleep 
microstructure (using spectral analysis), and a range of psychological variables (including 
pain experience, sleepiness, fatigue, depression, anxiety, perceived social support, health 
locus of control, pain catastrophizing and personality). The results indicated that the 
alpha-delta sleep anomaly is not unique to FMS, but appears to be a feature found in the 
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sleep of normal healthy adults and (to a greater extent) those with FMS and osteoarthritis.  
The incidence of the anomaly was statistically similar in both clinical (FMS and 
osteoarthritis) groups, a pattern consistent of its being a secondary feature of pain, rather 
than a primary abnormality of FMS. Overall, the psychometric assessments of state and 
trait anxiety and depression better discriminated between the three groups than did the 
sleep variables.  Nevertheless, on measures of sleep, perceived social support, health 
locus of control, and pain catastrophizing, FMS and osteoarthritis patients were not 
significantly different, though both clinical groups differed on these variables from 
healthy controls.  
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1. Introductory Review 
1.1.  Functions of Pain and Chronic Pain 
Pain has been defined as an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage (Merskey & 
Bogduk, 1994). The majority of what we perceive as pain, amounts to various cortical 
processes and activations, giving us information which helps localize the pain and inform 
us as to the intensity of the sensation. Pain is thus a vastly subjective term, and its 
application to such sensations is learned through previous experiences of injury to the 
body (Coderre, Mogil, & Bushnell, 2003). 
In the infancy of pain research, there had been suggestions that the phenomenon 
of pain was completely unrelated to the cortex, for example it was found that those who 
sustained injuries to the cerebral cortex continued to feel pain (Campbell, 1912) leading 
to conclusions that the cortex played a minimal role. However contemporary 
investigations have led to speculations that there are specific parts of the cortex which are 
connected to the processing of pain, and damage to one area of the cortex does not 
necessarily lead to a complete debilitation in pain perception. The main cortical regions 
found to be activated during pain sensations include the limbic, paralimbic and sensory 
areas; these comprise of the anterior cingulate cortex (ACC), insular cortex, prefrontal 
cortex and primary (SI) and second (SII) somatosensory cortices (Bushnell, 2005; Peyron, 
Laurent, & Garcia-Larrea, 2000). 
Pain can express itself in two forms that can be either ‘acute’ or ‘chronic’. Acute 
pain is short-lived, chronic pain however is specific to “actual or potential tissue damage” 
that persists beyond the expected time frame for healing or the occurrence in disease 
processes where healing may never occur (Ospina & Harstall, 2002). The nociceptive 
system consists of sensory fibres which help modulate pain sensations throughout the 
body; these include two types of fibres, namely thinly myelinated Aδ fibres that are 
rapidly conductive and unmyelinated C fibres that conduct much slower; the latter of 
which are most associated with chronic pain conditions such as that of ‘fibromyalgia 
syndrome’ (Williams & Gracely, 2007). 
1.1.1.  Prevalence of Chronic Pain and Healthcare Costs 
It has been estimated that more than 1.5 billion people worldwide suffer from varying 
degrees of chronic pain (Pain Management: A Global Strategic Business Report, 2010). 
The prevalence of chronic pain in the general population ranges from 10-55% (Clark & 
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Treisman, 2004), and can have far reaching implications for productivity and quality of 
life. It has been found, for example, that during a two-week period, 13% of the US 
workforce reported loss in productivity due to common pain conditions such as arthritis 
or other musculoskeletal pain (Stewart, Ricci, Chee, Morganstein, & Lipton, 2003). A 
large scale study in 15 European countries and Israel looked at prevalence, severity, 
treatment and impact of chronic pain. Chronic pain of moderate to severe intensity was 
found to occur in 19% of the sample, affecting quality of social and working lives 
(Breivik, Collett, Ventafridda, Cohen, & Gallacher, 2006). Sleep disturbance is one of the 
most common co-morbid complaints to accompany reports of chronic pain, with sleep 
dysfunction linked to an increase in pain sensitivity or to an attenuation effect of analgesic 
medication (Okifuji & Hare, 2011a). 
1.1.2. Gate Control Theory of Pain 
The Gate Control Theory of Pain was formulated to provide a mechanism for coding the 
nociceptive component of cutaneous sensory input. It was first published in 1965 by 
Melzack and Wall. The theory suggested that thin (nociceptive) and large (innocuous) 
nerve fibres transmit information from the site of injury to two destinations (the 
‘inhibitory’ cells and the ‘transmission’ cells) which are located in the bodies’ spinal cord. 
Signals from both the thin and large nerve fibres excite the transmission cells. When the 
output of the transmission cells exceeds a critical level (unique to individuals), pain is 
felt, and it is the brain that makes sense of it. The role of the inhibitory cells is just that- 
to inhibit activation of the transmission cells. In other words, the transmission cells are 
the ‘gate on pain’ and responsible for opening it, and the inhibitory cells have the capacity 
to ‘shut the gate’, meaning a reduction/cease in pain experienced. To reiterate, the more 
the ‘gate’ is opened, the more pain is felt and vice versa. The two types of fibres are often 
activated at the same time so they become almost in competition with one another. 
Melzack & Wall posited that at times, pain signals travelling from the site of injury 
actually bypass these inhibitory and transmission cells altogether, thereby sending a 
message directly to the brain. This in turn, could trigger a signal back down the spinal 
cord to control inhibitory cell activity and therefore reduce pain experience. Importantly, 
it is the ‘status’ of the brain itself that is modulated by psychological and behavioural 
factors, and hence these can help to determine the extent to which the ‘gate’ is opened, 
and pain is experienced. As an example, Melzack and Casey (1968) described pain as 
having three characteristics/dimensions as follows: 
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 Pain could be viewed in terms of its ‘sensory-discriminative’ dimension, which 
refers to an individual’s sense of the pain’s intensity, location, quality and 
duration. 
 Pain could also be analysed in terms of its ‘affective motivational’ aspect, which 
refers to the degree of perceived unpleasantness and the individuals’ urge to 
escape that unpleasantness. 
 Finally, the third dimension of pain was seen by the authors as ‘cognitive 
evaluative’. This dimension relates to factors such as how the pain is judged by 
the individual; how the pain is viewed in terms of cultural values/norms; how 
much available distraction there is at the time the pain is experienced etc. 
These ‘components’ of the pain experience offered the potential for modern medicine, to 
treat pain not purely by addressing the sensory output (e.g. via pharmacological therapy) 
as is the norm, but also methods which positively influenced the motivational-affective 
and cognitive factors. The theory was therefore a powerful development in pain theory as 
it viewed the individual as proactive in the pain experience, rather than a passive recipient 
of medical intervention (Bushnell, 2005; Melzack & Casey, 1968). 
1.2. Fibromyalgia Syndrome 
Fibromyalgia syndrome (FMS) is a chronic condition characterised by widespread 
musculoskeletal pain. The condition was first noted by Gowers (1904) who described it 
as numerous vague painful disorders of the locomotor system which he termed ‘fibrositis’ 
(Gowers, 1904). The term ‘fibrositis’ was used due to the assumption that the exhibited 
musculoskeletal pain is due to inflammation of muscular/connective tissue; further 
inspection from muscle biopsies of tender points, however, found no consistent 
inflammation or damage (Pearce, 2004). Smythe & Moldofsky (1977) were the first to 
set a ‘rigorously defined’ criteria for fibrositis. They included four symptoms of chronic 
aching, non-restorative sleep, morning stiffness and fatigue (Smythe & Moldofsky, 
1977). FMS is today regarded as a form of non-articular rheumatism (Harth, 1995); and 
the pain experience in FMS now described as a ‘central sensitization’, or that which is 
related to the pathophysiological processes of the central nervous system (Bennett, 
2005a).  
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1.2.1. Prevalence and Characteristics 
The prevalence of FMS is estimated to range between 0.5 to 5% of the general population 
(Branco et al., 2010 [fig. 1.1.]; White & Harth, 2001) with 90% being female (Yunus, 
2001). The diagnosis and treatment options for FMS are associated with significant 
societal and health care costs (Hughes, Martinez, Myon, Taı, & Wessely, 2006), with it 
being now more of an accepted clinical entity (Fitzcharles & Boulos, 2003). The 
prevalence and characteristics of FMS appear greater in older populations. The highest 
values of occurrence were found to be between the ages of 60 and 79 (Wolfe, Ross, 
Anderson, Russell, & Hebert, 1995). Similar findings have been observed in a study into 
the prevalence of FMS in five different European countries, with low prevalence in young 
adults followed by a rise from the age of 35-44 through to 74-85 (Branco et al., 2010); 
this appears to be a consistent feature of FMS. FMS considerably impacts the quality of 
life of sufferers who, around 90% of their time awake, experience pain and fatigue 
(Henriksson & Burckhardt, 1996). Presently, the disease aetiology is still largely 
unknown, with differing opinions and attitudes amongst healthcare professionals; for 
example, a study of knowledge and attitudinal challenges affecting optimal care in FMS 
found that GPs reported insufficient knowledge and skill in diagnosing FMS, with 23% 
of GPs and 12% of specialists characterizing patients as malingerers (Hayes et al., 2010). 
In addition, there has been evidence to suggest that trauma is linked to the manifestation 
and development of FMS, but this evidence is controversial and not definitive (White, 
Carette, Harth, & Teasell, 2000). 
 
Figure 1.1. A graph depicting overall prevalence of FMS per age group in the general population. Image adapted 
from Branco et al. (2010). 
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The severity and complexity of the symptomology of FMS can be characterised 
in roughly three differing dynamics. These are broadly pain, sleep disturbance and 
psychosocial function. These three dynamics have been shown to relate to each other in 
various ways (Bigatti, Hernandez, Cronan, & Rand, 2008).  
1.2.2. Diagnosis of Fibromyalgia Syndrome 
One of the most significant issues in FMS is that the symptom manifestation does not 
seem to have an understandable organic pathology (McBeth, Macfarlane, Benjamin, & 
Silman, 2001). Indeed prior to the recognition of FMS as a syndrome, there had been no 
standardized criteria to diagnose such a condition. The development of diagnostic criteria 
more than twenty years ago has developed an increased interest in the nature and 
manifestation of the syndrome. The 1990 American College of Rheumatology’s criteria 
(1990 ACR) for the classification of FMS has been the hallmark in such diagnoses; the 
criteria comprises briefly of widespread pain in the four quadrants of the body (axial plus 
upper and lower segment plus left- and right- side pain) in combination with tenderness 
at 11 of the 18 defined tender point sites (Figure 1.2.;Wolfe et al., 1990). The standardized 
tender-point sites include bilateral points at the occiput, low cervical, trapezius, 
supraspinatus, second rib, lateral epicondyle, gluteal, greater trochanter and the knee.  
Tenderness is determined upon palpation using approximately 4kg of pressure 
with the pulp of the thumb. For each site to be considered a ‘positive’ tender point, the 
patient must rate it as ‘painful’ rather than ‘tender’ as ‘tender’ is not considered painful. 
Although the combination of the two criteria in diagnosing FMS yields a sensitivity of 
88.4% and specificity of 81.1%, it must be taken into account that FMS is usually 
accompanied by co-morbid debilitating complaints and symptoms; the manifestation of 
FMS is rarely the same in any two patients (e.g. Thieme, Turk, & Flor, 2004). 
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Figure 1.2. An image to illustrate the 18 tender point sites as defined in the ACR 1990 Diagnostic Criteria for 
Fibromyalgia Syndrome. Image adapted from Wolfe et al. (1990; The Three Graces, after Baron Jean-Baptiste 
Regnault, 1793, Louvre Museum, Paris). 
While we have well-established criteria for diagnosis, the process of diagnosis 
still has its shortcomings. The need for a physical tender point examination is an example 
of such an issue; the number of tender points can vary within an individual. For example, 
patients who meet the 11 tender point criteria may have less than 11 tender points on a 
second examination; secondly the reliability of the tender point exam has been examined 
frequently (Bédard et al., 1992; Tunks et al., 1995). The ACR recently proposed symptom 
based practical criteria for a clinical diagnosis of FMS suitable for both primary and 
specialty care; the aim of the new criteria is not to replace the 1990 ACR, but instead to 
serve as a complementary instrument, recognizing a wide spectrum of manifestations and 
symptom severity that is characteristic of primary FMS. A widespread pain index (WPI) 
of 19 areas of the body and symptom severity score (SS) are considered. For a diagnosis 
of FMS, a WPI of at least 7 and an SS of at least 5 is required, or alternatively a WPI of 
3-6 with an SS of 9. The 2010 revision was found to correctly classify 88.1% of cases 
previously classified using the 1990 ACR criteria (Wolfe et al., 2010). 
1.2.3. Current Theories on Fibromyalgia Symptom and Manifestation 
The physiological dysfunction in the pain experience has been well researched (Smith, 
Harris, & Clauw, 2011). FMS patients tend to have a lower threshold for nociceptive 
processing (Staud, 2002); it is thus implied that they have an alteration in their pain 
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processing pathways from pain receptors to the cortical processing level, suggestive of 
central sensitization of the central nervous system (CNS). 
 Moreover, it has previously been found, that nociception is qualitatively altered 
in patients with fibromyalgia, suggesting that fibromyalgic pain may be due to abnormal 
central pain mechanisms (Bendtsen, Nørregaard, Jensen, & Olesen, 1997).  
1.2.3.1. Neural Connectivity 
Recent studies have found certain abnormalities of neural connectivity in patients 
with fibromyalgia compared with control subjects. Studies by Napadow and colleagues 
have found that neural connections between parts of the pain pathways and other networks 
(default mode network, executive attention network etc.) are highly correlated with pain 
(Napadow et al., 2010). Other studies have found a range of both positive and negative 
connectivity in fibromyalgia compared with healthy control participants; some studies for 
example have found a reduction in connectivity in the brain’s pain inhibitory network 
(Jensen et al., 2012; Napadow, Kim, Clauw, & Harris, 2012).   
1.3.  Sleep 
1.3.1. Function of Human Sleep 
Sleep can be described as a state of immobility, reduced responsiveness with rapid 
reversibility, so as to differentiate between states of coma or anaesthesia ( Siegel, 2005); 
The phenomenon of sleep in mammals has perplexed humans for centuries, and even at 
present, there is no objective evidence to suggest the reasons as to why we sleep. There 
is, however, a growing importance in sleep research, both in theory and in medicine; after 
pain, sleep disturbances are the second most frequent indicator of illness (Šušmáková, 
2004). Sleep structures differ widely among mammals; it is thus difficult to grasp its 
function between species, let alone use this information to better understand sleep 
dysfunction in humans.  
Its importance has been underestimated in several early theories of the 
physiological significance of our sleep. But it is evidently of great significance to our 
wellbeing. For example, the process of ‘sleep rebound’ post-deprivation gives us a clue 
as to the physiological need for sleep. Findings have consistently indicated increases in 
‘deep’ sleep rather than increases in duration (Ferrara, De Gennaro, & Bertini, 1999) that 
may signify specific aspects of the sleep structure as being more significant than others 
towards a “recovery” process. There have been multiple theories regarding the function 
of sleep, for example tissue restoration and growth (Adam & Oswald, 1977), 
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thermoregulation or consolidation of memory and learning ( Siegel, 2001) just to name a 
few. However, it is difficult for theories to encompass all aspects of sleep function. Sleep 
is a complex process regulated by various systems; they in turn interact with different 
bodily processes. 
1.3.2. Classification and Definition of Sleep States 
Berger (1929) first discovered that the electrical activity of the human brain could be 
measured by electrodes placed on the scalp, whereby changes in voltage are plotted over 
time. He found that the frequency and amplitude changes were consistently correlated 
with vigilance, drowsiness and sleep periods (Berger, 1929). Consequently, modern 
forms of sleep research are largely connected to the invention and discovery of the 
electroencephalograph (EEG). Loomis, Harvey, & Hobart (1937) observed the changes 
in sleep states during the course of a night, and thus described several stages of sleep 
based on EEG. The sleep stages are divided into two categories of non-rapid eye 
movement (NREM) and rapid eye movement (REM) sleep; with NREM further divided 
into four stages from the lightest stage 1 to the deepest stage 4 with each cycling of stages 
lasting for approximately 90 minutes. An average person will exhibit four to six cycles 
per night. With a need for standardization for comparability and replication of results 
Rechtschaffen and Kales (1968) developed a set of rules involving parameters, techniques 
and wave patterns of three physiological signals to evaluate each stage of sleep; the 
signals include the electroencephalogram (EEG), electrooculogram (EOG) and the 
electromyogram (EMG).  
As illustrated in figure 1.3 each stage of sleep is characterized by a distinct EEG 
pattern; with stage 1 characterized by low voltage, mixed frequency (generally in 3-7 
cycles per second range) with the highest amplitudes in the 2-7 Hz range called theta 
waves. A feature of stage 2 involves the anomaly of sleep spindles and K-complexes; 
sleep spindles being bursts of activity in the 12-16 Hz frequency and K-complexes 
involving a sharp negative wave followed by a slower positive wave; these anomalies 
may occur randomly within stage 2. Stages 3 and 4 are what are called ‘Slow Wave Sleep’ 
involving much slower ‘Delta’ waves in a range of less than 2 Hz, however with 
amplitudes greater than 75μV (Šušmáková & Krakovská, 2007). Researchers presently 
do not distinguish between stages 3 and 4 as the attributes they carry are the same with 
the only difference being the percentage occurrence during each stage; differentiation is 
thus deemed unnecessary. Figure 1.4 illustrates the electrode placements for evaluating 
sleep stages with the rules of Rechtschaffen and Kales (1968). The properties of the REM 
stage show low voltage mixed frequencies, which is comparable to stage 1; sawtooth 
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wave patterns are often observed, and EMG reaches its lowest level in conjunction with 
episodic rapid eye movements shown on the EOG.  
Presently, the most widely used standard for defining sleep stages is the 
‘American Academy for Sleep Medicine’ criteria (Iber, Ancoli-Israel, Chesson, Quan, & 
Chesson Jr., 2007; Silber et al., 2007). This involves updated labelling rules for sleep 
stages as N1, N2, N3 and REM. The main difference is in the elimination separate slow 
wave sleep stages, rather than having Stages 3 and 4, it is now replaced with stage N3. In 
addition, the criterion by which sleep stages are classified has also been simplified (Silber 
et al., 2007). 
 
 
Figure 1.3. An illustration depicting the EEG waveforms for sleep, with typically observed waves during awake, 
drowsy, N1, N2, N3 and REM sleep. CPS depicts cycles per second. Amplitude measurements in microvolts. 
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Figure 1.4. Illustration of electrode placements for the evaluation of sleep stages as recommended by Rechtschaffen 
and Kales (1968). *AASM criterion incorporates frontal and occipital channels additional to those shown. 
1.3.3. Alternative Assessments of Sleep 
In addition to the ‘Gold Standard’ measure of sleep using polysomnography, there are 
other ways of sleep detection that have their own advantages and disadvantages. 
1.3.3.1. Actigraphic Method 
Actigraphy is a method used to study sleep-wake patterns and circadian rhythms by 
assessing wrist motor activity. This is usually packaged into a wristwatch like device with 
a piezoelectric accelerometer, band pass filters, timers, memory storage, battery and a 
connective interface such as USB. The movements the actigraph detects are continually 
recorded, with some units also measuring light exposure. The data allows an indirect 
assessment of sleep, through the usage of algorithms. These algorithms are automatic 
scoring methods developed to distinguish sleep from wakefulness (de Souza et al., 2003; 
Littner et al., 2003; Morgenthaler et al., 2007). 
 The usage of actigraphy is increasing in clinical research and in practice due to 
their low cost nature, and possibilities for long term study efficiency. The use of 
actigraphy has been rising, and is used frequently to study patients with chronic sleep 
disorders, both to determine circadian rhythm cycles or effects of treatments on sleep. 
Actigraphic algorithms in detecting sleep-wake status have been consistently shown to be 
a sensitive method, but in some cases demonstrate low specificity, at times overestimating 
sleep latency, total sleep time and sleep efficiency and underestimating the number of 
awakenings (de Souza et al., 2003; Marino et al., 2013). 
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 The usage of PSG has been a gold-standard in determining sleep wake cycles, but 
also allows an in depth look at sleep stage variations and in some cases allow a more 
detailed analysis such as through the use of spectral analysis. However, PSG studies are 
costly to run, and challenging to conduct home studies where the environment is 
uncontrolled, additionally it is a time consuming process, not just with data collection but 
also with analysis and scoring of sleep stages. Moreover, long term studies are more 
difficult to implement and sometimes not viable. Actigraphy on the other hand is low 
cost, allows long term efficient monitoring of sleep and wake cycles and is simpler to 
implement and analyze. Both methods have their advantages and disadvantages, it would 
therefore be useful to implement both where possible; PSG for a more detailed analysis, 
and actigraphy for a general overview of a participant’s sleep and wake cycle/rhythm.  
 The usage of actigraphy however is under researched in conditions other than 
sleep disorders. For example, in chronic pain, there are little well validated studies for 
using actigraphy in these patient populations. 
1.3.4. Two Process Model of Sleep Regulation 
A basic model of sleep regulation is the two-process model, which covers an interaction 
between the homeostatic (Process S) and circadian (Process C) processes that generate 
the timing of sleep and wakefulness. Process S is sleep/wake dependent, whereby it 
increases with increasing time of wakefulness and decreases when you are asleep; the 
level of Process S at sleep onset is thus a function of prior wake time. Process C on the 
other hand is independent of sleep and waking; it is governed by the biological clock 
regulating the timing in periods of sleep and wakefulness over a 24 hour period, thus sleep 
propensity is rhythmically varied during the circadian cycle (Borbély, 1982). 
1.3.5. Sleep Dysfunction 
1.3.5.1. Insomnia 
Insomnia is one of the most prevalent sleep and health complaint in the general 
population. Approximately 9% of people regularly suffer from insomnia, with 30% 
suffering occasionally (LeBlanc et al., 2009). In a review of epidemiology of sleep 
quality, it was concluded that insomnia can be defined in four ways (Ohayon, 2002). 
1. Insomnia symptoms: subjective complaints of sleep onset or sleep maintenance 
difficulties, or early morning awakening (prevalence rates were highest when this 
definition was used, ranging from 30-48%) 
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2. Insomnia symptoms accompanied with daytime consequences (e.g. daytime 
fatigue, lack of concentration, memory lapses, decreased quality of life, decreased 
job performance and greater absenteeism from work). When using this definition, 
prevalence rates ranged from 9-15%. 
3. Dissatisfaction (based on subjective reports) with sleep quality or quantity 
(prevalence rates ranged from 8-18%). 
4. Insomnia diagnoses based on formal clinical diagnostic criteria such as that 
seen in the 1994 APA fourth edition of the ‘Diagnostic and Statistical Manual of 
Mental Disorders’ (DSM-IV) and the second edition of the ‘International 
Classification of Sleep Disorders’ (ICSD-2) published by the AASM in 2005. 
Prevalence rates were found to be much lower when such criteria was used – 
typically 6%. 
There have been an abundant of research studies investigating the co-morbidity of chronic 
pain conditions with insomnia, and it appears to be a common occurrence in the general 
adult population; this has mainly been due to sleep dysfunction/disturbance as a result of 
chronic pain, and a large number of chronic pain sufferers are able to meet the diagnostic 
criterion for insomnia including FMS (e.g. Benca, Ancoli-Israel, & Moldofsky, 2004; Siu, 
Chan, Wong, & Wong, 2012; Wong & Fielding, 2012). 
1.3.5.2. Non Restorative Sleep 
There has been a recent rise in interest in to the pathology of non-restorative sleep (NRS). 
NRS was first recognised as an insomnia symptom in the DSM-III-R in 1987 and 
describes sleep as being restless, light, or of poor quality regardless of the duration 
(Ohayon, 2005). NRS indeed lacks a standard, operational definition; a more refined 
definition explains it as reports of persistently feeling unrefreshed upon awakening in the 
presence of normal sleep duration, occurring in the absence of a sleep disorder (Stone, 
Taylor, McCrae, Kalsekar, & Lichstein, 2008). Although not specific to FMS, it has been 
proposed that NRS has led to the aetiologies of chronic fatigue syndrome and 
fibromyalgia; this stems from the fact that NRS is common to these conditions (Gotts et 
al., 2013). 
Due to individuals perceiving sleep as insufficiently refreshing, despite an 
appearance of normal sleep according to standard sleep assessment parameters, 
researchers have pursued alternative physiological markers of non-restorative sleep with 
inconclusive and sometimes controversial results (Wilkinson & Shapiro, 2012). The 
prevalence of NRS as a symptom varies between countries, however it is quite frequently 
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observed in the general population. Ohayon (2005) found 10.8% prevalence in seven 
European countries. In addition, a 1991 general social survey of approximately 12,000 
Canadians found a high prevalence of insomnia (24%), with a high proportion reporting 
unrefreshing and non-restorative sleep (Sutton, Moldofsky, & Badley, 2001). 
1.4.  Medication and its Effects on Sleep Physiology 
One of the key methodological challenges of studying sleep structure in chronic 
conditions like FMS is the likelihood that patients will be prescribed drugs which not only 
impact their condition, but also impact sleep. Various medications affect an individual’s 
sleep physiology. Population groups such as those with chronic pain conditions (e.g. FMS 
or OA) are usually prescribed a myriad of medications for their primary symptoms or co-
morbid disorders. Typical types of drugs prescribed for such individuals include anti-
depressant medication of the serotonin reuptake inhibitor variety (SSRIs) and non-
steroidal anti-inflammatory drugs (NSAIDS). Many SSRIs have been shown to affect 
sleep physiology. The SSRI ‘citalopram’ for example has been shown to alter several 
polysomnographic variables; these include a significant decrease in REM sleep, an 
increase in REM sleep latency and an increase in the percentage of Stage 2 sleep (Van 
Bemmel, Van Den Hoofdakker, Beersma, & Bouhuys, 1993). All types of anti-depressant 
drug therapies will affect sleep architecture which can be positive or negative. It is thus 
necessary to have wash-out periods of anti-depressants where possible. 
In addition to SSRIs, non-steroidal anti-inflammatory drugs (NSAIDS) are 
primarily used for analgesic affects and in higher doses anti-inflammatory uses and so are 
relatively prevalent in patients with FMS or OA. Studies on the effects of NSAIDS on 
sleep have shown mixed results. Gengo (2006) looked at the use of Ibuprofen, on healthy 
adults. Polysomnographic and subjective measures were taken. It was found that a total 
daily dose of 1200mg did not produce clinically or statistically significant alterations in 
night time sleep in comparison to a control group who received a placebo (Gengo, 2006). 
In contrast, a similar study conducted looked at the effect of prostaglandin-inhibiting 
drugs on sleep. These included aspirin, acetaminophen or ibuprofen. In this case, in 
comparison to a placebo, both aspirin and ibuprofen were found to increase the number 
of awakenings, increase percentage time in wake, and decrease sleep efficiency. 
Ibuprofen also appeared to delay the onset of SWS. The NSAID acetaminophen however, 
did not differ significantly from the placebo (Murphy, Badia, Myers, Boecker, & Wright, 
1994). 
The mixed results from the use of NSAIDS in sleep disruption cause some 
concern. Caution should always be used when studying clinical populations such as these 
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and certain types of drugs must be taken into account when looking at outcomes of sleep 
pathology. 
1.5.  Chronic Pain and Sleep 
There have been numerous studies into the effect chronic pain has on sleep physiology, 
daytime functioning and psychosocial variables. It has been well documented that sleep 
dysfunction is a highly prevalent symptom in differing chronic pain conditions, but how 
it actually affects sleep should be investigated further. Research that has looked into this 
area utilizes both subjective and physiological metrics (e.g. Smith & Haythornthwaite, 
2004; Tang, Goodchild, Hester, & Salkovskis, 2012; Tang, Wright, & Salkovskis, 2007). 
1.5.1. Fibromyalgia and Sleep Dysfunction 
Sleep plays an important role in our lives and its interaction with chronic pain conditions 
is well documented; sleep disturbance is one of the most common complaints in patients 
suffering from chronic pain (Smith & Haythornthwaite, 2004). A major symptom 
reported by FMS sufferers is a dysfunctional sleep characterised by symptoms of 
insomnia (i.e. problems getting to sleep, problems staying asleep, unrefreshing sleep, and 
early morning awakening). These reports suggest that increases in sleep symptom severity 
can negatively impact pain experience in FMS (Bigatti et al., 2008). This novel approach 
to FMS has led to suggestions as to a reciprocal relationship between sleep disturbance 
and pain; pain disturbs sleep quality and poor sleep further exacerbates pain (Smith & 
Haythornthwaite, 2004). Sleep disturbance has recently been viewed as a more cardinal 
symptom of FMS than was previously thought with more than 90% of patients describing 
some form of impaired sleep quality (Moldofsky, 2008). A major and common sleep 
complaint in FMS is the apparent unrefreshing and fragmented sleep that patients 
experience which has been coined ‘non-restorative’ sleep (NRS). The consequences of 
NRS can lead to more debilitating daytime symptoms, such as an increase in the number 
of tender points, increased pain, fatigue (both mental and physical), sleepiness and 
negative mood (Wilkinson & Shapiro, 2012). 
1.5.2. Non Restorative Sleep in FMS 
It is not known whether non-restorative sleep in fibromyalgia is a primary or secondary 
phenomenon. One problem that has been highlighted numerous times in terms of FMS is 
whether the poor sleep they experience is a contributing factor to FMS or a consequence 
of the illness. A recent longitudinal study investigated the association between self-
reported sleeping problems and the risk of FMS among adult women. 12, 350 adult 
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women from Norway were assessed at baseline (1984-1986) and again at follow-up 
(1995-1997). Incident FMS was reported by 327 (2.65%) women at follow up and a 
strong dose-dependent association was discovered between sleep problems and the risk 
of FMS; the association was found to be stronger (albeit not significant) in middle-aged 
and older women as opposed to younger women. Sleeping problems at baseline appeared 
to predict an increased risk of FMS in comparison to those that had never experienced 
sleeping problems (Mork & Nilsen, 2011). Although it cannot infer a cause and effect 
relationship, it does suggest sleeping problems early on, are fundamental to the 
development of FMS and not a consequence of the illness. 
Many studies have investigated the nature and pathology of NRS using traditional 
sleep assessment parameters including polysomnography and actigraphy. Such measures 
have also been used to investigate sleep in FMS patients. Moldofsky and colleagues 
investigated the NREM sleep disturbances in FMS patients in relation to healthy subjects. 
They found a significant overnight increase in dolorimeter (pain threshold) scores of those 
with FMS with a coincidental NREM sleep disturbance. Moreover, a study of healthy 
subjects who underwent Stage 4 sleep deprivation was found to lead to temporary 
development of musculoskeletal and mood symptoms (Moldofsky, Scarisbrick, England, 
& Smythe, 1975). This highlights a possible link between NRS and daytime symptoms 
in FMS, in this case, of an increase in tenderness in the morning. In addition to this 
finding, a decrease in pain and fatigue has also been observed from mid-morning to mid-
afternoon, during which time patients were described as hitting a cognitive ‘brick wall’ 
that is, reaching a point in the day where patients expressed an inability to think or 
concentrate properly (C-oté & Moldofsky, 1997). This shows NRS not only affects 
patients physically in terms of pain and tenderness, but there also appears to be an 
additional decline in cognition. 
The general consensus is that a physiological sleep disturbance leads to 
complaints of NRS which in turn moderates/mediates daytime and cognitive impairment. 
For example, what is described as ‘periodic limb movements in sleep’ (PLMS), a 
phenomenon found most frequently in association  with ‘restless legs syndrome’ 
(Hornyak, Feige, Riemann, & Voderholzer, 2006) is one of many comorbid disorders 
related to FMS. The wakeful symptoms of experiencing NRS include a sense of physical 
and mental fatigue, variable nonspecific bodily pain, and increased sensitivity to noxious 
stimuli, dysphoria and autonomic disturbances (Moldofsky, 2006). A study into cognitive 
performance in relation to daytime symptoms and sleep found that in comparison to 
asymptomatic controls, FMS patients had lower accuracy in cognitive tasks, greater 
sleepiness, fatigue, pain and negative mood. However on more complex tasks, they were 
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significantly slower in speed rather than impaired accuracy (C-oté & Moldofsky, 1997). 
This could possibly branch from a distraction due to the pain, but its findings are found 
to be inconclusive. 
Rather than psychological distress, NRS has been found to correlate with the 
number of tender points and myalgia in FMS patients ( Yunus, Ahles, Aldag, & Masi, 
1991); and on occasions when a patient achieved a restful night’s sleep, there are 
significant improvements in daytime symptoms. This may emphasize the importance of 
focussing on improved management of sleep in order to better improve FMS symptoms 
including comorbid disorders. 
1.5.3. Evidence from a Polysomnography Perspective 
As discussed, there have been many attempts at observing NRS using various standard 
sleep measurement tools. Evidence in this area is contentious, however there have been 
several significant features observed using polysomnography. 
The fundamental structure of sleep has been shown to be altered in FMS patients. 
Typically, FMS patients show an increase in Stage 1 sleep, a reduction in delta sleep 
(Slow-wave-sleep; Stage N3) and an increase in the number of arousals (Harding, 1998). 
A prominent feature that has evoked controversy is the alpha (α) EEG sleep anomaly; 
first described by Moldofsky et al (1975) and has been a recurrent finding, not just in 
FMS patients, but in those with other chronic pain or sleep disorders as well (e.g. Wittig, 
Zorick, Blumer, Heilbronn, & Roth, 1982). The alpha anomaly is found to occur in 
NREM sleep and has been described as large amplitude alpha waves in the frequency of 
8-13 Hz superimposed onto delta (δ) waves. This type of alpha ‘intrusion’ is known as 
‘alpha-delta’ (α-δ) sleep, a term first coined by Hauri and Hawkins (1973). The alpha 
wave anomaly was presumed to be a product of an internal arousal mechanism which in 
turn, disrupted the restorative functions of NREM sleep, leading to symptom 
manifestation and development (Moldofsky et al., 1975). Figure 1.5 illustrates an 
example of α-δ sleep in a 28 year old with FMS from C4-A1 and C3-A2 EEG derivations 
(Dauvilliers & Touchon, 2001). 
 
Figure 1.5. Example of alpha-delta sleep in a 28-year-old patient with FMS from C4-A1 and C3-A2 EEG 
derivations. Adapted from Dauvilliers & Touchon (2001). 
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Scrutinising the alpha EEG anomaly further, three distinct patterns were 
ascertained to be associated with it. These were described as phasic, tonic and low alpha. 
The phasic pattern was predominant in those with FMS, being found in 50% of FMS 
patients in comparison to only 7% of normal controls. The tonic pattern was found in 
20% of FMS patients compared to 9% of controls, and low alpha in 30% of FMS patients 
compared to 84% of controls. The phasic pattern is expressed as alpha waves occurring 
simultaneously with delta waves; The tonic patterns are alpha waves occurring 
continuously throughout NREM stages of sleep; The low alpha patterns are generally low 
levels of alpha activity throughout NREM sleep. The phasic pattern of the alpha anomaly 
appears to be the strongest correlate of an increase in symptomology; these include the 
worsening of pain, increase in number of tender points and longer durations of pain post-
sleep; 
FMS patients generally exhibit less total sleep time, lower sleep efficiency and 
less slow-wave sleep (Roizenblatt, Moldofsky, Benedito-Silva, & Tufik, 2001). This 
study by Roizenblatt and colleagues, suggests that there are distinct patterns of the alpha 
anomaly in all FMS patients. However there appears to be a specific (phasic) type that 
predominates, which is linked to the most severe of clinical symptoms; it is interesting to 
note that this typing of alpha pattern as an ‘intrusion’ of alpha into delta wave sleep may 
have implications for NRS, as delta waves have been associated with restorative functions 
during sleep (e.g. Peigneux et al., 2004; Shapiro, Bortz, Mitchell, Bartel, & Jooste, 1981).  
The localisation of alpha sleep generation has also been investigated using 
multichannel EEG or brain imaging techniques; the most prominent alpha during sleep is 
normally observed in the occipital region, however there has been documented alpha 
activity typings which differ in site generation, scalp distribution and behavioural 
correlates (Pivik & Harman, 1995). For example, a study looking specifically at the alpha 
rhythm used simultaneous EEG and fMRI to map MRI changes in the cortex in relation 
to a modulation of alpha activity. They found an increased alpha power in the thalamus 
and insula regions. The group were drawn toward the conclusion that the increased alpha 
power was related to an index of cortical inactivity (Goldman, Stern, Engel, & Cohen, 
2002). An earlier study observed a frontal prevalence of ‘alpha-like activity’ in people 
with FMS; it was postulated that it may relate to a typing of ‘kappa’ activity (Horne & 
Shackell, 1991). Kappa type activity is usually observed in the ‘theta’ (4-7 Hz) or ‘alpha’ 
(8-13 Hz) range; it was previously thought to be an eyelid fluttering artefact usually 
observed in prefrontal leads that sit above the eye; it is now regarded as a form of mental 
activity e.g. (Glanzer, Chapman, Clark, & Bragdon, 1964). The ‘alpha-like’ activity in 
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the frontal regions of those with FMS could suggest a manner of mentation or rumination 
during sleep, which may lead or contribute to disturbed sleep;  
Although the alpha-delta EEG anomaly is reported in several studies, the literature 
at present is still inconsistent in its findings and conclusions. There are some researchers 
who find alpha-delta occurrence in all the FMS patients they examined ( Branco, Atalaia, 
& Paiva, 1994), and some who found no difference between FMS and control subjects in 
terms of the alpha-delta anomaly (González et al., 2011). These differences can be 
explained via differing methodological employments, equipment and EEG or statistical 
analysis methods used; these factors also make comparisons across studies difficult. In 
addition, there is no standardization in the detection of the alpha-delta rhythm; various 
studies utilize different electrode montages, machinery, analysis methods and even in 
patient selection criteria. 
Even though alpha-delta sleep is a highly likely contributor to sleep fragmentation 
and NRS in FMS, there are other features of the sleep EEG which may be related to sleep 
disturbance in FMS. Those with FMS may exhibit alterations in a variation of periodic 
arousal disturbance in their sleep EEG. The ‘cyclic alternating pattern’ (CAP; [Figure 
1.6.]) is a periodic EEG activity of NREM sleep. CAP is characterized by “transient 
electro-cortical events distinct from background EEG activity and can recur up to 1 
minute intervals” (Terzano et al., 2001); it may signify sleep instability, sleep 
disturbances or both. There are many documented varieties of CAP; the type that is found 
to be most associated with arousal disturbances in FMS is the periodic K-alpha Complex, 
figure 1.7. The periodic K-alpha occurs in two phases, the first phase (phase A) is a K-
complex observed in stage N2, followed immediately by a burst of alpha activity lasting 
for less than five seconds; phase A is followed by a quiescent period of NREM sleep, the 
cycle is then repeated after 20-30 seconds (Terzano et al., 2001). 
CAP sequences can be found to occur in all stages of NREM sleep, the CAP 
sequences commence typically at sleep-onset and at sleep recovery post-nocturnal-
awakening. It has been found that almost 50% of all NREM sleep stage changes are 
accompanied by a CAP sequence; the CAP rate (CAP time/Total REM) in young adults 
was found to be around 23% with increases in age (Terzano, Parrino, & Spaggiari, 1988). 
A high prevalence of the periodic K-alpha CAP was found in FMS patients, with 
correlations to symptom severity (tender points) and decreases in sleep efficiency; in 
comparison to controls, FMS patients were found to be significantly less sleep efficient, 
had greater increase in N1 sleep and more than twice the number of arousals per hour 
(Rizzi et al., 2004). This may point to a new marker for sleep alteration in FMS patients. 
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Another interesting aspect of sleep EEG in FMS patients is in their spindle 
morphology. FMS patients tend to have a decrease in spindle activity, a marker for stage 
N2 onset; one study found women with FM pain have fewer sleep spindles and reduced 
EEG power in spindle activity in comparison to healthy sleepers (Landis, Lentz, 
Rothermel, Buchwald, & Shaver, 2004). This may be linked to the greater CAP rate 
observed in FMS patients, due in part to K-complexes not being followed by normal 
spindles, but rather by a burst of alpha activity; consequently, the spindle rate will 
decrease; however, this reported phenomenon should be scrutinised further.  
 
Figure 1.6. Example of cyclic alternating pattern in sleep stage 2. The box outlines the CAP, with phase A and phase 
B. Adapted from Terzano et al. (2001). 
 
Figure 1.7. Example of K-alpha complex in stage 2 of sleep. Adapted from Terzano et al. (2001). 
There has been some evidence to suggest a genetic link in FMS manifestation. 
Although FMS is most prevalent in adult populations, there are a portion of cases that 
occur in young people who are diagnosed with ‘juvenile FMS’ [JF] (Yunus & Masi, 
1985). One investigation found a greater proportion of children who had JF had mothers 
who also had a diagnosis of FMS. In addition, they both exhibited alpha prominence 
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during SWS in comparison to asymptomatic controls, an example of the phasic pattern of 
alpha. However, the mothers had a greater level of subjective sleep complaints and a more 
noticeable polysomnographic anomaly than their child counterpart (Roizenblatt et al., 
1997). This implies a familial link to FMS; this could be described via a genetic influence, 
environmental or psychological effects or even an interaction between these factors e.g. 
(Kashikar-Zuck et al., 2008). 
1.6.  Psychosocial Characteristics, Symptoms & Manifestations in FMS 
Research has demonstrated that there are distinct psychosocial differences between those 
with FMS and normal healthy individuals. This distinct ‘profile’ may be a contributing 
factor to the manifestation or maintenance of FMS. For example, many cases of FMS 
have documented onset of symptoms after a traumatic event such as a non-injurious motor 
accident (Moldofsky et al., 1975). It has also been shown that FMS patients’ 
psychological profile is somewhat distinct from those with other chronic conditions 
(Shuster, McCormack, Riddell, & Toplak, 2009). For example they may exhibit greater 
depression and anxiety and a greater external locus of control (Gustafsson & Gaston-
Johansson, 1996; Kurtze, Gundersen, & Svebak, 1998).  It must then be speculated that 
there are certain ‘types’ of individuals who are more at risk or prone to developing FMS 
than others. It is thus necessary when observing FMS patients that this is controlled and 
accounted for. In order to greater understand FMS pathology, it is essential to build a 
psychosocial profile of FMS patients in order to understand the effect differing 
dimensions of psychology may have on their symptom and syndrome development. 
Depression and anxiety are two major comorbid disorders exhibited in FMS 
patients (Thieme et al., 2004). However, it must be noted that the cause and effect 
relationship between these factors and major FMS symptomology is unknown. These 
factors were found to be highly elevated in a study into psychiatric disorders in those with 
FMS (Epstein et al., 1999). In addition, those that took part in the study were found to 
have a high lifetime and current prevalence of major depression and panic disorders. 
Moreover, current anxiety was found to predict a proportion of variance in physical 
functioning (Epstein et al., 1999). The prevalence of depression comorbidity in FMS is 
found to be in the range of 28.6% and 70% across studies (Shuster et al., 2009). In 
addition, 30-40% of FMS patients have been found to suffer from depression, stress and 
anxiety. Moreover, both depression and anxiety have been found to be strongly related to 
the severity of FMS symptoms (Kurtze et al., 1998). In a study comparing FMS with pain 
controls, they looked into psychological distress and observed several measures including 
anxiety and depression; FMS patients were found to be more symptomatic on all 
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measures of psychological distress; those who scored above cut-off points for anxiety and 
depression had more physical symptoms and poorer function that those who scored below 
(White, Nielson, Harth, Ostbye, & Speechley, 2002). These findings highlight the 
importance of taking into account affective distress as an intervention consideration. 
Aside from anxiety and depression, there are other psychological aspects of FMS 
to take into consideration. These include perceived social support, health locus of control, 
pain catastrophizing and personality dimensions. A study by Shuster and colleagues 
looked at the psychological profile of women with FMS. Their results showed that women 
with FMS had a higher external locus of control, lower levels of adaptive cognitive bias, 
less perceived family social support and lower mood in comparison to a control group 
(Shuster et al., 2009). In addition, many of these psychological dimensions appear to be 
linked to depression and anxiety. For example external health locus of control was 
significantly associated with ratings of both anxiety and depressed mood (Shuster et al., 
2009). It was hypothesised in a study by Walteros and colleagues (2011) that chronic pain 
conditions such as FMS, were associated with deficits in decision making and associated 
learning. Those with FMS compared to a healthy control group had a poorer performance 
in both an emotional decision making task (Iowa Gambling Task) and a conditional 
associative learning task (CALT). In addition associated learning was shown to be 
mediated by depression, indicating that pain and depressive symptoms in FMS may lead 
to deficits in certain emotional cognitive tasks (Walteros et al., 2011).  
Looking at social support, findings from a recent study of FMS patients found 
significant reductions in pain sensitivity and subjective pain ratings in the presence of 
their significant other compared to when they were alone (Montoya, Larbig, Braun, 
Preissl, & Birbaumer, 2004). In addition, comparative studies into those with FMS and 
those with other chronic rheumatic diseases found that FMS patients are more externally 
oriented in terms of health locus of control. Patients believed their symptoms depended 
on uncontrollable events and the disease could not be influenced by the individual 
(Gustafsson & Gaston-Johansson, 1996; Pastor et al., 1993). This indicates an aspect of 
cognition that is distinct in FMS patients rather than those with other rheumatic diseases. 
It may serve as a further contributing factor in FMS development and maintenance and 
should be observed with care. 
Pain catastrophizing has also been found to be highly associated with increased 
pain and depression and greater disability (Carol S Burckhardt, Clark, O’Reilly, & 
Bennett, 1997). This finding was also found to be true once compared to a control group 
exhibiting similar symptoms to those with FMS, namely rheumatoid arthritis (Hassett, 
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Cone, Patella, & Sigal, 2000). Looking at factors of personality, FMS patients have been 
shown to score highly on the dimension of ‘neuroticism’ (Epstein et al., 1999), a term for 
‘emotional instability’. It has been suggested that FMS may be a manifestation of 
neuroticism, as high subjective pain sensitivity and low thresholds of pain perception are 
common features in both highly neurotic controls and highly neurotic FMS patients. The 
aspect of neuroticism is seemingly related to higher depression, anxiety and experience 
of stress in FMS and other pain conditions (Netter & Hennig, 1998). 
Further to this, the processes of sleep disturbance may also be more intricately 
related to various psychological processes than first thought. A study by Hamilton et al. 
(2012), looked to test their ‘Sleep and Pain Diathesis Model’ (SPDM), the model predicts 
that sleep quality is related to fibromyalgia outcomes such as disability and depression 
and these relationships are mediated by both pain and emotional dysregulation. They 
administered a battery of questionnaires to 35 patients with FMS and found a greater 
report of sleep disruption that coincides with a greater report of ‘psychological disability’, 
which in turn was mediated by certain cognitive processes (Hamilton et al., 2012). This 
study has provided insight and links into how the effect of sleep disturbance, non-
restorative sleep even, can affect psychological outcomes via mediation through cognitive 
processes such as pain helplessness and therefore pain itself. The various psychological 
factors (i.e. social support, health locus of control etc.) may thus be linked in more 
intricate ways than first thought and should be observed in more detail. Of course the 
study into the SPDM utilized a questionnaire based approach, so a possible limitation 
concerns the accuracy or objectivity of the sleep measures used.  
In addition, there have been investigations into the potential associations between 
various types of trauma (emotional, physical and sexual) and fibromyalgia. A recent 
meta-analysis investigated this association and found significant associations between 
FMS and self-reported physical abuse in childhood and adulthood, and sexual abuse in 
childhood and adulthood (Häuser, Kosseva, Üceyler, Klose, & Sommer, 2011). However, 
these findings are inconclusive, with a meta-analysis the authors reported a poorer study 
quality, which were associated with higher effect sizes for sexual abuse in childhood. 
Additional exploration in this area of FMS should be explored further. 
1.7.  Summary 
1.7.1.  Present Study Aims and Hypotheses 
After careful consideration of the literature, the review has detailed some unexplored 
areas in which an investigation is needed. Firstly, it is evident that those with FMS have 
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disturbed sleep, research has proposed a number of areas in which to explain their sleep 
disturbance. However, the EEG evidence is inconsistent in what it finds, especially with 
regards to the alpha wave anomaly. The main question that should be posed is whether 
disturbed sleep in terms of varying EEG phenomena, (alpha-delta sleep, periodic K-alpha, 
the amount of SWS and frontal alpha-like activity), is a result of the symptomology of 
FMS or whether it is fundamental to the development of the syndrome. Recent evidence 
has suggested the latter (i.e. Mork et al. in press), but the exact pathology of the sleep 
disturbance is still largely unknown. Secondly, FMS patients have been found to have 
psychological dimensions in certain extremes, it is wise thus to build a more robust 
psychological profile of such individuals, and control for such variables when looking at 
their sleep architecture. It is also important to investigate the significance of these factors 
in terms of mediation and moderation and how they relate to each other. It is therefore 
necessary to compare variables within FMS with a control group which does not have a 
diagnosis of FMS, but which does experience similar levels of musculoskeletal pain. Such 
a group could be selected from those with osteoarthritis, a patient population which also 
experiences sleep disruption/disturbance due to their chronic pain condition. 
The present study will therefore utilize an observational comparative design, 
comparing FMS patients with those who have osteoarthritis (OA). In order to provide age 
and gender specific normative data for comparison, a third group of normal healthy 
controls (NHC) recruited locally from the general population will also be included. 
Because OA experience similar levels of chronic pain to those with FMS, and their sleep 
disturbance is largely due to chronic pain, the sleep disturbance, especially of non-
restorative sleep, is less clear-cut in FMS and therefore utilizing OAs as a control group 
would be appropriate. As yet no study has both compared FMS patients with a comparator 
group experiencing similar levels of pain and explored or controlled for the influence of 
psychological attributes in FMS sleep studies. 
1.7.2.  Research Aims and Objectives 
The aim is thus to combine actigraphy (as an objective measure), PSG and psychometric 
variables in a series of controlled analyses addressing the following key research 
questions: 
1. When scored according to AASM criteria, does the polysomnographic sleep of 
FMS, OA, and healthy control participants show significant differences on 
measures of: total sleep time; sleep onset latency; sleep efficiency; wake after 
sleep onset; and the percentage of time spent in each stage of sleep? 
Chapter 1: Introductory Review 
24 
 
2. Through spectral analysis, do FMS patients exhibit a significantly greater 
frequency and power of alpha-delta sleep than OA patients or healthy controls? 
 
3. Through spectral analysis, do FMS patients exhibit significant differences in the 
microstructure of sleep across the standard frequency range for sleep PSG than 
OA patients or healthy controls?  
 
4. Do FMS, OA, or healthy control participants show significant differences on 
objective (PSG and Actigraphy) and subjective (PSQI, ESS and FSS) measures 
of sleep disturbance and quality? 
 
5. Do measures of total sleep time, sleep onset latency, wake after sleep onset and 
sleep efficiency correlate between polysomnography and actigraphy across the 
groups? 
 
6. In comparisons of mean values, do FMS, OA and healthy control participants 
show differences on psychometric assessments of: pain, depression, anxiety, 
‘perceived social support’, ‘health locus of control’, ‘pain catastrophizing’ and 
personality? 
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2. Methodology 
In order to address the research objectives, set out in Chapter 1, a cross-sectional 
observational sleep study was designed to include polysomnography, actigraphy and self-
assessment. The study comprised of three parallel groups: 
1. A Fibromyalgia Syndrome (FMS) group, meeting diagnostic criteria for FMS and 
reporting significant sleep disturbance 
2. An Osteoarthritis (OA) group, which was age-matched with the FMS group, and 
included participants who did not meet FMS criteria, but who experienced night-
time chronic pain and significant sleep disturbance; and 
3. An age-matched healthy control group which included participants who were 
generally healthy, and free of any chronic pain 
Ethical approval for the study was provided by the NHS Research Ethics Service. The 
recruitment process and study procedures are fully described below. (Appendix A, NRES 
Committee North West – Greater Manchester East, REC 05/Q1402/50, 22-06-2011) 
2.1.  Participants 
2.1.1. Power Calculation 
Power for the study was calculated using the G*Power software (Faul, Erdfelder, 
Buchner, & Lang, 2009). The main outcome of the study is alpha power prevalence during 
slow wave sleep. Alpha power band dominance in FMS patients was obtained from the 
literature (Moldofsky et al., 1975), the within group standard deviation of alpha activity 
was 8.3%. If the difference between the FMS and OA control group means is 7.5%, a 
sample size of twenty participants per group will achieve 80% power confidence, at 5% 
significance level, in rejecting the null hypothesis. 
2.1.2. Eligibility 
Adult women aged 18 to 65 years of age were included in the study. All participants were 
female due to the high proportion (9:1) of females suffering from FMS. The full 
inclusion/exclusion criteria are presented below. 
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2.1.3. Participant Criteria 
Table 2.1. Inclusion criteria into the study for participants with Fibromyalgia (FMS), 
Osteoarthritis (OA) and Normal Healthy Controls (NHC) 
Group Inclusion Criteria 
FMS  Women aged between 18 and 65 years 
 Newly diagnosed with at least six-month symptom prevalence 
 Meeting the 1990 American College of Rheumatology criteria 
for FMS at the time of the study 
 Experience sleep disturbance 
OA  Women aged between 18 and 65 years 
 Current localized non-inflammatory joint pain with symptom 
prevalence of at least six-months 
 Not meeting the 1990 American College of Rheumatology 
criteria for FMS at the time of the study 
 Experiencing sleep disturbance due to pain as measured by the 
PSQI (score of >5) and a pain questionnaire 
 
NHC  Women aged between 18 and 65 years 
 In current general good health 
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Table 2.2. Exclusion criteria for recruitment into the study with Fibromyalgia, 
Osteoarthritis and Normal Healthy Controls 
Group Exclusion Criteria 
FMS  Currently receiving hormone replacement therapy (HRT) 
 Currently being prescribed psychotropic drugs, including: 
o Hypnotics 
o Tricyclic antidepressants 
o Other antidepressant drug therapy 
 History of any form of severe psychiatric illness 
(schizophrenia, depression etc.) 
 Currently/recently pregnant (12 months) 
 History of medical conditions which could mimic FMS 
symptoms, including: 
o Morbid obesity 
o Autoimmune/inflammatory diseases 
o Cardiopulmonary disorders 
OA  Currently receiving hormone replacement therapy (HRT) 
 Currently being prescribed psychotropic drugs, including: 
o Hypnotics 
o Tricyclic antidepressants 
o Other antidepressant drug therapy 
 History of any form of severe psychiatric illness 
(schizophrenia, depression etc.) 
 Currently/recently pregnant (12 months) 
 History of medical conditions which could mimic FMS 
symptoms, including: 
o Morbid obesity 
o Autoimmune/inflammatory diseases 
o Cardiopulmonary disorders 
NHC  Currently suffer from conditions or disorders that could affect 
their sleep 
 Currently exhibit chronic or acute pain. 
 Currently on medication that could affect their sleep 
 Currently receiving hormone replacement therapy (HRT) 
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 Currently being prescribed psychotropic drugs, including: 
o Hypnotics 
o Tricyclic antidepressants 
o Other antidepressant drug therapy 
 History of any form of severe psychiatric illness 
(schizophrenia, depression etc.) 
 Currently/recently pregnant (12 months) 
 
Participants who wished to take part in the study, but were taking hypnotic drugs were 
given the option of undertaking a wash-out period two weeks prior to the study; their 
condition was monitored closely by a consultant rheumatologist. If they were taking non-
steroidal anti-inflammatory drugs, a three-day washout period prior to the study was 
offered, again with clinical monitoring provided by a consultant rheumatologist. 
 All participants completed a health screening questionnaire (Appendix B) prior to 
taking part in the study.  
2.1.4. Participants 
Nineteen newly diagnosed FMS patients (M=40.74, SD=11.45), seventeen patients 
exhibiting OA symptoms (M=46.47, SD=11.61), including localized joint pain and sleep 
disturbance, and ten healthy normal controls (HNC; M=38.40, SD=13.79) from the local 
population were recruited for the study. All participants were female. The purpose of 
recruiting a HNC group was to obtain a baseline measure for EEG, actigraphy and 
psychometric data; this allows for a better comparison of results across the clinical 
sample. Age was matched at a group level rather than at an individual level. The groups 
were broadly matched by looking at the means and standard deviations during the 
recruitment process. No participants were excluded due to age mismatch. 
2.1.5. Recruitment 
The clinical participants in the FMS and OA groups were recruited from a single 
rheumatology facility based at Trafford General Hospital, Trafford, UK. They were 
recruited from August 2011 to April 2014. FMS patients were recruited through regular 
outpatient clinics. OA patients were selected and recruited through orthopaedic waiting 
lists, these included those on the list for hip, knee, and shoulder related surgeries. 
Participants in the healthy control group were recruited by advertising (Appendix C) 
through local community organisations and local employers within the East Midlands and 
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Greater Manchester areas. The healthy control group were recruited from February 2012 
to June 2014. 
2.2.  Use of NSAIDS (Non-Steroidal Anti-inflammatory Drugs) 
There are many medications which are known to affect sleep pathology and these need to 
be taken into account when recruiting participants from clinical populations. Non-
steroidal anti-inflammatory drugs (NSAIDS) such as Ibuprofen are primarily used for 
their analgesic effects and, in higher doses, for their anti-inflammatory effects. Since both 
effects are beneficial for those with painful inflammatory conditions, NSAIDS are widely 
used by patients with FMS or OA (Wolfe, Zhao, & Lane, 2000). 
Studies on the effects of NSAIDS on sleep structure and quality report mixed 
results. Gengo (2006) looked at the use of ibuprofen on healthy adults. Polysomnographic 
and subjective measures were taken. It was found that a total daily dose of 1200mg did 
not produce clinically or statistically significant alterations in night time sleep in 
comparison to a control group who received a placebo (Gengo, 2006). 
In contrast, a similar study on the effects of prostaglandin-inhibiting drugs on 
sleep including aspirin, acetaminophen and ibuprofen increased the number of 
awakenings, increased the percentage time in wake, and decreased sleep efficiency. 
Ibuprofen also appeared to delay the onset of SWS, though the effects of the NSAID 
acetaminophen on sleep did not differ significantly from the placebo group (Murphy et 
al., 1994). 
Given that the FMS and OA groups in the present study were all diagnosed 
patients receiving medical care for their conditions, it would have been impractical to 
exclude patients prescribed NSAIDS. However, two factors supported the sometimes 
unavoidable use of NSAIDS. First, the available evidence is insufficient to suggest a 
robust detrimental effect on our sleep structure and quality; and second, the use of NSAID 
drugs was considered a random (possible) effect which, in the event, would still allow 
meaningful comparisons between the FMS, OA and NHC groups. 
2.3.  Materials 
2.3.1. Monitoring Equipment 
2.3.1.1. Polysomnography (PSG) 
Digital PSG was conducted using the Embla A10 (Figure 2.1.) unit ambulatory recorder 
and Somnologica software (Flaga-Medcare Somnologica 5.1®, Flaga hf medical devices, 
Reykjavik, Iceland). The device converts analogue electrophysiological signals into 
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machine readable digital formats; these are transmitted and recorded onto a PCMCIA 
memory card.  
The recording montage consisted of a maximum of seven electrophysiological 
derivations for both nights of recordings. The basic montage included two electro-
oculographic (EOG) channels referenced to the single mastoid (LOC/A1 & ROC/A1), 
two electroencephalographic (EEG) channels referenced to each mastoid (C3/A2 & 
C4/A1), a bipolar-mentalis electromyogram (EMG), a bipolar prefrontal EEG channel 
(Pf1/F3) and a bipolar occipital EEG channel (O1/P3). EEG and EMG channels were 
sampled at 200 Hz, EOG channels were sampled at 100 Hz. Electrodes were attached in 
accordance with the 10:20 system (Figure 2.2.) of electrode placement (Jasper, 1958);  
In order to maintain amplifier inputs within a small voltage range relative to the 
amplifier’s zero voltage level, a ground (pgnd) electrode was placed on the Fpz electrode 
site, 10% above the Nasion. The electrodes used for EEG recordings were AgAgCl 
(Silver-silver chloride) cup electrodes with a 10mm diameter and 1.5m leads. EOG, EMG 
and mastoid placements used disposable wet-gel electrodes with a 1m lead and 
standardized plug (Biosense Medical, UK).  
The PSG system and montage outputs eight digital files in total that are loaded 
onto the Somnologica software for sleep scoring. Variables derived from PSG and their 
definitions are displayed in table 2.3. Variables were also derived from spectral analysis 
for the C3 channel that included the logarithmic average spectral power of sleep 
frequencies from delta up to gamma. 
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Table 2.3. Polysomnography definitions for descriptive sleep variables 
Variable Definition 
Time in Bed From ‘lights off’ to ‘lights on’ as assessed via PSG events 
Duration Beginning of sleep period to end of sleep period 
Sleep Onset Latency Time (minutes) to reach the first occurrence of stage N2 
sleep 
Sleep Efficiency Sleep efficiency referred to sleep period 
Wake After Sleep 
Onset 
Time (minutes) spent awake during sleep period 
Total Sleep Time Total amount of time spent sleeping 
Awakenings A duration of awakening during the sleep period that 
equates to 60 seconds or greater 
Arousals A duration of 3 seconds or longer where frequency band 
thresholds are exceeded 
 
Thresholds used: 
‐ Delta 0.5-4.0Hz 
‐ Theta 4.0-8.0Hz 
‐ Alpha 8.0-12.0Hz 
‐ Sigma 12.0-16.0Hz 
‐ Beta 16.0-20.0Hz 
 
Stage N1% Percentage of time (as a function of TST) spent in Stage N1 
Stage N2% Percentage of time (as a function of TST) spent in Stage N2 
Stage N3% Percentage of time (as a function of TST) spent in Stage N3 
Stage REM% Percentage of time (as a function of TST) spent in Stage 
REM 
Sleep Stage Transitions The number of transitions into or out of a sleep stage during 
the sleep period 
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Figure 2.1. Embla A10 unit (Flaga hf. Medical Devices, Reykjavik, Iceland) for ambulatory PSG monitoring 
 
 
 
Figure 2.2. An illustration of the equipment setup protocol, and the EEG montage that was used. The montage 
displayed shows seven channels which are C3-A2, C4-A1, O1-P3, Fp1-F3, EOGL-A1, EOGL-A1 and 
Electromyogram-submentalis (SMG).  
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2.3.1.2. Actigraphy 
Actigraphy was recorded using Actiwatch 2 (Figure 2.3.) devices in conjunction with 
Respironics Actiware 6 software (Philips Respironics, USA). The actiwatch was set up to 
capture two consecutive weeks of data, with monitoring beginning on the first night of 
PSG. The devices were setup to record activity and photopic light data, at epochs of 30 
seconds, for two weeks. Participants were also asked to complete a bed time diary during 
these two weeks, they were asked to complete the time they went to bed and the time they 
got up in the morning for each day; this data was used as a standardized way to calibrate 
the times on the Actiwatch device (Appendix D). For all variables obtained via actigraphy, 
the averaged data from the two-week recording were used. Photopic light data for this 
study was not utilised. 
Table 2.4. Actigraphic definitions for descriptive sleep variables as computed by 
Respironics Actiware 6 
Variable Definition 
Duration/Time in Bed Period from ‘Lights Out’ to ‘Lights On’ specified using a 
bed-time diary 
Total Sleep Time Total number of epochs (Minutes) scored as sleep during 
‘time in bed’ 
Sleep Efficiency The percentage of time spent in bed sleeping as a function 
of total time in bed 
WASO The total number of epochs scored as wake after sleep 
onset 
Sleep Onset Latency Time required for sleep to start after initiating intent to 
sleep. Controlled by the sleep interval detection algorithm 
Awakenings Total number of continuous blocks of epochs where each 
epoch is scored as wake 
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Figure 2.3. Actiwatch 2 device by Phillips Respironics, USA. The device was setup to capture 14 days of data, 
monitoring activity and photopic light using the inbuilt accelerometer. 
2.3.2. Descriptions and Properties of Psychometric Instruments 
Two questionnaire sets were given to the participants to complete; the first set focussed 
on health status and symptomatology while the second set focussed on psychological 
factors. It must be noted that NHC participants completed identical questionnaires to the 
clinical groups, except for the Fibromyalgia Impact Questionnaire. 
2.3.2.1. Fibromyalgia Impact Questionnaire (FIQ) 
The FIQ (Appendix E) is designed to measure components of health status that are most 
affected by FMS. It is composed of 10 items, with the first item comprising of 11 
questions related to physical functioning, rated on a 4 point Likert type scale from Always 
to Never or Not Applicable (scored 0-3). Item 1 is scored by summing the items and 
dividing by the number of questions answered, as patients may not be able to answer 
some of them due to inapplicability; Items 2 and 3 (labelled 12 & 13) ask the patient to 
mark the number of days, out of a maximum of seven; that they felt good; and that they 
were unable to work because of fibromyalgia symptoms respectively. Items 2 and 3 are 
scored inversely, so a lower number indicates a greater disability. Lastly items 4 to 10 
(labelled 14-20) are horizontal 100mm linear scales, marked in 10mm increments on 
which respondents can rate work difficulty, pain, fatigue, morning tiredness, stiffness, 
anxiety and depression (Burckhardt, Clark, & Bennett, 1991). The FIQ includes items 
from the Arthritis Impact Measurement Scale (AIMS) and the Health Assessment 
Questionnaire (HAQ). Each of the 10 items can achieve a maximum score of 10, thus the 
maximum score that can be obtained is 100, with higher scores indicating a greater FMS 
impact. A typical FMS patient will score around 50, severely affected patients usually 
score 70 or greater. The FIQ has been shown to have good construct validity, test-retest 
reliability and sensitivity to change (Bennett, 2005b). 
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2.3.2.2. Pittsburgh Sleep Quality Index (PSQI) 
The PSQI (Appendix E) is designed to assess sleep quality in clinical populations; it is a 
self-rated questionnaire assessing sleep quality and disturbances over the previous 1-
month period. Items assess (and deliver component scores for) subjective sleep quality, 
sleep latency, sleep duration, sleep efficiency, sleep-disturbances, use of sleeping 
medication and daytime dysfunction. It is also able to deliver a diagnostic sensitivity and 
specificity in differentiating between ‘good’ and ‘poor’ sleepers in the region of 90%, and 
was found to have good reliability and validity. The PSQI incorporates a global score, 
calculated from its component scores or subscales; the global score has a maximum 
possible score of 21; a general cut-off for the global score is 5, the lower the score is the 
better the overall quality of sleep (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). 
2.3.2.3. Epworth Sleepiness Scale (ESS) 
The ESS (Appendix E) is a measure of daytime sleepiness. Participants rate their chances 
of falling asleep (or dozing off) in eight different situations commonly encountered in 
daily life, such as when sitting and reading (Johns, 1991). For each of the eight situations, 
respondents provide ratings from 0 (would never doze) to 3 (high chance of dozing). The 
scale is scored by summing the values, thus there is a maximum possible score of 24. ESS 
scores 10 or more are considered sleepy; scores 18 or greater are indicative of a high level 
of daytime sleepiness (Johns, 1991); additionally, the ESS has been found to have a high 
level of internal consistency (Johns, 1992). 
2.3.2.4. Fatigue Severity Scale (FSS) 
The FSS (Appendix E) is a self-rated questionnaire consisting of nine statements that rate 
the severity of fatigue symptoms during the past week. Statements are rated on a scale 
from 1-7 with the lower end in disagreement, increasing to the upper end in agreement. 
It was demonstrated to have good internal consistency, reliability and validity; The FSS 
is scored by summing up the raw scores; scores of 36 or more are used as a cut-off to 
determine fatigue severity, with a greater score indicating greater amounts of fatigue 
(Krupp, LaRocca, Muir-Nash, & Steinberg, 1989). 
2.3.2.5. Brief Pain Inventory Short Version (BPI-S) 
The brief pain inventory (Appendix E) is used to assess intensity of pain and interference 
of pain in a patients’ life. It also evaluates pain relief, quality and perception of the cause 
of pain; it was first developed to assess pain dimensions in cancer patients (Cleeland & 
Ryan, 1994); however it has also been shown to be a reliable tool in pain assessment in 
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non-cancer pain patients (Keller et al., 2004). The scale produces two sub-scales of pain 
severity and pain interference and both are assessed differently. Questions 3-6 are used 
as an assessment of pain severity and comprise of a 11 point Likert type scale that ranges 
from ‘No Pain’ (0) to ‘pain as bad as you can imagine’ (10). The score is calculated by 
averaging these four items, with a greater score indicating greater pain severity.  
 Item 9 of the BPI-S is used to measure how much pain has interfered with seven 
daily activities (labelled from A-G) in the past 24 hours. These are scored on 11 point 
Likert type scales from ‘Does not interfere’ (0) to ‘Completely interferes’ (10). This sub-
scale is scored as a mean of the seven items, with a maximum score of 10 and a greater 
score indicating greater pain interference. The scale also comprises of a pain manikin for 
patients to indicate areas on the body in which they feel pain, this is useful as an extra 
tool to assess widespread versus localised pain (Keller et al., 2004) 
 The visual analogue scale for pain (under item 10 in our BPI-S) is a single item 
measure. It is a 10 point Likert type scale and was added as a simple supplementary 
assessment of pain severity (McCormack, Horne, & Sheather, 1988). 
2.3.2.6. National Institute of Health Restless Legs Screening 
Questionnaire (NIH-RLS) 
The NIH screening questionnaire for RLS (Appendix E) is a four item diagnostic 
instrument. An individual is considered to have RLS if he/she answered ‘yes’ to the first 
three items; the fourth item considers the frequency of occurrence of RLS symptoms and 
assesses the severity of the RLS (Popat et al., 2010). 
2.3.2.7. Centre for Epidemiologic Studies Depression Scale (CES-D) 
The CES-D (Appendix E) is a self-report scale designed to measure depressive symptoms 
in the general population. The items of the scale are symptoms of depression used in 
previously validated longer scales. The CES-D is a 20 item measure and rates the 
frequency participants have felt a certain way, from ‘Rarely or none of the time (less than 
1 day) to ‘Most or all of the time (5-7 days). The final scores range from 0-60, high scores 
on the CES-D indicate high levels of distress. A score of 16 or greater suggests a clinically 
significant level of psychological distress; about 20% of the general population would be 
expected to score in this range. It is shown to have very high internal consistency and 
reliability, and is deemed suitable for epidemiological studies (Radloff, 1977). 
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2.3.2.8. State and Trait Anxiety Inventory (Forms 1 and 2; STAI) 
The STAI (Appendix E) was developed to provide a reliable assessment for state and trait 
anxiety in research and clinical practice. It consists of two 20-item scales, one measuring 
the emotional state of anxiety (Form 1) and another measuring the personality trait of 
anxiety (Form 2). Items are rated on a 4-point Likert type scale in response to self-
reported feelings of anxiety ‘right now, at this moment’ and ‘generally’. Scores in each 
scale range from 20-80, with higher scores suggesting greater levels of anxiety. Low 
scores tend to suggest mild anxiety, median scores moderate anxiety and high scores 
severe anxiety (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983).  
2.3.2.9. Multidimensional Scale of Perceived Social Support (MSPSS) 
The MSPSS (Appendix E) is a validated 12-item instrument designed to assess 
perceptions about support from family, friends and significant others. The items are 
divided into factor groups related to the source of support, with scores ranging from 1 to 
7. A total score is also calculated by averaging the ratings for all 12 items. Greater scores 
are indicative of higher levels of perceived social support (Zimet, Powell, Farley, 
Werkman, & Berkoff, 1990). 
2.3.2.10. Multidimensional Health Locus of Control Scale Form C 
(MHLOC) 
MHLOC (Appendix E) was developed to assess health locus of control in the general 
population. It consists of three six-item subscales that measure internality, powerful 
others externality and chance externality. Form C however is designed to be condition 
specific and can be tailored to specific conditions such as fibromyalgia or osteoarthritis. 
Similar to forms A and B, it contains two six-item subscales measuring internality and 
chance externality, however the powerful others externality subscale is split into two 
three-item subscales (External Doctors & External Others). Each subscale item is rated 
from 1 ‘strongly disagree’ to 6 ‘strongly agree’, and the scores of each subscale are the 
sum of the rated items. For the ‘internality’ and ‘chance’ subscale, they give a possible 
score range from 6-36, with a higher score indicative of greater internality or greater 
chance externality. For the ‘doctor’ or ‘other people’ externality subscales, gives a 
possible score range from 3-18, again with a higher score indicating greater ‘doctor’ or 
‘other people’ externality (Wallston, Stein, & Smith, 1994). 
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2.3.2.11. Pain Catastrophizing Scale (PCS) 
The PCS (Appendix E) was developed to assess three components of catastrophizing 
(rumination, magnification and helplessness) in a 13 item self-rated questionnaire. Each 
item is rated on a 5-point Likert type scale from 0 (not at all) to 4 (all the time). PCS total 
score is calculated by summing responses to all 13 items, the total score can range from 
0-52; a greater score indicates a greater level of pain catastrophization; the PCS also 
incorporates three subscales, rumination (items 8-11), magnification (items 6, 7 & 13) 
and helplessness (items 1-5 & 12); these component scores are calculated by summing 
their respective items. (Sullivan, Bishop, & Pivik, 1995). 
2.3.2.12. Eysenck Personality Questionnaire (EPQ-R) 
The EPQ-R (Appendix E) is a questionnaire designed to gauge four dimensions of 
personality; Psychoticism/socialisation, extraversion/introversion, neuroticism/stability 
and a fourth Lie scale. It consists of 106 yes or no questions that are scored using a 
specialised scoring tool; Each subscale are independent of each other and higher scores 
indicate greater comparative levels of psychoticism, extraversion, neuroticism or 
propensities to lie (Eysenck & Eysenck, 1977). 
2.4.  Procedure 
Section 2.4.1. details flowcharts depicting the study sequence for each participant, from 
giving consent to study completion. There are separate diagrams for clinical patients and 
healthy controls.  
2.4.1. Clinical Patients 
 FMS and OA patients were recruited in and around the Greater Manchester area, 
either through direct referral from the rheumatology outpatient clinic (FMS) or through 
invitations sent to patients on the orthopaedic surgery waiting list (OA). Interested 
participants were sent full study details (Appendix F) to review, a researcher was 
contactable to answer any questions they may have had. Each participant was given a 24 
hour ‘cool-off’ period after being given study information to consider taking part in the 
research. 
 Once the potential participant has expressed a wish to proceed with the study, they 
were mailed a health screening form (Appendix B) with a return envelope. The screening 
form was to ensure eligibility, and was reviewed by the researcher. These include 
calculating questionnaire scores for sleep quality, pain experience and general health 
condition to ensure eligibility was met on these criteria. Once the participant met 
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eligibility, the patients were seen by a consultant rheumatologist (Trafford General 
Hospital) prior to signing consent. For FMS patients, this was to ensure they met the ACR 
1990 criteria for fibromyalgia, and for OA patients, to ensure they had localized chronic 
pain, in addition to understanding their medical history and what types of drug therapies 
these patients may be on. It was also explained to the patient that they may be asked to 
come off the medication they are on for the duration of the study period. Additionally, 
patients were assessed on whether they have any diagnosed sleep disorders (those with 
diagnosed sleep disorders, such as insomnia or sleep apnea were excluded), OSA was 
loosely assessed by evaluating whether they exhibited typical OSA characteristics (i.e. 
weight, age, self-report). 
 Once the patients were happy to take part and were accepted onto the study, the 
researcher went through the consent form (Appendix G) with them before signing. Two 
consecutive weeknights were scheduled by the researcher for the study to commence, this 
would be after taking into account any potential drug weaning off period.  
On the first night visit, the researcher visited the patients home with a secondary 
aide (rheumatology nurse) to conduct the domiciliary PSG; the patients were asked to 
complete two sets of questionnaires (Appendix E) and begin wearing the actiwatch, which 
was setup to record activity for two consecutive weeks from 1900hrs. Prior to the PSG, 
the participants were asked to refrain from taking certain drugs/medication, drinking 
coffee or alcohol, and consuming nicotine during the evening of the recording. After 
attaching EEG, EOG and SMG channels, the participant was free to move around until 
bed time; participants were instructed to press an event button every time they get into 
and out of bed. The researcher attended each morning to remove the electrodes and setup 
the machine for the next evening where this process repeated. 
Actiwatches and bed time diaries were collected 14 days after the first night of 
PSG, and the participants were verbally debriefed about the study. Each participant was 
given a full sleep report based on their PSG and Actigraphy. 
2.4.2. Healthy Controls 
 Healthy control participants were recruited through advertisements (Appendix C) 
placed in newspapers and on public notice boards in and around the Leicestershire and 
Greater Manchester area. 
 Interested participants were sent a study information sheet and a health screening 
questionnaire (Appendix B). Once a participant returned the health screening 
questionnaire, the researcher assessed their suitability for the study before confirming 
with the participant their interest in taking part. Once the participants were happy to take 
Chapter 3: Results I: Descriptive and Demographic Data 
40 
part and were accepted onto the study, the researcher went through the consent form 
(Appendix G) with them before signing. Two consecutive weeknights were scheduled by 
the researcher for the study to commence. 
On the first night visit, the researcher visited the patients home with a secondary 
aide (rheumatology nurse/trained sleep researcher) to conduct the domiciliary PSG; the 
patients were asked to complete two sets of questionnaires (Appendix E) and begin 
wearing the actiwatch, which was setup to record activity for two consecutive weeks from 
1900hrs. Prior to the PSG, the participants were asked to refrain from taking certain 
drugs/medication, drinking coffee or alcohol, and consuming nicotine during the evening 
of the recording. After attaching EEG, EOG and SMG channels, the participant was free 
to move around until bed time; participants were instructed to press an event button every 
time they get into and out of bed. The researcher attended each morning to remove the 
electrodes and setup the machine for the next evening where this process repeated. 
Actiwatches and bed time diaries were collected 14 days after the first night of 
PSG, and the participants were verbally debriefed about the study. Each participant was 
given a full sleep report based on their PSG and Actigraphy. 
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2.4.3. Data Collection Flow Charts 
2.4.3.1. Clinical Patients 
 
   Patient given study information 24-hour ‘cool off’ period 
Is participant 
interested? 
YES NO Thank for their interest 
Complete health 
screening questionnaire 
Is patient 
eligible? 
NO Indicate reason on 
screening log 
YES 
Patient seen by 
consultant 
rheumatologist 
Does patient 
require drug 
washout? 
YES 
Drug washout period 
Signed informed consent 
NO 
Home visit 1: 
Psychometric battery, 
actigraphy day 1, PSG 
monitoring night 1 
Home visit 2: PSG 
monitoring night 2 
14 day actigraphy 
monitoring ends & 
participant debriefed 
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2.4.3.2. Healthy Controls 
 
   
Participant given study 
information 24-hour ‘cool off’ period 
Is participant 
interested? 
YES NO Thank for their interest 
Complete health 
screening questionnaire 
Is participant 
eligible? 
NO Indicate reason on 
screening log 
YES 
Signed informed consent 
Home visit 1: 
Psychometric battery, 
actigraphy day 1, PSG 
monitoring night 1 
Home visit 2: PSG 
monitoring night 2 
14 day actigraphy 
monitoring ends & 
participant debriefed 
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2.5.  Preparation of equipment for sleep recording 
2.5.1. Polysomnography 
The Embla A10 unit utilises two lithium batteries. These were charged each night prior 
to the recording using standard Sony chargers. Each participant recording was setup using 
Somnologica and anonymised to a participant identification number. Sampling rates, gain 
factors and band pass filter settings were calibrated. The unit digitises data onto a 
PCMCIA memory card, which is inserted into the machine and connected to the battery 
pack. The machine is connected to a power isolation unit which feeds into the computer 
using a serial data connection (Figure 1.2.). Each night’s recording was set to begin 
recording at 2000 hours and end the next morning at 0900 hours. The impedance of each 
channel was ascertained during the electrode wiring up process using a standard Embla 
model impedance meter. All channels were reduced to 10kΩs or less to decrease the risk 
of noise in the traces. 
2.5.2. Actiwatch 
Each actiwatch was charged the night prior to the first PSG recording using an Actiwatch 
Docking Station (Philips Respironics). Using the Actiware software, each participant 
recording was setup and anonymised according to the participant identification number. 
The devices were setup to record continuously 30 second epochs of activity and photopic 
light from 1900 hours on the first night for fourteen consecutive days. 
2.6.  Electrode attachment and removal 
Electrode sites were measured using a tape measure according to the standardised 10-20 
system of electrode placement (Jasper, 1958). Each site is marked with a Chinagraph 
pencil which is water soluble. A special abrasive paste (Lemonprep) was then used to 
gently clean the skin before EEG scalp electrodes were attached with EC2 (Grass 
Technologies) paste.  The paste is designed to completely fill the cup of the electrode 
providing both adhesive and conductive properties. A square piece of gauze material is 
then placed over the electrode to secure it and finally a small piece of microporous tape 
to ensure the electrode does not become dislodged. Other electrodes including EOG, 
EMG, ground and Mastoid are attached by cleaning each area gently with the same light 
abrasive paste and attached using the adhesive gel on each ‘wet-gel electrode’. These are 
then secured using a small piece of microporous tape. Inter-electrode impedance was 
reduced to 10kΩ, checked using an impedance meter. 
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The electrode leads were subsequently connected to the ‘Embla A10’ unit ready 
for recording. To prevent electrode wires from tangling during the night and for the 
comfort of the participant, all wires were secured using a protective sleeve. The Embla 
unit included a strap so that the participant can carry the machine around comfortably 
prior to sleeping.  
The electrodes are removed by detaching the leads from the Embla unit and warm 
water applied to each electrode site, slowly peeling each electrode off the scalp and face. 
2.7.  Data Management 
2.7.1. Polysomnography 
The Embla A10 (Flaga-Medcare Somnologica 5® software, Flaga hf medical devices, 
Reykjavik, Iceland) digitizes each channel/trace into a separate file. The file formats used 
are EBM for each channel used and EBE for event markers (e.g. event button presses). 
Each night’s recording resulted in eight files in total (one EBE and seven EBM files). 
EEG and EOG traces were high pass filtered at 0.3 Hz and low pass filtered at 30 Hz. The 
EMG trace was high pass filtered at 10 Hz and low pass filtered at 70 Hz. 
2.7.1.1. Sleep Scoring 
PSG sleep scoring was only performed for the second night of PSG monitoring. Each 
night of data was imported into Somnologica 5.1., each were viewed and scored on a 
computer monitor with a minimum resolution of 1600 x 1200 as per AASM 
recommendations. Each night was scored in 30-s epochs by a trained sleep researcher 
using the AASM criteria defined by Silber and colleagues (2007) (Silber et al., 2007). 
Arousals were computed automatically by the system; the sensitivity of detection was 
calibrated to be in accordance with AASM defined criteria; this is an abrupt shift in 
frequency lasting for at least 3 seconds with 10 seconds of stable sleep preceding. 
Arousals from 20% of participant recordings were scored visually to ensure reliability of 
the auto-scorer.  
For concordance in sleep staging, each night of data was divided into quartiles; 
each quartile was subsequently divided equally into 15 minute segments; a random 15-
minute segment from each quartile was then scored by an independent secondary rater. 
Inter-rater concordance was then calculated based on each 15-minute segment. All sleep 
recordings met the 83% concordance guideline (Rosenberg & Van Hout, 2013). 
The beginning of sleep scoring was determined by ‘lights out’ time. This was 
achieved by an event button that the participant depressed when going to sleep and ends 
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when the button was depressed at wake time. This protocol was also used for the 
definition of the values of: sleep onset latency; wake after sleep onset; sleep efficiency; 
and total sleep time. For participants who failed/forgot to press the event marker button, 
values from their bedtime diary was used for lights out and lights on. 
Sleep onset latency is defined as the period it takes from ‘lights out’ to the first 
two epochs of uninterrupted stage N2 sleep.  
2.7.1.2. Spindle Analysis 
Analysis of spindle morphology was carried out by using spectral power density in the 
bands associated with spindle frequency (14-20Hz). Averaged spectral power has been 
shown to be the most robust method of analysing spindles as opposed to other methods 
(Knoblauch, Martens, Wirz-Justice, & Cajochen, 2003). 
2.7.1.3. Spectral Analysis 
C3-A2, C4-A1, fp1-F3 and O1-P3 channels were available for spectral analysis, this was 
conducted using open source software written in the python programming language 
(avg_q, Feige). Sleep staging events from Somnologica were exported into a text file for 
each night of sleep; the RAW (ebm) EEG and event files were then imported into the 
avg_q software and processed. Spectral analysis was performed after demeaning, 
detrending and applying a Welch taper to each single FFT window. Each analysis window 
equates to 512 points (2.56 seconds) long, giving a frequency resolution of 1/2.56 = 
0.39Hz. 23 overlapping windows cover each 30s epoch. An artefact rejection algorithm 
was also used to discard outlier epochs from the computation of average spectral power. 
Each frequency band (delta, theta, alpha, sigma, beta, and gamma) was decomposed and 
power averaged over the whole night of sleep. Frequency bands were also separated into 
sleep stages N2, N3 and REM and cycles per night (for cycle per cycle analysis). Sleep 
cycles are defined as the beginning of the REM period and ending when the subsequent 
REM period begins (thus naturally the first cycle of sleep will not include a REM period). 
Due to NREM sleep intruding into REM at particular time points, a NREM period of 15 
minutes or greater must be present before that REM period should end (Merica & 
Gaillard, 1986). Following standard practice, the natural logarithmic transformations for 
all power bands were computed (log[e]^x where x is log of the value) in order to 
normalise (Gaussian) the distribution for multivariate analyses.  
 For the analysis, only the second night of PSG data was analysed. Additionally, 
the C3-A2 channel was selected for spectral analysis as it was deemed to produce the 
most robust signal, the traces were separated into frequency bins of Total (0.1-48Hz), 
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Delta-1 (0.1-1Hz), Delta-2 (1-3.5Hz), Theta (3.5-8Hz), Alpha (8-12Hz), Sigma-1 (12-
14Hz), Sigma-2 (14-16Hz), Beta-1 (16-24Hz), Beta-2 (24-32Hz) and Gamma (32-48Hz). 
 For inferential analyses, non-parametric Kruskall Wallis rank test was employed 
to investigate group differences in each powerband, over the whole night and also during 
the first three cycles of sleep. To investigate specific group differences, multiple Mann-
Whitney comparisons were used with Bonferroni corrections applied. 
2.7.2. Actigraphy 
Actiware 6 software (Philips Respironics) was used to automatically calculate rest 
intervals. Total time in bed was determined by entering bed time and wake time from the 
sleep diaries.  
2.7.3. Psychometrics 
The questionnaires were scored in accordance with author instructions. Questionnaire 
data were analysed using IBM SPSS ver. 22. 
2.8.  Data Analyses 
All data were entered into IBM SPSS ver. 22. All variables underwent a standard data 
cleaning procedure to ensure variables were of the correct range and entered correctly 
into the dataset. All data were deemed to have been entered correctly at the time of 
analysis. 
2.8.1.  Missing Data 
Pattern analysis was applied to all outcome variables and cases to explore possible areas 
of missing data (250 variables in total). The analysis indicated that 24.50% of variables, 
19.57% of cases and 0.794% of values either contained missing data or are missing (figure 
2.4). The data appeared to show no distinct pattern of missing data (figure 2.5), thus the 
values were deemed missing completely at random with no monotonicity observed. 
Additionally, the most common pattern indicated no missing data (figure 2.6). 
Due to the data showing no observation of monotonicity and data missing at 
random, in addition, the missing values were at less than 1% it was deemed not necessary 
to employ replacement methods such as imputation; the missing values have a low 
probability of affecting the final outcome. Moreover, the missing values/variables did not 
constitute a part of the main outcome set. Figures 2.4-2.6 illustrate summaries of missing 
values. 
 
Chapter 3: Results I: Descriptive and Demographic Data 
47 
  
Figure 2.4. Summary of missing variables sorted by variables missing, cases missing and values missing. The green 
shade depicts percentage missing. 
 Figure 2.5. Missing pattern chart, with Y axis indicating the pattern, and X axis indicating the variable. The red 
blocks indicate missing data, and the white indicate not missing. This chart shows no distinct pattern to the missing 
data and no monotonicity. 
 
 Figure 2.6. Histogram showing the most common pattern of missing data, with the Y axis indicating percentage of 
cases following each pattern along the X axis. The most common pattern is no missing data (1). 
 
Chapter 3: Results I: Descriptive and Demographic Data 
48 
2.8.2. Outliers 
Potential outliers in the data were checked using the ‘outlier labelling rule’ as identified 
by Tukey (Tukey, 1977). The rule is based on taking the difference between the 25th and 
75th percentile of values for each variable and multiplying by a factor of 2.2 (Hoaglin & 
Iglewicz, 1987). The result is either added to the 75th percentile value or removed from 
the 25th percentile value. The resulting upper and lower bound values can be used to 
explore potential values that fall outside this range and therefore determine whether 
outliers are present.  
There were no distinct outliers found that would affect the final outcome of the 
analyses, thus all values were included in the final analysis. 
2.8.3. Statistical Analysis 
Inferential statistics were used to compare mean differences between FMS, OA and NHC 
participants in order to answer the research questions. All assumptions of data were 
checked for each inferential statistic used. These are described in more detail throughout 
each results chapter.  
2.8.3.1. Data Assumptions 
All dependent variables analysed are assumed to be at the interval level. They are also 
assumed to be of a normal distribution. To test for normality, Z scores were calculated to 
determine if the data are skewed or kurtotic, this was conducted by dividing the skewness 
and kurtosis by their respective standard errors; if the Z score is greater than ±1.96 it 
would be deemed non-normal. Although analysis of variance (ANOVA) is relatively 
robust to non-normal distributions, certain situations such as platykurtosis may negatively 
affect the outcome and inflate the Type I error rate significantly. In situations such as this, 
log transformations were attempted to normalise the data.  
In situations where transformations are not practical (e.g. for the spectral analysis 
data), non-parametric tests were used instead (e.g. Kruskall-Wallis; Mann-Whitney) to 
compare the groups. Alpha is set at 5%, in cases where multiple comparisons are made, 
a Bonferroni correction was applied to the alpha level. 
Homogeneity of variance was ascertained using the Levene’s F test. For situations 
where unequal variances were found, the Welch’s F statistic was used instead, omitting 
the need for equal variances, additionally, post-hoc comparisons were conducted with a 
Games-Howell correction for multiple comparisons. Partial Eta squared expresses the 
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amount of variance that is accounted for by each specific variable; it is used as an effect 
size index in all parametric multivariate analyses. 
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3. Results I: Descriptive and Demographic Data 
3.1.  Participants 
A total of 20 FMS patients were approached for the study, one FMS patient was excluded 
as they displayed atypical FMS characteristics. 19 FMS participants were recruited into 
the study; all met the ACR 1990 criteria for fibromyalgia (general widespread pain, and 
11/18 tender points), and ages ranged from 19 to 58. The total FIQ score indicated that 
the FMS impact on their day to day functioning was moderate to severe (M=65.91, 
SD=16.03). FMS patients were newly diagnosed (mean=5 months; range=3-12 months) 
with a symptom prevalence of 6.4 years. None of the FMS patients were taking NSAIDS 
and one patient was required to have a two-week drug washout. 
A total of 54 OA patients showed interest, 16 dropped out/failed to respond, and 
21 were excluded due to ineligibility. 17 patients with OA were recruited into the study. 
Their age ranged from 19 to 63, these patients were on a waiting list for various 
orthopaedic surgeries including knee, hip and shoulder operations. OA patients were 
diagnosed using radiography by orthopaedic surgeons at Trafford General Hospital. OA 
diagnosis was within a 1-year time period (mean=6.53 months; range=4-11 months). 
None of the OA patients were taking NSAIDS and none were required to have a drug 
washout period. 
Ten healthy controls were recruited into the study to act as a baseline measure. 
Their age ranged from 23 to 61, they were recruited from the community in and around 
the Leicestershire, and Greater Manchester areas. All participants met the inclusion 
criteria for the study. 
3.1.1.  Participant Characteristics 
Table 3.1. Demographic characteristics of fibromyalgia, osteoarthritis and healthy 
control participants 
 FMS M ± SD (n) OA M ± SD (n) NHC M ± SD (n) 
Age 40.74 ± 11.45 (19) 46.47 ± 11.61 (17) 38.40 ± 13.79 (10) 
BMI 26.72 ± 6.93 (15)* 30.20 ± 5.12 (17)** 23.04 ± 2.73 (10) 
*Missing data; ** OA significantly greater BMI than NHC, p<.01; FMS, fibromyalgia syndrome; OA, osteoarthritis; NHC, normal 
healthy controls. 
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There are no significant differences between the groups in terms of age (p=n.s.). 
However, patients with osteoarthritis had a significantly greater BMI than normal healthy 
controls (p=.008). 
Table 3.2 displays percentages on marital status, ethnicity, employment and 
education for the three participant groups. These give a general overview of the groups. 
As the values were not imperative for the study, no further statistical analyses were 
conducted for this. It may be of worth to note that the majority of the participants were of 
Caucasian ethnicity. In addition, the majority of the healthy control group come from an 
educated background as opposed to the clinical groups. It should also be noted that shift 
workers were only in the FMS group, however there should be no difficult implications, 
as participants were monitored on consecutive days in which they were not working, 
although there should be some caution when approaching the results. 
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Table 3.2. Demographic percentages in participants with fibromyalgia, osteoarthritis 
and normal healthy controls 
 FMS (n=19) OA (n=17) NHC (n=10) 
Marital Status (%)    
    
Single 21.1 29.4 20 
Married 42.1 47.1 40 
Cohabiting 15.8 5.9 30 
Separated 10.5 11.8 0 
Divorced 10.5 11.8 10 
Widowed 0 5.9 0 
    
Ethnicity (%)    
    
Caucasian 89.5 94.1 60 
Chinese 0 0 20 
Black 5.3 0 0 
Asian 5.3 0 20 
Mixed 0 5.9 0 
    
Employment (%)    
    
Day Time Work 42.1 41.2 70 
Shift Work Inc. Nights 15.8 0 0 
Shift Work Day 0 29.4 10 
Unemployed/Retired 42.1 29.4 20 
    
Education (%)    
    
No Formal Qualification 21.1 11.8 0 
Degree 26.3 17.6 20 
O-Level or GCSE Equiv. 26.3 35.3 10 
Postgrad 5.3 11.8 40 
As/A Level 15.8 11.8 20 
Vocational 5.3 11.8 10 
 
3.2.  Pain Scores 
Pain was assessed using the Brief Pain Inventory and a 10-point visual analogue scale; 
their means and standard deviations are displayed in table 3.3. One-way independent 
analysis of variance was conducted on all three variables of pain severity, pain 
interference and on the visual analogue scale. The results of the ANOVAs are displayed 
in table 3.3. In some cases, where homogeneity of variance was not met, a Welch’s F test 
was used instead, this is denoted in table 3.3.  
For the Brief Pain Index’s subscale of pain severity, normality was checked for 
each group looking at the skewness and kurtosis in the scores. To determine normality, 
either skewness or kurtosis scores were divided by its standard error, if the result is greater 
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than ±1.96, it would be deemed non-normal. Fibromyalgia (Skew=1.74; Kurt=0.17) and 
osteoarthritis (Skew=0.64; Kurt=-0.70) groups were deemed to be normally distributed, 
however NHCs were found to be positively skewed (4.60) and leptokurtotic (7.50). As 
the analysis of variance is relatively robust to non-normal distributions, it was not deemed 
necessary for data transformations. In this case, Levene’s F test for homogeneity of 
variance was not met (F=7.28, p=.002), thus the Welch’s F statistic was used instead. 
Table 3.3 displays the result of the test, a significant difference between the three groups 
was found (p<.001). 
 Post-hoc comparisons were conducted using the Games-Howell to correct for 
multiple comparisons, for a more reserved analysis from use of the Welch’s F. FMS and 
OA groups were found to be significantly different to NHC with a mean difference of 
6.07 and 4.83 respectively (p<.001). Comparisons between FMS and OA were found to 
not be significantly different (p=n.s.). Our clinical groups were thus shown to have similar 
levels of pain severity. 
For the second subscale of the BPI (pain interference), FMS (Skew=0.21; Kurt=-
0.41) and OA (Skew=0.35; Kurt=-0.35) were normally distributed, NHC were again 
found to be positively skewed (4.60) and leptokurtic (7.50). Unequal variances were also 
assumed in this case due to significant difference in variance between means (F=8.09, 
p=.001), thus Welch’s F was used. An overall significant difference was observed within 
the groups (p<.001). Post-hoc analysis using Games-Howell correction found a 
significant difference between the clinical groups and the healthy control group with a 
mean difference of 6.29 and 4.53 for FMS and OA respectively (p<.001). There were no 
differences observed between FMS and OA (p=n.s.), implying similar levels of pain 
interference for both groups. 
The 10-point visual analogue scale for pain indicated normality for FMS 
(Skew=0.12; Kurt=-1.08) and OA (Skew=-0.56; Kurt=-0.89), but positive skew (4.60) 
and leptokurtic (7.50) for NHC. Levene’s indicated unequal variances (F=11.31, p<.001), 
thus Welch’s F was used. An overall significant difference was observed (p<.001). Post-
hoc comparisons with Games-Howell correction found a significant difference between 
the clinical groups and NHC group with mean differences of 7.46 and 5.93 for FMS and 
OA respectively (p<.001). No difference was observed between FMS and OA (p=n.s.).  
Overall, pain measures have suggested that our clinical groups are statistically equal in 
terms of pain severity, pain interference and on a 10-point visual analogue scale. In turn, 
they are all significantly different to our pain free NHC group. However, the means 
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displayed in table 3.3. Show a trend of FMS participants exhibiting a greater pain 
experience followed by OA and lastly NHC. Figure 3.1. Highlights the differences in pain 
experience visually. Appendix H shows the pain manikins provided by the BPI for our 
three groups; with FMS showing widespread pain, OA localised pain and NHC showing 
no pain. 
Table 3.3. Pain characteristics of fibromyalgia, osteoarthritis and healthy control 
participants 
 FMS M 
± SD (n) 
OA M ± 
SD (n) 
NHC M 
± SD (n) 
F df p ηp2 
BPI-S1 6.17 ± 
1.75 
(19) 
4.93 ± 
2.01 
(17) 
0.10 ± 
0.32 
(10) 
144.098† 2, 24.62 .000*** .674 
BPI-I2 6.30 ± 
2.04 
(19) 
4.55 ± 
2.43 
(17) 
0.01 ± 
0.04 
(10) 
116.103† 2, 22.62 .000*** .606 
VAS3 7.56 ± 
1.74 
(16)* 
6.03 ± 
2.85 
(17) 
0.10 ± 
0.32 
(10) 
166.268† 2, 22.06 .000*** .672 
1. Brief Pain Inventory – Pain Severity, 2. Brief Pain Inventory – Pain Interference, 3. Visual Analogue Scale for Pain; *N=16 due 
to missing data; ***p<.001; † - Welch’s F Statistic; 
 Figure 3.1. Bar chart comparing pain scores in fibromyalgia, osteoarthritis and healthy control participants. The Y-
axis depicts the mean scores in visual analogue scale, pain interference and pain severity. Standard error bars are 
shown for each group. *p<.001 
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3.3.  Subjective Sleep Characteristics 
Sleep characteristics were measured using the PSQI, ESS and FSS, measuring subjective 
sleep quality, sleepiness and fatigue, three of the most common sleep complaints in 
patients with FMS. Table 3.4. Displays the means and standard deviations of these 
variables in all three groups. One way independent ANOVAs were conducted to 
investigate group differences in these three variables.  
 Sleep quality was measured using the PSQI, table 3.4 displays the global sleep 
score produced with the PSQI. A higher score indicates poorer sleep quality, and a score 
greater than five, an indicator for clinical sleep dysfunction. Normality tests indicated that 
FMS (Skew=-1.06; Kurt=0.34), OA (Skew=0.04; Kurt=-1.26) and NHC (Skew=-0.50; 
Kurt=-0.92) were normally distributed. Levene’s test indicated unequal variances 
between means (F=4.87, p=.012), thus a Welch’s F was used for inferential analysis 
(Table 3.4.). An overall significant effect was found (p<.001). Post-hoc analysis with a 
Games-Howell correction observed a significant difference between the clinical groups 
and the healthy control group, with mean differences of 10.19 and 7.18 for FMS and OA 
respectively (p<.001). Between FMS and OA, a significant difference was observed with 
a mean difference of 3.01 (p=.023). 
 Sleepiness was measured using the Epworth Sleepiness Scale. Tests for normality 
indicated FMS (Skew=-0.38; Kurt=0.11), OA (Skew=1.47; Kurt=-0.74) and NHC 
(Skew=1.25; Kurt=0.45) were normally distributed. Levene’s test for equality of variance 
indicated that the means were of equal variances (F=.507, p>.05). One-way ANOVA 
showed an overall significant main effect (p=.011). Post-hoc comparisons with a 
Bonferroni correction applied found that FMS had a significantly greater sleepiness score 
than both OA and NHC participants with mean difference of 3.42 (p=.033) and 3.99 
(p=.034) respectively. No difference was observed between OA and NHC (p=n.s.). 
 Fatigue was assessed using the Fatigue Severity Scale. FMS (Skew=-1.24; 
Kurt=1.02), OA (Skew=0.98; Kurt=0.07) and NHC (Skew=0.85; Kurt=0.16) were shown 
to be normally distributed. Levene’s test indicated equal variances between the groups 
(F=1.569, p>.05). One-way ANOVA showed a significant main effect (p<.001). Post-
hoc comparisons with a Bonferroni correction applied found that FMS participants had 
significantly greater fatigue than OA (M diff=14.41, p<.001) and NHC (M diff=29.87, 
p<.001); in turn, OA also exhibited significantly greater fatigue than the NHC group (M 
diff=15.46, p<.001).  
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 Measures of sleep characteristics in these three groups have presented a consistent 
trend in the means, of the greatest score achieved by FMS participants, followed by OA, 
and then NHC. Inferential analyses also indicated consistently that the FMS group have 
significantly worse sleep quality, greater sleepiness, and greater fatigue than the NHC 
and OA groups. 
Table 3.4. Subjective sleep characteristics of fibromyalgia, osteoarthritis and healthy 
control participants. 
 FMS M 
± SD 
(19) 
OA M ± 
SD (17) 
NHC M 
± SD 
(10) 
F df p η2 
PSQI1 13.89 ± 
3.40 
10.88 ± 
3.08 
3.70 ± 
1.16 
89.225† 2, 28.15 .000*** .648 
ESS2 9.89 ± 
4.54 
6.47 ± 
3.20 
5.90 ± 
3.45 
4.998 2, 43 .011* .189 
FSS3 52.47 ± 
6.74 
38.06 ± 
10.57 
22.60 ± 
10.91 
35.238 2, 43 .000*** .621 
1. Pittsburgh Sleep Quality Index Global Score, 2. Epworth Sleepiness Scale, 3. Fatigue Severity Scale; ***p<.001, *p<.05; † 
Welch’s F Statistic; 
 
 
 Figure 3.2. Bar chart comparing subjective sleep scores in fibromyalgia, osteoarthritis and healthy control 
participants. The Y-axis depicts the mean scores in the Global PSQI, Epworth Sleepiness Scale and Fatigue Severity 
Scale. Standard error bars are shown. **p<.001; *p<.05; 
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4. Results II: Sleep Comparisons 
In this chapter, subjective and objective sleep is compared across all three participant 
groups including fibromyalgia, osteoarthritis and healthy control groups. Subjectively, 
sleep is compared in overall sleep quality using the PSQI and its subscales; sleepiness is 
compared using the Epworth Sleepiness Scale; and daytime fatigue is measured using the 
Fatigue Severity Scale. It should be noted, although some of this data was already 
presented previously in Chapter 3, the present analysis takes a more in depth look at the 
PSQI and its subscales and its relationships/differences within our sample groups. 
 Sleep was objectively measured using both polysomnography and actigraphy to 
investigate differences between groups on various sleep variables (TST, WASO, S.E., 
SOL etc.). Where actigraphy was recorded over a two-week period, it allowed a general 
overview of the participants’ sleep, in addition, recording throughout the day using 
actigraphy, allowed an insight into general activity levels and measures of circadian 
rhythm.  
 In order to answer the main hypothesis regarding the microstructure of sleep, the 
polysomnography data was processed using spectral analysis to determine the amplitude 
differences in certain frequency bins and during certain stages of sleep or certain cycles 
of over one night of sleep. 
4.1.  Subjective Sleep Variables 
Table 4.1. Displays means and standard deviations of subjective sleep variables including 
the PSQI, ESS and FSS. Looking at the means, on the outset, there appeared to be a trend 
of FMS patients having a worse mean score across all the scales, followed by OA patients 
and lastly healthy control participants. This is true for all subscales of the PSQI apart from 
sleep onset latency. 
4.1.1. PSQI 
One way independent ANOVAs were conducted between the three groups on all PSQI 
subscales, sleepiness and fatigue.  
4.1.1.1. Sleep Duration 
For sleep duration (PSQI-A; Total Sleep Time), normality tests indicated that FMS 
(Skew=-1.27; Kurt=-0.92), OA (Skew=0.15; Kurt=-1.05) and NHC (Skew=1.51; Kurt=-
0.92) were normally distributed.  
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Levene’s test showed non-equal variances between groups (F=3.51, p=.039), 
accordingly a Welch’s F statistic was used (Table 4.1). An overall significant effect was 
observed (p<.001). Post-hoc comparisons with a Games-Howell correction found 
significant effects between the clinical groups and the healthy control group, with mean 
differences of 1.65 (p<.001) and 1.11 (p=.003) for FMS and OA respectively. No 
significant differences between FMS and OA were observed (p=n.s.).  
4.1.1.2. Sleep Disturbance 
For the sleep disturbance subscale, in normality tests, FMS (Skew=2.95; Kurt=0.41) and 
OA (Skew=-2.49; Kurt=-0.14) were both skewed positively and negatively respectively. 
In addition, the NHC group had 0 variance for this subscale. 
 Levene’s test additionally observed unequal variances between the groups 
(F=10.552, p<.001). Due to the NHC group observing zero variance, it was not possible 
to calculate a Welch’s F statistic thus the standard between groups ANOVA was used 
instead. An overall significant effect was found between the groups (p<.001). Post-hoc 
comparisons with a Bonferroni correction found significant differences between the 
clinical groups and NHC, with mean differences of 1.21 (p<.001) and .76 (p<.001) for 
FMS and OA respectively. FMS was also shown to have a greater sleep disturbance than 
OA, with a mean difference of .45 (p=.003). This indicates a significantly greater sleep 
disturbance for both clinical groups as opposed to the NHC group, additionally a greater 
sleep disturbance in FMS patients as opposed to OA. 
4.1.1.3. Sleep Onset Latency 
The sleep onset latency subscale measured the time participants think it takes for them to 
fall asleep. In normality tests, FMS (Skew=-0.43; Kurt=-1.91) although slightly 
negatively skewed and platykurtotic, falls within the range for normally distributed data. 
For OA (Skew=2.44; Kurt=-2.44) and NHC (Skew=2.13; Kurt=2.71), both were found 
to be skewed and kurtotic.  
Levene’s test found equal variances amongst the groups (F=1.449, p>.05). In the 
one-way independent ANOVA, an overall significant effect was observed (p=.001). Post-
hoc comparisons with Bonferroni correction found a significant difference between the 
clinical groups and the NHCs, with a mean difference of 1.21 (p=.004) and 1.39 (p=.001) 
for FMS and OA respectively. No difference was observed between FMS and OA 
(p=n.s.). 
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4.1.1.4. Daytime Dysfunction 
For the PSQI daytime dysfunction subscale, FMS (Skew=0.40; Kurt=-0.65) and NHC 
(Skew=0; Kurt=-1.93) were normally distributed; however, the OA group (Skew=2.49; 
Kurt=-0.14) were positively skewed.  
Levene’s test indicated equal variances among the groups (F=1.526, p>.05). An 
overall significant effect was found between the three groups (p<.001). Post-hoc 
comparisons with Bonferroni corrections found significant differences between the 
clinical groups and NHC with mean differences of 1.34 (p<.05) and .74 (p=.007) for FMS 
and OA respectively. There was also a significant difference found between FMS and OA 
with a mean difference of .61 (p=.008). FMS patients are shown to have a greater daytime 
dysfunction due to sleep than OA, both of which are greater than NHC. 
4.1.1.5. Sleep Efficiency 
For the sleep efficiency subscale, a greater score indicates poorer sleep efficiency. FMS 
(Skew=-1.86; Kurt =-0.38), OA (Skew=-0.23; Kurt=-1.30) and NHC (Skew=1.51; Kurt=-
0.92) were all normally distributed.  
Levene’s test indicated unequal variances between groups (F=5.291, p=.009), 
thus the Welch’s F was used. An overall significant effect was found (p<.001). Post-hoc 
comparisons with a Games-Howell correction found significant differences between the 
clinical groups and the NHC, with mean differences of 1.96 (p<.001) and 1.46 (p=.001) 
for FMS and OA respectively. There were no differences observed between FMS and OA 
(p=n.s.).  
4.1.1.6. Overall Sleep Quality 
The subscale measuring overall sleep quality was not normally distributed for FMS 
(Skew=-3.24; Kurt=1.69) or NHC (Skew=-2.59; Kurt=1.05); OA group met a normal 
distribution (Skew=-0.29; Kurt=-0.63).  
Levene’s test indicated equal variances (F=1.162, p>.05). One-way ANOVA 
showed an overall effect between the groups (p<.001). Post-hoc analysis with a 
Bonferroni correction found the clinical groups had significantly worse overall sleep 
quality than NHC participants with mean differences of 1.83 (p<.001) and 1.32 (p<.001) 
for FMS and OA respectively. FMS and OA showed no significant differences (p=n.s.).  
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4.1.1.7. Use of Medication for Sleep 
Lastly the final subscale of the PSQI is whether the participants utilized somnolence 
aids/medication. FMS (Skew=2.16; Kurt=-0.37) and OA (Skew=4.56; Kurt=5.39) were 
found to be non-normal, with positive skew and kurtosis. The NHC group appeared to 
have no variance in their data, which is expected.  
Levene’s test indicated unequal variances (F=11.393, p>.05), however due to the 
NHC group lacking variance in their data, a Welch alternative could not be run, it was 
thus decided to employ the standard ANOVA statistic. The overall results indicated no 
significant differences between the groups (p=n.s.).  
4.1.1.8. PSQI Global Score 
The PSQI outputs a global sleep score for each participant. A higher score indicates 
poorer sleep quality, and a score greater than five, an indicator for clinical sleep 
dysfunction. Normality tests indicated that FMS (Skew=-1.06; Kurt=0.34), OA 
(Skew=0.04; Kurt=-1.26) and NHC (Skew=-0.50; Kurt=-0.92) were normally distributed. 
 Levene’s test indicated unequal variances between means (F=4.87, p=.012), thus 
a Welch’s F was used for inferential analysis. An overall significant effect was found 
(p<.001). Post-hoc analysis with a Games-Howell correction observed a significant 
difference between the clinical groups and the healthy control group, with mean 
differences of 10.19 and 7.18 for FMS and OA respectively (p<.001). Between FMS and 
OA, a significant difference was observed with a mean difference of 3.01 (p=.023). 
4.1.2. Epworth Sleepiness Scale 
Sleepiness was measured using the Epworth Sleepiness Scale. Tests for normality 
indicated FMS (Skew=-0.38; Kurt=0.11), OA (Skew=1.47; Kurt=-0.74) and NHC 
(Skew=1.25; Kurt=0.45) were normally distributed.  
Levene’s test for equality of variance indicated that the means were of equal 
variances (F=.507, p>.05). One-way ANOVA showed an overall significant main effect 
(p=.011). Post-hoc comparisons with a Bonferroni correction applied found that FMS had 
a significantly greater sleepiness score than both OA and NHC participants with mean 
difference of 3.42 (p=.033) and 3.99 (p=0.34) respectively. No difference was observed 
between OA and NHC (p=n.s.). 
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4.1.3. Fatigue Severity Scale 
Fatigue was assessed using the Fatigue Severity Scale. FMS (Skew=-1.24; Kurt=1.02), 
OA (Skew=0.98; Kurt=0.07) and NHC (Skew=0.85; Kurt=0.16) were shown to be 
normally distributed.  
Levene’s test indicated equal variances between the groups (F=1.569, p>.05). 
One-way ANOVA showed a significant main effect (p<.001). Post-hoc comparisons with 
a Bonferroni correction applied found that FMS participants had significantly greater 
fatigue than OA (M diff=14.41, p<.001) and NHC (M diff=29.87, p<.001); in turn, OA 
also exhibited significantly greater fatigue than the NHC group (M diff=15.46, p<.001).  
4.1.4. Sleep variables as calculated from PSQI 
4.1.4.1. Sleep Efficiency Percentage 
Percentage sleep efficiency was also calculated from the PSQI measure (Table 4.1) using 
the following equation ௐ௔௞௘	்௜௠௘்௢௧௔௟	்௜௠௘	௜௡	஻௘ௗ ∗ 100 . This is not to be confused with the sleep 
efficiency subscale which is part of the overall PSQI score. FMS (Skew=-0.48; Kurt=-
1.18) and NHC (Skew=-0.51; Kurt=1.05) were normally distributed, however OAs 
(Skew=-2.09; Kurt=2.06) were negatively skewed and leptokurtotic.  
Levene’s test indicated unequal variances (F=5.568, p=.007); overall, a 
significant effect between the groups were found (p<.001). Post-hoc comparisons with a 
Games-Howell correction found the clinical groups to have significantly less sleep 
efficiency than NHC with mean differences of 30.41 (p<.001) and 19.74 (p=.010) for 
FMS and OA respectively. No differences were observed between FMS and OA (p=n.s.). 
Overall sleep efficiency was worse in the clinical groups compared to NHC. FMS and 
OA exhibited similar levels of sleep efficiency. 
4.1.4.2. Total Sleep Time 
For subjective total sleep time as measured by PSQI, normality scores indicated a normal 
distribution for all three groups FMS (Skew=-0.23; Kurt=-0.86), OA (Skew=1.05; Kurt=-
0.05) and NHC (Skew=-0.05; Kurt=-0.98).  
Levene’s test indicated a similar difference in variance between means (F=3.040, 
p=.058). From the outset, the clinical groups had a much lower TST as compared to NHC, 
with FMS having the least amount of perceived sleep. Multivariate analysis indicated an 
overall significant difference within the group (Table 4.1). Post-hoc analysis with 
Bonferroni corrections found that FMS patients have a significantly lower amount of self-
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reported TST than NHC participants (Mdiff=138.32, p<.001). However, no differences 
were observed between FMS and OA (Mdiff=66.32, p=.062) or OA and NHC 
(Mdiff=72.00, p=.103). 
4.1.4.3. Time in Bed 
Measures of total time in bed taken as the difference between subjective bed time and 
wake time also indicated a normal distribution of scores for FMS (Skew=-0.20; 
Kurt=0.26), OA (Skew=0.51; Kurt=-1.08) and NHC (Skew=0.64; Kurt=0.29).  
Levene’s test found a significant difference in variance within the groups 
(F=3.040, p=.015) thus a Welch’s F was used for test robustness. The outset suggested a 
greater amount of time spent in bed for the clinical patients compared to the healthy 
controls, however the analysis did not find a significant effect between them. 
4.1.4.4. Sleep Onset Latency 
Subjective sleep onset latency found a slightly skewed distribution for FMS patients 
(Skew=2.79; Kurt=0.96), a skewed and kurtotic distribution for OA (Skew=6.83; 
Kurt=13.92) and a normal distribution for NHC (Skew=1.09; Kurt=-0.22).  
Levene’s test found a significant difference in variance within the groups 
(F=4.456, p=.017) thus a Welch’s F was used. The outset suggested a much longer 
perceived sleep onset latency for the clinical patients as compared to the healthy control 
group. Post-hoc analysis with a Games-Howell correction found a significantly greater 
self-reported sleep onset latency in FMS patients as compared to NHC (Mdiff=54.90, 
p=.010). Although no significant differences were found between FMS and OA 
(Mdiff=15.41, p=n.s.) or OA and NHC (Mdiff=39.49, p=n.s.). 
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Table 4.1. Subjective sleep characteristics of fibromyalgia, osteoarthritis and healthy 
control participants 
 FMS M ± SD (19) OA M ± SD (17) NHC M ± SD (10) F df p η2 
        
PSQI-A1 1.95 ± 1.13 1.41 ± 1.06 0.30 ± 0.48 17.409† 2, 28.59 .000*** .292 
PSQI-B2 2.21 ± 0.42 1.76 ± 0.44 1.00 ± 0.00 9.609 2, 43 .000*** .607 
PSQI-C3 2.11 ± 0.94 2.29 ± 0.85 0.90 ± 0.88 13.433 2, 43 .001** .282 
PSQI-D4 1.84 ± 0.69 1.24 ± 0.44 0.50 ± 0.53 12.024 2, 43 .000*** .461 
PSQI-E5 2.26 ± 0.99 1.76 ± 1.09 0.30 ± 0.48 29.229† 2, 28.42 .000*** .397 
PSQI-F.6 2.63 ± 0.68 2.12 ± 0.70 0.80 ± 0.42 22.127 2, 43 .000*** .554 
PSQI-G7 0.79 ± 1.18 0.35 ± 0.86 0.00 ± 0.00 4.373 2, 43 .091 .106 
        
PSQI8 13.89 ± 3.40 10.88 ± 3.08 3.70 ± 1.16 89.225† 2, 28.15 .000*** .648 
ESS9 9.89 ± 4.54 6.47 ± 3.20 5.90 ± 3.45 4.998 2, 43 .011* .189 
FSS10 52.47 ± 6.74 38.06 ± 10.57 22.60 ± 10.91 35.238 2, 43 .000*** .621 
        
PSQI-S.E.11 59.13 ± 20.22 69.80 ± 13.95 89.54 ± 7.24 22.810† 2, 28.66 .000*** .356 
PSQI-TST12 293.68 ± 94.12 360.00 ± 88.74 432.00 ± 31.46 9.427 2, 43 .000*** .305 
PSQI-TIB13 505.89 ± 66.06 521.47 ± 94.15 484.50 ± 43.49 1.116† 2, 27.27 .342 .035 
PSQI-SOL14 66.50 ± 71.98 51.09 ± 66.00 11.60 ± 7.05 8.038† 2, 23.40 .002*** .108 
1. PSQI Sleep Duration, 2. PSQI Sleep Disturbance, 3. PSQI Sleep Onset Latency, 4. PSQI Daytime Dysfunction, 5. PSQI Sleep 
Efficiency, 6. PSQI Sleep Quality, 7. PSQI Medication for Sleep, 8. PSQI Global Sleep Score, 9. Epworth Sleepiness Scale, 10. 
Fatigue Severity Scale, 11. PSQI Percentage Sleep Efficiency, 12. PSQI Total Sleep Time (Minutes), 13. PSQI Time in Bed (Minutes), 
14. PSQI Sleep Onset Latency; *p<.05, **p<.01, ***p<.001; †Welch’s F;  
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 Figure 4.1. Bar chart comparing subjective sleep scores in fibromyalgia, osteoarthritis and healthy control participants. 
The Y-axis depicts the mean scores in all subscales of the PSQI. The X-axis depicts each subscale of the PSQI. Standard 
error bars are displayed. 
 
 Figure 4.2. Plot of means comparing subjectively assessed sleep efficiency percentages in fibromyalgia, osteoarthritis 
and healthy control participants. The Y-axis depicts the mean sleep efficiency percentage as calculated from the PSQI. 
Standard error bars are shown for each observation. 
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Figure 4.3. Plot of means comparing subjectively assessed total sleep time and total time in bed in fibromyalgia, 
osteoarthritis and healthy control participants. The Y-axis depicts the time in minutes. Standard error bars are shown 
for each observation. 
4.2.  Actigraphy and Polysomnography Comparisons 
Objective measurements of sleep were compared using a correlational analysis applied to 
the sleep variables between actigraphy and polysomnography data. This was done to 
observe the differences or similarities between a single night of monitoring versus a two-
week period of observation. Assumptions for parametric analysis was met prior to 
running a ‘Pearson’s Product Moment Correlation’ and this was applied to variables TST, 
SOL, WASO and S.E. across the whole group. Table 4.2. Summarizes results from the 
Pearson’s correlation, it shows significant correlations between all variables apart from 
‘Total Sleep Time’. Due to the more accurate nature of determining sleep onset time and 
wake time via PSG, it was deemed that a weaker correlation with ‘Total Sleep Time’ was 
due to the downsides of the actigraphic methodology. Figures 4.4-4.8 display graphically, 
the relationships between these variables. 
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Table 4.2. Pearson’s correlations between sleep variables in polysomnography and 
actigraphy across the whole group. 
Variable 
(N=43) 
TST (ACT) SOL (ACT) WASO (ACT) S.E. (ACT) 
TST (PSG) .223 (p=.151)    
SOL (PSG)  .502 
(p=.001)** 
  
WASO (PSG)   .314 (p=.040)*  
S.E. (PSG)    .310 (p=.043)* 
TST=Total Sleep Time; SOL=Sleep Onset Latency; WASO=Wake after Sleep Onset; S.E. =Sleep Efficiency; ACT=Actigraphy; 
PSG=Polysomnography; **significant at the .001 level; *significant at the .05 level; 
 Figure 4.4. Scatter plot comparing PSG total sleep time on the X-axis to actigraphy total sleep time on the Y-axis. 
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Figure 4.5. Scatter plot comparing PSG sleep onset latency on the X-axis to actigraphy sleep onset latency on the Y-
axis. 
 Figure 4.6. Scatter plot comparing PSG wake after sleep onset on the X-axis to actigraphy wake after sleep onset on 
the Y-axis. 
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Figure 4.7. Scatter plot comparing PSG sleep efficiency on the X-axis to actigraphy sleep efficiency on the Y-axis. 
 
 
Figure 4.8. Bar chart depicting total sleep time and total time in bed using actigraphy between fibromyalgia, 
osteoarthritis and healthy control participants. Standard error bars are shown. 
   
360
380
400
420
440
460
480
500
TST TIB
FIBROMYALGIA OSTEOARTHRITIS HEALTHY CONTROLS
Chapter 4: Results II: Sleep Comparisons 
69 
4.3.  Objective Sleep Variables 
4.3.1. Actigraphy Scores 
Actigraphy was conducted on all participants for a two-week period. 3 actiwatches 
exhibited recording failure during data collection (1 FMS & 2 OA), thus their actigraphy 
data could not be used for analysis. The mean values across the two-week period were 
used for all further actigraphic analyses (n size: FMS=18; OA=15; NHC=10). Table 4.4 
displays the means and standard deviations of sleep variables from actigraphy parameters 
between the three groups. In the FMS group there was one actiwatch failure, and in the 
OA group there were two actiwatch failures; this brought the groups sizes to 18:15:10 for 
FMS, OA and NHC respectively.   
Looking at the distribution of these scores, in variables sleep duration, sleep 
efficiency and total sleep time, all three groups were normally distributed. However, in 
sleep onset latency, wake after sleep onset and total sleep time, the OA group had a 
positive skew distribution (Table 4.3.). 
Tests for homogeneity of variance indicated that all variables were of equal 
variance between the three groups. This included sleep duration (F=3.103), sleep onset 
latency (F=2.453), sleep efficiency (F=2.454), wake after sleep onset (F=.029), total 
sleep time (F=2.082) and awakenings (F=.493) which were all significantly greater than 
the alpha level (p>.05) 
Table 4.3. Skewness and Kurtosis Z scores for actigraphic sleep variables in 
fibromyalgia, osteoarthritis and healthy control participants 
 FMS 
Skew 
n=18 
FMS 
Kurt 
n=18 
OA 
Skew 
n=15 
OA 
Kurt 
n=15 
NHC 
Skew 
n=10 
NHC 
Kurt 
n=10 
Duration1 ‐0.56 ‐0.18 ‐1.72 0.51 ‐1.79 1.04 
SOL2 1.59 ‐0.18 2.06* 0.33 1.17 0.44 
Efficiency3 ‐0.04 1.28 ‐1.90 ‐0.20 ‐1.18 0.31 
WASO4 0.29 ‐1.20 2.77* 1.62 1.36 0.09 
TST5 ‐0.92 0.16 ‐1.48 0.28 ‐1.52 0.14 
Awakenings6 1.09 ‐0.71 2.43* 1.72 ‐0.49 ‐0.02 
1. Sleep Duration, 2. Sleep Onset Latency, 3. Sleep Efficiency Percentage, 4. Wake after Sleep Onset, 5. Total Sleep Time, 6. 
Awakenings; *Z>±1.96; 
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One way independent ANOVAs were run on each variable comparing the means 
between the groups. Overall none of the variables were found to be significantly different 
between the groups (Duration; SOL; Efficiency; WASO; TST; Awakenings). However, 
it is beneficial to note that the standard deviations are relatively high for each of the 
parameters. Figures 4.9 to 4.11 display graphically, the mean values for each group and 
variable. 
Table 4.4. Actigraphic sleep profiles of fibromyalgia, osteoarthritis and healthy 
control participants 
 FMS (M 
± SD) 
n=18 
OA (M ± 
SD) 
n=15 
NHC (M 
± SD) 
n=10 
F p η2 
Duration1 468.29 ± 
56.63 
459.43 ± 
37.16 
457.69 ± 
27.67 
.247 .783 .012 
SOL2 26.65 ± 
13.62 
30.41 ± 
19.60 
22.14 ± 
10.28 
.885 .421 .042 
Efficiency3 80.06 ± 
4.54 
78.32 ± 
10.41 
81.40 ± 
9.67 
.118 .889 .006 
WASO4 61.01 ± 
20.18 
66.24 ± 
46.10 
53.94 ± 
37.75 
.154 .857 .008 
TST5 407.26 ± 
57.12 
393.19 ± 
49.56 
403.75 ± 
40.87 
.153 .859 .008 
Awakenings6 33.03 ± 
9.89 
31.12 ± 
8.79 
32.66 ± 
8.71 
.214 .809 .011 
1. Sleep Duration, 2. Sleep Onset Latency, 3. Sleep Efficiency Percentage, 4. Wake after Sleep Onset, 5. Total Sleep Time, 6. 
Awakenings 
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Figure 4.9. Bar graph depicting sleep onset latency and wake after sleep onset using actigraphy between fibromyalgia, 
osteoarthritis and healthy control participants. 
 
Figure 4.10. Plot of means depicting sleep efficiency measured using actigraphy between fibromyalgia, osteoarthritis 
and healthy control participants. Includes standard error bars for each observation. 
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Figure 4.11. Plot of means depicting awakenings measured using actigraphy between fibromyalgia, osteoarthritis and 
healthy control participants. Includes standard error bars for each observation. 
4.3.2. Polysomnography Sleep Variables 
For PSG measured sleep variables including TST, SOL, WASO and S.E. one way 
independent ANOVAs were run to compare the three groups. Normality and equality of 
variance scores are displayed in Table 4.5. All variables met the homogeneity of variance 
assumption. 
Table 4.5. Skewness and Kurtosis Z scores and Levene’s test for PSG sleep variables 
in fibromyalgia, osteoarthritis and healthy control participants  
 FMS 
Skew 
n=19 
FMS 
Kurt 
n=19 
OA 
Skew 
n=17 
OA 
Kurt 
n=17 
NHC 
Skew 
n=10 
NHC 
Kurt 
n=10 
Levene’s 
F, p 
TST1 ‐0.38 ‐0.78 1.02 ‐0.51 ‐1.15 0.18 2.78, n.s. 
SOL2 1.75 0.17 2.30* 1.97* 3.40* 4.65* 0.77, n.s. 
S.E.3 ‐1.98* ‐0.09 ‐0.47 ‐0.74 ‐0.54 ‐0.77 2.67, n.s. 
WASO4 1.73 ‐0.12 1.59 0.43 3.06* 3.40* 1.42, n.s. 
1. Total Sleep Time, 2. Sleep Onset Latency, 3. Wake after Sleep Onset, 4. Sleep Efficiency; *Z>±1.96; 
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Table 4.6 displays the polysomnography results for total sleep time, sleep onset latency, 
wake after sleep onset and sleep efficiency. No significant differences between the three 
groups were found, except for sleep efficiency, which showed a statistically significant 
difference in sleep efficiency within the three groups (p=0.25). 
Post-hoc comparisons with a Bonferroni correction showed that the fibromyalgia 
group were less sleep efficient compared to healthy controls (Mdiff=7.22, p=.028). 
However, no significant differences were observed between OA and NHC, or with FMS 
and OA. These results are demonstrated graphically in figures 4.12 to 4.15. 
Table 4.6. Polysomnographic sleep variables in fibromyalgia, osteoarthritis and 
healthy control participants 
 FMS (M 
± SD) 
n=19 
OA (M ± 
SD) 
n=17 
NHC (M 
± SD) 
n=10 
F p η2 
TST1 431.26 ± 
84.61 
407.18 ± 
56.18 
429.40 ± 
46.71 
.639 .533 .029 
SOL2 29.76 ± 
16.18 
32.47 ± 
23.80 
24.55 ± 
24.20 
.447 .643 .020 
WASO3 47.16 ± 
32.75 
38.29 ± 
25.34 
24.10 ± 
24.15 
2.156 .128 .091 
S.E. 4 85.22 ± 
7.74 
86.08 ± 
6.98 
92.44 ± 
3.61 
4.032 .025* .158 
1. Total Sleep Time, 2. Sleep Onset Latency, 3. Wake after Sleep Onset, 4. Sleep Efficiency; *p<.05; 
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 Figure 4.12. Plot of means depicting total sleep time measured using polysomnography between fibromyalgia, 
osteoarthritis and healthy control participants. Includes standard error bars for each observation. 
 
 
Figure 4.13. Bar chart depicting sleep onset latency and wake after sleep onset as measured using polysomnography 
between fibromyalgia, osteoarthritis and healthy control participants. Standard error bars are displayed. 
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Figure 4.14. Plot of means depicting sleep efficiency as measured using polysomnography between fibromyalgia, 
osteoarthritis and healthy control participants. Includes standard error bars for each observation. 
 
 
Figure 4.15. Plot of means depicting number of awakenings as measured using polysomnography between 
fibromyalgia, osteoarthritis and healthy control participants. Includes standard error bars for each observation. 
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4.3.3. Sleep Staging and Awakenings 
The amount each group spent in each sleep stage was compared across the three groups. 
In addition, the number of sleep stage transitions, awakenings and arousals were also 
compared; these are utilised as measures of sleep fragmentation or sleep continuity. The 
results of the PSG data are displayed in table 4.8. Analysis of normality and homogeneity 
of variance are displayed in table 4.7. All variables met the assumption of equality of 
variance. 
Table 4.7. Skewness and Kurtosis Z scores and Levene’s test for PSG sleep staging 
variables in fibromyalgia, osteoarthritis and healthy control participants  
 FMS 
Skew 
n=19 
FMS 
Kurt 
n=19 
OA 
Skew 
n=17 
OA 
Kurt 
n=17 
NHC 
Skew 
n=10 
NHC 
Kurt 
n=10 
Levene’s 
F, p 
N11 4.26* 5.72* 2.45* 1.28 4.36* 6.91* 1.83, n.s. 
N22 1.25 ‐0.37 ‐0.47 ‐0.31 0.55 ‐0.42 1.92, n.s. 
N33 ‐1.40 0.05 2.21* 1.39 0.85 ‐0.13 1.08, n.s. 
REM4 ‐0.85 ‐0.41 0.27 ‐0.44 0.60 ‐0.24 0.87, n.s. 
SST5 0.91 ‐0.17 2.32* 1.75 1.64 0.53 1.21, n.s. 
SST PH6 0.22 ‐0.60 1.22 0.30 0.93 0.42 2.94, n.s. 
Awakenings7 4.54* 7.98* 0.95 ‐0.59 1.08 ‐0.51 0.22, n.s. 
Awakening-I8 2.57* 3.75* 0.05 ‐1.30 0.71 ‐0.81 0.55, n.s. 
Arousals9 3.38* 4.28* 2.92* 1.82 1.25 ‐0.71 0.57, n.s. 
Arousal-I10 4.44* 7.18* 3.29* 3.19* 1.17 ‐0.76 0.85, n.s. 
1. Non-REM Stage 1, 2. Non-REM Stage 2, 3. Non-REM Stage 3, 4. REM Stage, 5. Sleep Stage Transitions, 6. Sleep Stage 
Transitions per Hour of Sleep, 7. Number of Awakenings, 8. Awakening Index, 9. Number of Arousals, 10. Arousal Index; 
*Z>±1.96; 
Overall, no significant differences in sleep staging were observed between the 
groups, apart from sleep stage transitions, a useful indicator for sleep fragmentation. This 
was shown to be particularly significant, when evaluated per hour of sleep. Observing the 
mean values, there was a numerical difference between the clinical groups and the healthy 
control group, which also had a large standard deviation. The figures 4.15 and 4.16 help 
visualise the mean values for these variables.  
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Post-hoc comparisons with a Bonferroni correction for multiple comparisons 
found, for sleep stage transitions a significantly greater number of SST for FMS compared 
to NHC (Mdiff=42.49, p=.043); a significantly greater number of SST for OA compared 
to NHC (Mdiff=46.99, p=.025); however, no differences between the clinical groups 
(p=n.s.). For SST per hour of sleep, a similar finding where FMS had greater SSTPH than 
NHC (Mdiff=4.52, p=.032); in addition to a greater SSTPH for OA compared to NHC 
(Mdiff=6.57, p=.001); and lastly no significant difference between FMS and OA (p=n.s.). 
Overall, the groups had no significant differences between major sleep staging 
variables, however the sleep of the clinical groups appeared to be more fragmented (See 
Hypnograms [Appendix I]) than healthy controls via the measure of sleep stage 
transitions. 
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Table 4.8. Polysomnographic sleep variables in fibromyalgia, osteoarthritis and 
healthy control participants 
 FMS (M 
± SD) 
n=19 
OA (M ± 
SD) 
n=17 
NHC (M 
± SD) 
n=10 
F p η2 
NREM11 2.15 ± 
2.25 
2.56 ± 
2.13 
4.32 ± 
5.88 
1.449 .246 .063 
NREM22 47.73 ± 
12.33 
46.51 ± 
7.84 
46.52 ± 
9.06 
.080 .924 .004 
NREM33 26.41 ± 
10.98 
28.99 ± 
8.69 
23.52 ± 
8.40 
1.030 .366 .046 
REM4 23.72 ± 
3.37 
21.94 ± 
4.58 
25.63 ± 
4.51 
2.612 .085 .108 
SST5 119.79 ± 
46.50 
124.29 ± 
46.13 
77.30 ± 
24.06 
4.334 .019* .168 
SST PH6 14.69 ± 
4.06 
16.74 ± 
5.34 
10.17 ± 
2.42 
7.297 .002** .253 
Awakenings7 14.58 ± 
7.89 
14.71 ± 
6.56 
10.10 ± 
5.04 
1.703 .194 .073 
Awakening-I8 2.03 ± 
0.90 
2.15 ± 
0.85 
1.40 ± 
0.64 
2.748 .075 .113 
Arousals9 148.58 ± 
131.46 
125.71 ± 
127.35 
104.90 ± 
75.88 
.454 .638 .021 
Arousal-I10 20.04 ± 
18.32 
18.74 ± 
19.40 
14.28 ± 
9.57 
.371 .692 .017 
1. Non-REM Stage 1, 2. Non-REM Stage 2, 3. Non-REM Stage 3, 4. REM Stage, 5. Sleep Stage Transitions, 6. Sleep Stage 
Transitions per Hour of Sleep, 7. Number of Awakenings, 8. Awakening Index, 9. Number of Arousals, 10. Arousal Index; *p<.05; 
**p<.01; 
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 Figure 4.16. Bar chart depicting percentage of time spent in each stage of sleep as measured using polysomnography 
between fibromyalgia, osteoarthritis and healthy control participants.  
 
 Figure 4.17. Plot of means depicting number of sleep stage transitions as measured using polysomnography between 
fibromyalgia, osteoarthritis and healthy control participants. Includes standard error bars for each observation. 
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4.4.  Subjective and Objective Differences in Sleep Variables 
Differences in subjective and objective measures of total sleep time, sleep onset latency 
and sleep efficiency were examined. Paired samples t-tests were run on each group to 
observe differences between PSQI assessed TST, SOL and SE, and PSG assessed TST, 
SOL and SE. Table 4.7 displays the results. The results indicated that the clinical groups 
significantly underestimated the amount of sleep they had, and no significant differences 
were found in the NHC group. No differences in SOL perception were observed. In 
addition, a significant difference was also observed in subjective reports of sleep 
efficiency vs objectively measured sleep efficiency, where the clinical groups reported a 
much lower sleep efficiency (as calculated from the PSQI) than was objectively recorded 
(via PSG) vs the NHC group. Figures 4.18-4.20 display graphically the difference in 
subjective and objective scores. 
Table 4.9. T-Test results looking at differences between subjective and objective 
scores for FMS, OA and NHC in TST, SOL and SE 
 FMS (n=19) OA (n=17) NHC (n=10) 
 t df p t df p t df p 
TST1 -5.28 18 .000** -2.15 16 .047* .282 9 n.s. 
SOL2 2.06 18 .055 1.14 16 n.s. -1.68 9 n.s. 
SE3 -5.72 18 .000** -4.73 16 .000** -1.44 9 n.s. 
1. Subjective vs Objective Total Sleep Time, 2. Subjective vs Objective Sleep Onset Latency, 3. Subjective vs Objective Sleep 
Efficiency Percentage; *p<.05; **p<.001; 
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Figure 4.18. Plot of means comparing subjective and objective total sleep time as measured using the PSQI and 
polysomnography. Shows data for fibromyalgia, osteoarthritis and healthy control participants. Includes standard error 
bars for each observation. *p<.05 **p<.001; 
 
 
Figure 4.19. Plot of means comparing subjective and objective sleep onset latency as measured using the PSQI and 
polysomnography. Shows data for fibromyalgia, osteoarthritis and healthy control participants. Includes standard error 
bars for each observation. 
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Figure 4.20. Plot of means comparing subjective and objective sleep efficiency as measured using the PSQI and 
polysomnography. Shows data for fibromyalgia, osteoarthritis and healthy control participants. Includes standard error 
bars for each observation. **p<.001; 
 
Looking at these results, to further compare the significant findings in the clinical groups, 
differences in subjective vs objectively recorded TST and SE were calculated. The results 
were then compared between the clinical groups. For TST, an independent samples t-test 
(with assumed equality of variance) found that the FMS (M=-137.58±113.68) group had 
a greater discrepancy than OA (M=-47.18±90.45) in self-reported total sleep time [t (34) 
=-2.62, p=.013)] where they reported a significantly lower TST than the OA group.  
 For sleep efficiency, no differences between the FMS group (M=-26.09±19.87) or 
OA group (M=-16.28±14.20) were found [t (34) =1.685, p=n.s.)]. Figure 4.21 displays 
graphically the differences in TST and SE difference scores. 
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Figure 4.21. Plot of means comparing the subjective and objective difference values for total sleep time and sleep 
efficiency between fibromyalgia and osteoarthritis. Includes standard error bars for each observation. *p<.05; 
4.5.  Spectral Analysis  
The aim of spectral analysis for the PSG data from the three groups was to investigate the 
microstructure of sleep in FMS patients. Not only to answer the primary hypothesis of 
‘do patients exhibit a greater alpha power in delta wave sleep’ but also to explore other 
areas of sleep structure in these patient groups. One of which is looking at the higher 
frequency ranges such as sigma, which can be used as a robust indicator of sleep spindle 
activity (Knoblauch et al., 2003). 
 The following data represents findings obtained from the C3-A2 channel from the 
second night of PSG recording. The second night was used as a way for the 
patient/participant to adjust to sleeping with the PSG, thus giving a more reliable reading. 
The C3-A2 channel was opted for, as that was what appeared to be the most robust, with 
the least amount of noise.  
 Tables 4.10 to 4.13 display the means and standard deviations of logarithmic 
averaged absolute spectral power in their individual frequency bands with a range from 
0.1Hz to 48Hz. These are values that are separated in terms of sleep stages and also in 
terms of cycles per night for the first three cycles. Table 4.9 shows data across the whole 
night of sleep; Table 4.11 to 4.13 are data from cycles 1-3.  
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4.5.1. Whole Night Sleep Analysis 
4.5.1.1. Comparisons for NREM Merged 
Looking at the full night of sleep (Table 4.10), on the outset, gradients where the greatest 
absolute power was observed for the FMS group, followed by OA and lastly NHC having 
the lowest spectral power, were observed for the alpha (8-12Hz), sigma-2 (14-16Hz) and 
beta-1 (16-24Hz) frequency. During NREM sleep no significant differences were 
observed between the three groups for absolute power other than sigma-2, this was also 
true for N2 sleep separated. Post-hoc analysis with Bonferroni corrections for multiple 
comparisons were conducted using the Mann-Whitney U test. During NREM merged, no 
significant differences were found between FMS and OA (U=150.00, p=n.s.). No 
significant differences were found between FMS and NHC (U=53.00, p=n.s.). However, 
the OA group had significantly greater sigma-2 power than the NHC group (U=33.00, 
p=0.003). 
4.5.1.2. Comparisons for N2 
For the whole of N2, a similar gradient observation was made for alpha, sigma-2 and 
beta-1. However, sigma-2 was the only significant variable. After post-hoc analysis for 
sigma-2, no significant differences were observed for FMS compared to OA (U=146.00, 
p=n.s.) and FMS compared to NHC (U=50.00, p=n.s.); however, the statistic showed a 
significant difference prior to corrections for multiple comparisons, which may indicate 
a need for further data to increase the power statistic. Lastly OA were found to have a 
significantly greater sigma-2 power than NHC (U=35.00, p=.033). 
4.5.1.3. Comparisons for N3 & REM 
During N3 slow wave sleep, significant differences were observed between the groups in 
terms of total absolute power, delta-1 (0.1-1Hz) and sigma-2 (14-16Hz). Post-hoc 
analysis for total absolute power (0.1-48Hz range) in N3 showed no significant 
differences between FMS and OA groups (U=108.00, p=n.s.) or FMS and NHC 
(U=80.00, p=n.s.). However, OA had significantly lower total absolute power than the 
NHC group (U=37.00, p=.045).  
For delta-1, no differences were observed between FMS and OA (U=95.00, 
p=n.s.), but may be worth to note a significant effect prior to corrections for multiple 
comparisons. FMS and NHC groups also showed no significant differences (U=69.00, 
p=n.s.). Nevertheless, a significant difference was observed between OA and NHC group 
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(U=25.00, p=.006) where the OA group had significantly lower delta-1 power than the 
healthy control group. 
Lastly sigma-2 showed no differences between FMS and OA (U=158.00, p=n.s.) 
or FMS and NHC (U=49.00, p=n.s. [sig. prior to bf. correction]). OA patients had 
significantly greater sigma-2 power than the NHC group (U=37.00, p=.045). 
 REM sleep showed no differences in absolute power between any of the groups. 
4.5.2. Comparisons per Sleep Cycle Analysis 
Differences in absolute power spectra were analysed for the first three cycles of sleep to 
determine any differences between the three groups.  
4.5.2.1. Cycle 1 
For the first cycle of sleep (Table 4.11), no differences in absolute power spectra across 
the 0.1-48Hz frequency range for either NREM, N2 or N3 were observed. However, the 
same gradients were observed for alpha and sigma-2 with the greatest amount of absolute 
power in FMS, then OA and lowest being NHC. The same was true for alpha, sigma-2 
and beta-2 in N2. REM was not reported for cycle 1 due to the method by which we 
conducted cycle analysis. 
4.5.2.2. Cycle 2 
For the second cycle of sleep (Table 4.12), no significant differences in absolute power 
spectra were observed for NREM merged, N2 or REM. However similar gradients were 
observed for the alpha frequency for NREM merged, N2 and N3, where FMS had the 
greatest power, followed by OA and the lowest being the NHC group. During N3, 
significant mean differences were observed for total averaged power and also delta-1. 
Post-hoc comparisons for total averaged power found no differences between FMS and 
OA (U=95.00, p=n.s.) or FMS and NHC (U=61.00, p=n.s.). OA patients had a 
significantly lower total averaged power than NHC (U=24.00, p=.012). Comparisons for 
delta-1 found a significantly lower power in OA patients as compared to FMS patients 
(U=77.00, p=.033), and NHC participants (U=13.00, p<.001). No differences were 
observed between FMS and NHC group (U=51.00, p=n.s.). 
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4.5.2.3. Cycle 3 
4.5.2.3.1. Comparisons for NREM Merged 
Significant differences in sigma-2 were found for the whole period of NREM sleep during 
cycle 3 (Table 4.13). Gradient trends were observed for alpha and sigma-2. Post-hoc 
comparisons found no significant differences between FMS and OA (U=151.00, p=n.s.) 
or NHC (U=48.00, p=n.s. [although FMS had significantly greater power prior to multiple 
comparison corrections]). OA had a significantly greater sigma-2 power than NHC 
(U=29.00, p=.012).  
4.5.2.3.2. Comparisons for N2 
For N2, significant differences were observed in the delta-1 and sigma-2 frequency. 
Similar gradient trends were observed for alpha and beta-2. Post-hoc comparisons for 
delta-1 found no differences between FMS and OA (U=112.00, p=n.s.) or NHC 
(U=57.00, p=n.s.). OA patients had significantly lower delta-1 power than NHC 
(U=36.00, p=.039). For sigma-2, no differences were observed between FMS and OA 
(U=160.00, p=n.s.) or NHC (U=45.00, p=n.s. [although FMS had significantly greater 
sigma-2 power prior to corrections for multiple comparisons]). OA patients had a 
significantly greater sigma-2 power than NHC participants (U=23.00, p=.003). 
4.5.2.3.3. Comparisons for N3 and REM 
For NREM 3, no significant differences were observed across the frequency bands apart 
from delta-1 where the clinical groups appear to have lower delta power than the NHC 
group. The same gradient trends are observed for sigma-2. Post-hoc analysis for delta-1 
showed no significant differences between FMS and OA (U=132.00, p=n.s.), or NHC 
(U=50.00, p=n.s.). OA patients were found to have significantly lower delta-1 power than 
NHC (U=25.00, p=.006). Lastly, no significant differences were observed during the 
REM period for cycle 3 of sleep. 
4.5.3. Fast Frequency Sleep Interruptions 
4.5.3.1. Comparisons for Alpha Wave activity 
In relation to alpha wave activity during slow wave sleep, no significant differences were 
observed between the three groups. However, there was a trend towards an increase in 
alpha power in FMS patients compared with OA and both clinical groups had a 
numerically greater alpha power than healthy controls. This was true for averaged spectral 
power for N3 across the whole night (Table 4.10; Figure 4.22). The alpha power during 
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SWS in FMS was 3.19±1.03 compared with OA 2.92±0.60 and the healthy control group 
2.66±0.35. Although there appears to be greater variability in the FMS patients. Looking 
at this effect cycle by cycle, the effect is strongest during cycle 2 of sleep, with cycles 1 
and 3 not showing a clear difference between the clinical groups, although the clinical 
groups have shown a stronger power in alpha frequency consistently throughout the 
cycles as compared to the healthy control group. This may indicate a likely effect of pain 
on sleep restoration.  
 In addition to slow wave sleep, numerically, alpha power was generally stronger 
in FMS patients, with OA having the second greatest alpha power and the lowest being 
NHC. This is observed to be true for both NREM as a whole, and N2 separated, in 
addition to sleep cycles 1, 2 and 3 (Figure 4.22).  
4.5.3.2. Comparisons for Sigma-2 (14-16Hz) 
The averaged power in the sigma-2 variable were found to have significant group 
differences at certain periods of the night. The activity shown in the sigma-2 falls within 
possible spindle activity in the range of 11-16 Hz.  During the whole period of sleep, there 
were differences observed in NREM sleep, N2 and N3 separated. There appeared to be 
the greatest numerically observed power in the FMS group, followed by OA and lowest 
being the NHC group. However only the OA group appeared to have a significantly 
greater amount of sigma-2 power than the NHC group for all three sleep stage groupings. 
This was due to the greater variability of sleep in FMS patients.  
During cycle 1 of sleep, the same mean trends can be observed, the strongest 
difference seen during N2, however during N3, FMS had a lower sigma-2 power than OA 
patients. Although during cycle 1, no objective differences were found between the three 
groups. Cycle 2 showed similar results, with cycle 3 showing the strongest differences in 
the three groups. During this period, again it was found that the OA group had 
significantly greater sigma-2 power than the NHC group with no differences found for 
the FMS group. This may further imply the sigma-2 intrusions are perhaps solely a 
function/result of chronic pain. 
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4.5.4. Comparisons for Delta (Slow Wave Activity) 
During periods of the night, the groups showed significant differences in slow wave 
activity in the delta-1 range (0.1-1 Hz), where the OA group appeared to have 
significantly lower delta-1 power than FMS and NHC groups during N3. This was found 
to be true for averaged power across the whole night where the OA group had lower delta-
1 power than the healthy control group. During cycle 2 of sleep, OA were found to have 
significantly lower delta-1 power than both FMS and NHC, and during cycle 3 lower 
delta-1 power compared to NHC was found for OA patients during N2 and N3. This may 
further indicate a modified sleep structure as a function of chronic pain, in this patient 
groups.  
Figures 4.22 to 4.26 depict the spectral power for each frequency at different 
stages of sleep and for cycle by cycle observations. 
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Table 4.10. Profiles of Absolute Spectral Power for fibromyalgia, osteoarthritis and healthy control participants 
Logarithmic absolute mean power in all frequency bands (Total 0.1-48Hz, Delta-1 0.1-1Hz, Delta-2 1-3.5Hz, Theta 3.5-8Hz, Alpha 8-12Hz, Sigma-1 12-14Hz, Sigma-2 14-16Hz, 
Beta-1 16-24Hz, Beta-2 24-32Hz, Gamma 32-48Hz) in the sleep EEG (C3-A2 derivation) for sleep stages NREM Merged, N2-3 and REM. 
FMS, patients with fibromyalgia syndrome; OA, patients with osteoarthritis; NHC, normal healthy controls; *p<.05; **p<.01; 
 
 
 
 
Sleep Stage  Group (n) Total Delta-1 Delta-2 Theta Alpha Sigma-1 Sigma-2 Beta-1 Beta-2 Gamma 
             
NREM1-3  FMS (19) 5.64 ± .59 4.63 ± .69 4.54 ± .54 3.73 ± .60 2.99 ± .63 1.84 ± .67 1.12 ± .80 1.17 ± .80 .35 ± .88 .28 ± 1.02 
  OA (17) 5.49 ± .30 4.36 ± .42 4.49 ± .29 3.67 ± .33 2.82 ± .53 1.65 ± .50 .98 ± .39 1.08 ± .38 .10 ± .37 -.21 ± .31 
  NHC (10) 5.68 ± .30 4.77 ± .35 4.64 ± .31 3.70 ± .27 2.70 ± .38 1.82 ± .50 .61 ± .27 .97 ± .46 .18 ± .60 -.03 ± .62 
             
 K(p)  1.944(p=n.s.) 5.304(p=n.s.) 1.021(p=n.s.) .451(p=n.s.) 1.554(p=.460) .504(p=n.s.) 6.276(p=.043)* 1.789(p=n.s.) 1.824(p=n.s.) 5.681(p=n.s.) 
             
N2  FMS (19) 5.24 ± .35 4.02  ± .41 4.11 ± .31 3.50 ± .44 2.88 ± .49 1.82 ± .54 1.15 ± .62 1.20 ± .54 .34 ± .58 .21 ± .70 
  OA (17) 5.17 ± .28 3.84 ± .36 4.14 ± .26 3.50 ± .34 2.76 ± .50 1.67 ± .51 1.09 ± .42 1.18 ± .36 .18 ± .36 -.15 ± .30 
  NHC (10) 5.28 ± .24 4.14 ± .30 4.21 ± .22 3.51 ± .27 2.70 ± .42 1.97 ± .52 .72 ± .27 1.08 ± .50 .28 ± .64 .07 ± .68 
             
 K(p)  1.745(p=n.s.) 4.896(p=n.s.) .874(p=n.s.) .635(p=n.s.) 1.034(p=n.s.) 2.567(p=n.s.) 6.467(p=.039)* 2.502(p=n.s.) 2.071(p=n.s.) 4.733(p=n.s.) 
             
N3  FMS (19) 6.29 ± .90 5.50 ± .93 5.18 ± .84 4.08 ± .92 3.19 ± 1.03 1.88 ± 1.07 1.04 ± 1.21 1.11 ± 1.31 .33 ± 1.43 .34 ± 1.59 
  OA (17) 5.97 ± .27 5.07 ± .38 4.97 ± .28 3.90 ± .31 2.92 ± .60 1.62 ± .53 .82 ± .41 .94 ± .42 -.01 ± .40 -.29 ± .34 
  NHC (10) 6.27 ± .28 5.58 ± .35 5.19 ± .25 3.93 ± .23 2.66 ± .35 1.64 ± .44 .44 ± .33 .79 ± .49 .04 ± .60 -.16 ± .60 
             
 K(p)  6.000(p=.05)* 9.809(p=.007)** 3.999(p=n.s.) .506(p=n.s.) 3.439(p=n.s.) .055(p=n.s.) 6.267(p=.044)* 1.318(p=n.s.) .963(p=n.s.) 5.031(p=n.s.) 
             
REM  FMS (19) 4.56 ± .45 3.03 ± .55 3.45 ± .42 3.13 ± .53 2.20 ± .65 .61 ± .60 .33 ± .60 1.24 ± .59 .42 ± .60 -.01 ± .55 
  OA (17) 4.46 ± .42 2.86 ± .51 3.35 ± .43 3.02 ± .47 2.08 ± .57 .59 ± .42 .39 ± .41 1.33 ± .41 .44 ± .46 -.08 ± .32 
  NHC (10) 4.43 ± .28 2.93 ± .25 3.36 ± .21 2.92 ± .39 1.96 ± .56 .48 ± .45 .17 ± .46 1.12 ± .58 .31 ± .68 .03 ± .77 
             
 K(p)  1.248(p=n.s.) 1.171(p=n.s.) .314(p=n.s.) 2.567(p=n.s.) 1.495(p=n.s.) .682(p=n.s.) 2.305(p=n.s.) 3.584(p=n.s.) 1.447(p=n.s.) .829(p=n.s.) 
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Table 4.11. Means and Standard Deviations of Cycle 1 of Sleep 
Logarithmic absolute mean power in all frequency bands (Total 0.1-48Hz, Delta-1 0.1-1Hz, Delta-2 1-3.5Hz, Theta 3.5-8Hz, Alpha 8-12Hz, Sigma-1 12-14Hz, Sigma-2 14-16Hz, 
Beta-1 16-24Hz, Beta-2 24-32Hz, Gamma 32-48Hz) in the sleep EEG (C3-A2 derivation) for sleep stages NREM Merged, N2 & N3 during Cycle 1 of sleep. 
Sleep Stage  Group (n) Total Delta-1 Delta-2 Theta Alpha Sigma-1 Sigma-2 Beta-1 Beta-2 Gamma 
             
Cycle 1             
             
NREM1-3  FMS (19) 6.01 ± .59 5.07 ± .57 5.00 ± .57 3.89 ± .51 3.00 ± .46 1.76 ± .51 1.03 ± .58 1.13 ± .50 .35 ± .61 .34 ± .77 
  OA (17) 5.95 ± .43 4.90 ± .61 5.01 ± .45 3.97 ± .34 2.99 ± .62 1.72 ± .46 1.02 ± .38 1.18 ± .43 .19 ± .42 -.11 ± .41 
  NHC (10) 6.16 ± .47 5.33 ± .57 5.19 ± .49 3.97 ± .31 2.79 ± .35 1.77 ± .48 .62 ± .38 1.04 ± .55 .21 ± .59 .02 ± .81 
             
 K(p)  1.188(p=n.s.) 2.815(p=n.s.) .531(p=n.s.) .012(p=n.s.) 1.846(p=n.s.) .047(p=n.s.) 5.929(p=n.s.) .769(p=n.s.) .984(p=n.s.) 5.051(p=n.s.) 
             
N2  FMS (19) 5.46 ± .39 4.15 ± .48 4.44 ± .38 3.71 ± .50 2.95 ± .47 1.93 ± .54 1.34 ± .58 1.45 ± .53 .65 ± .67 .62 ± .87 
  OA (16) 5.40 ± .28 3.95 ± .37 4.45 ± .31 3.76 ± .31 2.90 ± .47 1.90 ± .54 1.29 ± .40 1.46 ± .37 .43 ± .37 .08 ± .37 
  NHC (10) 5.54 ± .30 4.31 ± .31 4.57 ± .34 3.80 ± .37 2.89 ± .44 2.07 ± .49 .97 ± .41 1.30 ± .51 .40 ± .52 .18 ± .69 
             
 K(p)  1.255(p=n.s.) 4.253(p=n.s.) .694(p=n.s.) .014(p=n.s.) .283(p=n.s.) .916(p=n.s.) 4.495(p=n.s.) 1.020(p=n.s.) 2.190(p=n.s.) 4.969(p=n.s.) 
             
N3  FMS (18) 6.28 ± .58 5.48 ± .71 5.24 ± .58 3.98 ± .48 3.02 ± .45 1.67 ± .51 .83 ± .49 .95 ± .49 .19 ± .66 .22 ± .81 
  OA (17) 6.19 ± .37 5.25 ± .49 5.24 ± .39 4.07 ± .32 3.03 ± .67 1.69 ± .49 .93 ± .43 1.05 ± .46 .09 ± .44 -.21 ± .44 
  NHC (10) 6.43 ± .37 5.71 ± .44 5.42 ± .39 4.05 ± .27 2.77 ± .33 1.67 ± .42 .49 ± .40 .92 ± .62 .11 ± .65 -.05 ± .86 
             
 K(p)  2.679(p=n.s.) 4.909(p=n.s.) 1.457(p=n.s.) .170(p=n.s.) 2.616(p=n.s.) .406(p=n.s.) 5.616(p=n.s.) .629(p=n.s.) .391(p=n.s.) 3.467(p=n.s.) 
FMS, patients with fibromyalgia syndrome; OA, patients with osteoarthritis; NHC, normal healthy controls. N.B. REM was not calculated for cycle 1 of sleep due to the nature of sleep cycle definition in this case. 
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Table 4.12. Means and Standard Deviations of Cycle 2 of Sleep 
Logarithmic absolute mean power in all frequency bands (Total 0.1-48Hz, Delta-1 0.1-1Hz, Delta-2 1-3.5Hz, Theta 3.5-8Hz, Alpha 8-12Hz, Sigma-1 12-14Hz, Sigma-2 14-16Hz, 
Beta-1 16-24Hz, Beta-2 24-32Hz, Gamma 32-48Hz) in the sleep EEG (C3-A2 derivation) for sleep stages NREM Merged, N2, N3 & REM, during Cycle 2 of sleep. 
Sleep Stage  Group (n) Total Delta-1 Delta-2 Theta Alpha Sigma-1 Sigma-2 Beta-1 Beta-2 Gamma 
             
Cycle 2             
             
NREM1-3  FMS (19) 5.79 ± .64 4.89 ± .81 4.67 ± .63 3.70 ± .53 2.90 ± .53 1.65 ± .57 .87 ± .57 .98 ± .50 .18 ± .65 .13 ± .82 
  OA (17) 5.62 ± .35 4.59 ± .51 4.61 ± .32 3.72 ± .34 2.86 ± .54 1.65 ± .53 .90 ± .41 1.03 ± .43 .06 ± .42 -.27 ± .37 
  NHC (10) 5.82 ± .45 5.00 ± .62 4.73 ± .44 3.73 ± .32 2.68 ± .39 1.71 ± .48 .59 ± .33 .90 ± .39 .13 ± .56 -.10 ± .65 
             
 K(p)  1.141(p=n.s.) 3.939(p=n.s.) .445(p=n.s.) .066(p=n.s.) 1.287(p=n.s.) .244(p=n.s.) 4.414(p=n.s.) .639(p=n.s.) .952(p=n.s.) 3.665(p=n.s.) 
             
N2  FMS (19) 5.31 ± .36 4.13 ± .45 4.21 ± .36 3.52 ± .45 2.86 ± .48 1.76 ± .58 1.05 ± .66 1.19 ± .54 .34 ± .68 .21 ± .88 
  OA (17) 5.27 ± .29 3.98 ± .43 4.26 ± .27 3.56 ± .33 2.82 ± .51 1.73 ± .52 1.07 ± .40 1.21 ± .43 .17 ± .41 -.23 ± .32 
  NHC (10) 5.33 ± .22 4.20 ± .37 4.25 ± .21 3.55 ± .24 2.77 ± .46 1.89 ± .51 .67 ± .29 1.04 ± .43 .18 ± .48 -.02 ± .62 
             
 K(p)  .429(p=n.s.) 1.201(p=n.s.) .330(p=n.s.) .013(p=n.s.) .257(p=n.s.) 1.105(p=n.s.) 5.884(p=n.s.) 1.968(p=n.s.) 1.031(p=n.s.) 3.671(p=n.s.) 
             
N3  FMS (18) 6.21 ± .45 5.51 ± .56 5.03 ± .48 3.91 ± .41 3.02 ± .49 1.62 ± .61 .84 ± .51 .91 ± .37 .14 ± .55 .12 ± .70 
  OA (17) 5.92 ± .28 5.05 ± .42 4.87 ± .27 3.85 ± .31 2.89 ± .59 1.61 ± .57 .78 ± .45 .91 ± .44 -.03 ± .43 -.32 ± .39 
  NHC (9) 6.31 ± .29 5.71 ± .31 5.12 ± .36 3.91 ± .23 2.69 ± .33 1.72 ± .49 .41 ± .41 .76 ± .49 .02 ± .68 -.19 ± .81 
             
 K(p)  8.379(p=.015)* 13.537(p=.001)** 2.421(p=n.s.) .534(p=n.s.) 2.733(p=n.s.) .339(p=n.s.) 5.649(p=n.s.) .922(p=n.s.) 1.696(p=n.s.) 5.946(p=n.s.) 
             
REM  FMS (18) 4.64 ± .54 3.07 ± .55 3.52 ± .50 3.24 ± .76 2.22 ± .70 .76 ± .63 .52 ± .64 1.30 ± .45 .38 ± .43 -.14 ± .27  
  OA (17) 4.49 ± .43 2.80 ± .45 3.36 ± .44 3.06 ± .53 2.13 ± .64 .70 ± .47 .56 ± .46 1.48 ± .43 .54 ± .48 -.07 ± .28 
  NHC (10) 4.72 ± .47 3.22 ± .67 3.62 ± .41 3.23 ± .53 2.22 ± .61 .79 ± .43 .47 ± .45 1.32 ± .57 .41 ± .68 .08 ± .92 
             
 K(p)  1.526(p=n.s.) 2.931(p=n.s.) 1.778(p=n.s.) .834(p=n.s.) .766(p=n.s.) .658(p=n.s.) .300(p=n.s.) 1.378(p=n.s.) 1.038(p=n.s.) .333(p=n.s.) 
FMS, patients with fibromyalgia syndrome; OA, patients with osteoarthritis; NHC, normal healthy controls; *p<.05; **p<.01; 
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Table 4.13. Means and Standard Deviations of Cycle 3 of Sleep 
Logarithmic absolute mean power in all frequency bands (Total 0.1-48Hz, Delta-1 0.1-1Hz, Delta-2 1-3.5Hz, Theta 3.5-8Hz, Alpha 8-12Hz, Sigma-1 12-14Hz, Sigma-2 14-16Hz, 
Beta-1 16-24Hz, Beta-2 24-32Hz, Gamma 32-48Hz) in the sleep EEG (C3-A2 derivation) for sleep stages NREM Merged, N2, N3 & REM, during Cycle 3 of sleep. 
FMS, patients with fibromyalgia syndrome; OA, patients with osteoarthritis; NHC, normal healthy controls; *p<.05; 
 
Sleep Stage  Group (n) Total Delta-1 Delta-2 Theta Alpha Sigma-1 Sigma-2 Beta-1 Beta-2 Gamma 
             
Cycle 3             
             
NREM1-3  FMS (19) 5.43 ± .49 4.42 ± .62 4.25 ± .50 3.56 ± .55 2.87 ± .52 1.76 ± .57 1.02 ± .63 1.02 ± .44 .18 ± .48 .11 ± .57 
  OA (17) 5.36 ± .34 4.21 ± .48 4.33 ± .32 3.58 ± .35 2.83 ± .5.3 1.67 ± .52 .98 ± .42 1.06 ± .39 .06 ± .41 -.24 ± .36 
  NHC (10) 5.56 ± .28 4.65 ± .39 4.46 ± .25 3.61 ± .25 2.72 ± .42 1.89 ± .55 .57 ± .18 .90 ± .24 .07 ± .26 -.07 ± .34 
             
 K(p)  1.965(p=n.s.) 4.531(p=n.s.) 1.711(p=n.s.) .341(p=n.s.) .711(p=n.s.) 1.119(p=n.s.) 7.530(p=.023)* 2.180(p=n.s.) 1.841(p=n.s.) 5.060(p=n.s.) 
             
N2  FMS (19) 5.26 ± .38 4.13 ± .45 4.08 ± .39 3.48 ± .52 2.85 ± .51 1.80 ± .57 1.08 ± .61 1.10 ± .45 .23 ± .48 .12 ± .59 
  OA (17) 5.21 ± .28 3.93 ± .35 4.17 ± .24 3.51 ± .34 2.80 ± .52 1.70 ± .54 1.08 ± .42 1.15 ± .41 .13 ± .40 -.20 ± .34 
  NHC (10) 5.39 ± .27 4.37 ± .39 4.29 ± .24 3.52 ± .28 2.74 ± .45 1.94 ± .57 .64 ± .21 .96 ± .23 .11 ± .24 -.02 ± .31 
             
 K(p)  2.394(p=n.s.) 7.407(p=.025) 2.663(p=n.s.) .138(p=n.s.) .331(p=n.s.) 1.201(p=n.s.) 8.932(p=.011)* 2.821(p=n.s.) 1.122(p=n.s.) 4.091(p=n.s.) 
             
N3  FMS (18) 5.74 ± .53 4.88 ± .73 4.55 ± .49 3.73 ± .54 2.95 ± .50 1.67 ± .55 .88 ± .68 .86 ± .50 .07 ± .53 .11 ± .64 
  OA (17) 5.73 ± .36 4.79 ± .46 4.67 ± .35 3.77 ± .35 2.95 ± .57 1.64 ± .52 .81 ± .43 .93 ± .40 -.03 ± .43 -.25 ± .44 
  NHC (10) 6.07 ± .24 5.35 ± .24 4.94 ± .34 3.89 ± .31 2.77 ± .42 1.84 ± .55 .51 ± .25 .91 ± .40 .08 ± .42 -.05 ± .49 
             
 K(p)  4.882(p=n.s.) 8.151(p=.017)* 4.624(p=n.s.) .289(p=n.s.) 1.576(p=n.s.) 1.044(p=n.s.) 5.043(p=n.s.) .015(p=n.s.) 1.211(p=n.s.) 3.987(p=n.s.) 
             
REM  FMS (19) 4.60 ± .47 2.99 ± .57 3.49 ± .47 3.23 ± .56 2.29 ± .66 .64 ± .57 .36 ± .55 1.19 ± .45 .26 ± .40 -.19 ± .27 
  OA (17) 4.48 ± .37 2.86 ± .47 3.38 ± .39 3.03 ± .43 2.09 ± .55 .63 ± .46 .44 ± .47 1.38 ± .48 .43 ± .49 -.13 ± .30 
  NHC (10) 4.47 ± .33 3.02 ± .52 3.41 ± .27 2.96 ± .40 2.00 ± .56 .49 ± .44 .14 ± .36 1.01 ± .28 .10 ± .41 -.24 ± .34 
             
 K(p)  1.054(p=n.s.) 1.283(p=n.s.) .942(p=n.s.) 3.308(p=n.s.) 2.144(p=n.s.) .556(p=n.s.) 3.120(p=n.s.) 4.297(p=n.s.) 3.428(p=n.s.) 1.314(p=n.s.) 
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Figure 4.22. Bar graph depicting absolute spectral power (logarithmic) in the alpha frequency bin. Represents N3 and NREM sleep for the whole night and separated into the first three sleep cycles as measured using 
polysomnography between fibromyalgia, osteoarthritis and healthy control participants. ± Standard error bars are also displayed.
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Figure 4.23. Bar graph depicting absolute spectral power (logarithmic) in the sigma-2 frequency bin. Represents the 
whole night of NREM sleep and NREM during the first three cycles of sleep. ± Standard error bars are also displayed. 
 
Figure 4.24. Bar graph depicting absolute spectral power (logarithmic) in the sigma-2 frequency bin. Represents the 
whole night of N2 sleep and N2 during the first three cycles of sleep. ± Standard error bars are also displayed. 
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Figure 4.25. Bar graph depicting absolute spectral power (logarithmic) in the sigma-2 frequency bin. Represents the 
whole night of N3 sleep and N3 during the first three cycles of sleep. ± Standard error bars are also displayed. 
 
 
Figure 4.26. Bar graph depicting absolute spectral power (logarithmic) in the delta-1 frequency bin. Represents N2 
and N3 sleep for the whole night and also the first three sleep cycles. ± Standard error bars are also displayed.
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5. Results III: Psychosocial Comparisons 
5.1.  Psychosocial Model 
Various psychosocial characteristics were measured to investigate differences in 
psychological status between FMS, OA and NHC participants. The aim of these 
measurements were to build a picture of the psychosocial profile of FMS sufferers. Tests 
of normality and equality of variances were run prior to conducting analyses of variance 
between the three groups in each measure and sub-measure. Overall for most of the 
assessments, the clinical groups record greater debilitation than the controls. In addition, 
the FMS patients tend to have greater values than those in the OA group. These were 
investigated further. 
5.1.1. Depression and Anxiety 
In the present study the FMS group appears to have the greatest amount of depression, 
state anxiety and trait anxiety, followed by OA and the lowest scores being the NHC 
group. The results show significant group differences for both depression and anxiety 
(Table 5.1). One way independent ANOVAs were conducted between the three groups 
on all three variables. For depression, normality tests using Z scores indicated that FMS 
(Skew=1.30; Kurt=.023), OA (Skew=1.29; Kurt=-0.52) and NHC (Skew=0.13; Kurt=-
0.63) fell within a normal distribution range. The Levene’s test indicated non-equal 
variances between groups (F=4.86, p=.013), thus a Welch’s F statistic was used (Table 
5.1). An overall significant main effect was observed (p<.001). Post-hoc comparisons 
with Games-Howell correction found significant effects between the clinical groups and 
the healthy control group, with mean differences of 18.31 (p<.001) and 11.26 (p<.001) 
for FMS and OA respectively. FMS and OA had similar levels of depression scores 
(Mdiff=7.05, p=.057).  
 For state anxiety (STAI-Y1), normality tests showed a normal distribution for 
FMS (Skew=1.14; Kurt=-0.03) and OA (Skew=1.10; Kurt=0.04). However, the healthy 
control group were both skewed and kurtotic (Skew=2.53; Kurt=2.49). The groups were 
found to have equality of variance (F=.881, p>.05). An overall significant main effect 
was observed (p=.001). Post-hoc analysis with Bonferroni correction applied found a 
significant effect between FMS and NHC (Mdiff=15.64, p<.001). However, no significant 
differences were observed between FMS and OA (Mdiff=6.21, p=n.s.) or OA and NHC 
(Mdiff=9.43, p=.052).  
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 FMS (Skew=0.32; Kurt=-0.69), OA (Skew=-0.02; Kurt=-1.39) and NHC 
(Skew=0.32; Kurt=-0.30) were all normally distributed for trait anxiety. Levene’s test 
indicated a homogeneity of variance within the groups (F=1.61, p>.05). A significant 
main effect was observed (p=.001). Post-hoc analysis with Bonferroni corrections 
observed a significantly greater trait anxiety between FMS with OA (Mdiff=9.81, p=.046) 
and with NHC (Mdiff=17.73, p=.001). However, no differences were found between OA 
and NHC (Mdiff=7.92, p=n.s.). 
Table 5.1. Means and standard deviations of depression and anxiety in fibromyalgia, 
osteoarthritis and healthy control participants 
 FMS (M 
± SD) 
n=19 
OA (M 
± SD) 
n=17 
NHC 
(M ± 
SD) 
n=10 
F df p η2 
CES-
D1 
23.11 ± 
10.13 
16.06 ± 
7.44 
4.80 ± 
2.62 
37.58† 2, 27.50 .000*** .441 
STAI-
Y12 
42.74 ± 
11.17 
36.53 ± 
8.12 
27.10 ± 
8.29 
8.819 2, 43 .001** .291 
STAI-
Y23 
49.63 ± 
12.59 
39.82 ± 
11.80 
31.90 ± 
7.52 
8.485 2, 43 .001** .283 
1. Centre for Epidemiological Studies for Depression Scale, 2. State and Trait Anxiety Scale (State), 3. State and Trait Anxiety Scale 
(Trait); †Welch’s F; **p<.01; ***p<.001; 
5.1.2. Social Support 
Table 5.2 details the normality Z scores for social support. The total score for the scale 
indicated a normal data distribution for the three groups. Support from family found a 
slight negative skew for both FMS and OA. Support from friends also indicated negative 
skew for FMS and OA, OA were also leptokurtotic. Social support from a significant 
other were negatively skewed for all three groups, and leptokurtotic for FMS and NHC. 
 One-way analysis of variance was run on the social support scale and its subscales 
(Table 5.3). Overall the three groups showed a similar level of perceived social support, 
both in terms of the total score and its subscores. No significant main effects were 
observed for the three groups. 
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Table 5.2. Skewness and Kurtosis Z scores and Levene’s test for multidimensional 
scale of perceived social support between fibromyalgia, osteoarthritis and healthy 
controls 
 FMS 
Skew 
n=19 
FMS 
Kurt 
n=19 
OA 
Skew 
n=17 
OA 
Kurt 
n=17 
NHC 
Skew 
n=10 
NHC 
Kurt 
n=10 
Levene’s 
F, p 
SS-TOTAL1 -0.96 -0.86 -0.97 -1.17 -0.30 -0.81 1.54, n.s. 
SS-FA2 -2.42* 0.57 -2.09* 0.78 -0.34 -1.20 .05, n.s. 
SS-FR3 -2.32* 0.62 -2.66* 2.48* -1.67 0.47 .49, n.s. 
SS-SO4 -3.11* 2.37* -2.68* 1.16 -2.53* 2.16* 1.87, n.s. 
1. Multidimensional Scale of Social Support Total, 2. Multidimensional Scale of Social Support Family, 3. Multidimensional Scale 
of Social Support Friends, 4. Multidimensional Scale of Social Support Significant Other; *±1.96; 
Table 5.3. Means and standard deviations the multidimensional scale of perceived 
social support in fibromyalgia, osteoarthritis and healthy control participants 
 FMS 
(M ± 
SD) 
n=19 
OA (M 
± SD) 
n=17 
NHC 
(M ± 
SD) 
n=10 
F df p η2 
SS-
TOTAL1 
5.71 ± 
1.03 
5.76 ± 
1.20 
5.99 ± 
0.78 
.246 2, 43 .783 .011 
SS-FA2 5.75 ± 1.50 
5.66 ± 
1.45 
5.58 ± 
1.23 
.051 2, 43 .950 .002 
SS-FR3 5.59 ± 1.44 
5.59 ± 
1.63 
5.95 ± 
1.18 
.235 2, 43 .791 .011 
SS-SO4 5.79 ± 1.68 
6.03 ± 
1.27 
6.45 ± 
0.82 
.743 2, 43 .482 .033 
1. Multidimensional Scale of Social Support Total, 2. Multidimensional Scale of Social Support Family, 3. Multidimensional Scale 
of Social Support Friends, 4. Multidimensional Scale of Social Support Significant Other; 
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5.1.3. Health Locus of Control 
Differences in health locus of control was analysed using one-way independent ANOVA. 
Table 5.4 presents normality Z scores and Levene’s test for the three groups looking at 
all the health locus of control subscales. For all subscales, the three groups fell within a 
normal distribution, except for internal locus of control where the NHC group was 
somewhat leptokurtotic. For homogeneity of variance, Levene’s test indicated all the 
groups in the HLOC scale met equality of variance. Consequently, the standard ANOVA 
F values were used, in addition to Bonferroni corrections for the post-hoc analysis. 
Table 5.4. Skewness and Kurtosis Z scores and Levene’s test for health locus of 
control between fibromyalgia, osteoarthritis and healthy controls 
 FMS 
Skew 
n=19 
FMS 
Kurt 
n=19 
OA 
Skew 
n=17 
OA 
Kurt 
n=17 
NHC 
Skew 
n=10 
NHC 
Kurt 
n=10 
Levene’s 
F, p 
HLOC-I1 -0.36 -0.91 -0.47 -0.34 0.78 2.25* 2.16, n.s. 
HLOC-EO2 -1.20 -0.64 0.02 0.00 -0.14 -0.91 .34, n.s. 
HLOC-ED3 -0.12 0.77 0.45 -0.06 -1.09 -0.96 .91, n.s. 
HLOC-C4 -0.92 0.29 -0.51 -0.97 -0.58 0.20 .75, n.s. 
1. Health Locus of Control Internal, 2. Health Locus of Control External Others, 3. Health Locus of Control External Doctors, 4. 
External Health Locus of Control Chance; *±1.96; 
Table 5.5 shows the means and standard deviations for the HLOC subscales, in addition 
to the results of the analysis of variance tests. From the outset, the clinical groups 
appeared to be less internally located than the NHC group. Inferential tests indicated a 
significant main effect and difference within the groups. Post-hoc analysis found the 
clinical groups FMS (Mdiff=8.66, p<.001) and OA (Mdiff=7.69, p=.001) were 
significantly less internally located than the healthy control group. No differences were 
observed between FMS and OA (Mdiff=.97, p=n.s.). 
 For external locus of control, in the ‘others’ subscale, the NHC group appeared to 
have a lower external locus of control than the clinical groups. However, an overall main 
effect was not observed. Looking at external ‘doctors’ subscale, again we can observe a 
lower score in the NHC group, with OA having the highest score. Post-hoc analysis 
indicated a significantly greater external-doctor locus of control for FMS (Mdiff=3.67, 
p=.007) and OA (Mdiff=5.55, p<.001) as compared to NHC. No differences were found 
between FMS and OA (Mdiff=1.88, p=n.s.). 
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 The health locus of control for ‘chance’ showed similar levels of belief between 
the three groups, however FMS patients showed a slightly higher mean score than both 
OA and NHC. ANOVA showed no significant main effects between the two groups. 
Table 5.5. Means and standard deviations of health locus of control in fibromyalgia, 
osteoarthritis and healthy control participants 
 FMS (M 
± SD) 
n=19 
OA (M 
± SD) 
n=17 
NHC 
(M ± 
SD) 
n=10 
F df p η2 
HLOC-
I1 
17.74 ± 
5.12 
18.71 ± 
5.77 
26.40 ± 
3.50 
10.317 2, 43 .000*** .324 
HLOC-
EO2 
8.21 ± 
2.80 
9.18 ± 
3.61 
6.30 ± 
2.45 
2.780 2, 43 .073 .115 
HLOC-
ED3 
10.47 ± 
2.78 
12.35 ± 
3.20 
6.80 ± 
2.53 
11.609 2, 43 .000*** .351 
HLOC-
C4 
18.47 ± 
5.55 
17.06 ± 
6.44 
17.60 ± 
5.17 
.270 2, 43 .765 .012 
1. Health Locus of Control Internal, 2. Health Locus of Control External Others, 3. Health Locus of Control External Doctors, 4. 
External Health Locus of Control Chance; ***p<.001; 
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5.1.4. Pain Catastrophizing 
Table 5.6 displays the skewness and kurtosis Z scores for normality and the Levene’s test 
for homogeneity of variance. For pain catastrophizing total score and its subscales, both 
the FMS and OA group showed a normal distribution that fell within the ±1.96 range. 
However, for the NHC group, on all PCS variables showed a positively skewed 
distribution. Additionally, Levene’s test indicated that all groups were not significantly 
different in terms of variance.  
Table 5.6. Skewness and Kurtosis Z scores and Levene’s test for the pain 
catastrophizing scale between fibromyalgia, osteoarthritis and healthy controls 
 FMS 
Skew 
n=19 
FMS 
Kurt 
n=19 
OA 
Skew 
n=17 
OA 
Kurt 
n=17 
NHC 
Skew 
n=10 
NHC 
Kurt 
n=10 
Levene’s 
F, p 
PCS-Total1 1.08 -0.30 0.96 -0.79 2.52* 1.62 .12, n.s. 
PCS-R2 0.73 -0.68 0.65 -1.41 2.23* 0.89 .33, n.s. 
PCS-M3 0.95 -0.77 1.88 0.11 2.08* 1.26 1.75, n.s. 
PCS-H4 1.32 -0.19 0.91 -0.41 2.66* 1.74 .51, n.s. 
1. Pain Catastrophizing Scale Total, 2. Pain Catastrophizing Scale Rumination, 3. Pain Catastrophizing Scale Magnification, 4. Pain 
Catastrophizing Scale Helplessness; *±1.96; 
One-way independent ANOVA indicated no significant differences between the 
groups in terms of the total PCS score, the subscales of rumination or magnification 
(Table 5.7). However, looking at the mean scores, there appeared to be a numerical 
gradient trend whereby FMS patients had the highest scores for total PCS, rumination, 
magnification and helplessness, with the OA patients having the second highest scores, 
and lowest scores observed in the NHC group. For helplessness, an overall significant 
effect was observed (p=.041). For helplessness, post-hoc analysis with Bonferroni 
corrections found a significantly higher score for FMS patients as compared to NHC 
(Mdiff=5.73, p=.040). However, no differences were found between the clinical groups 
(Mdiff=2.82, p=n.s.) or between OA and NHC (Mdiff=2.91, p=n.s.).  
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Table 5.7. Means and standard deviations of the pain catastrophizing scale in 
fibromyalgia, osteoarthritis and healthy control participants 
 FMS (M 
± SD) 
n=19 
OA (M 
± SD) 
n=17 
NHC 
(M ± 
SD) 
n=10 
F df p η2 
PCS-
Total1 
20.63 ± 
13.01 
16.06 ± 
11.93 
10.10 ± 
12.81 
2.328 2, 43 .110 .098 
PCS-
R2 
7.05 ± 
4.87 
6.35 ± 
5.26 
4.60 ± 
5.48 
.748 2, 43 .479 .034 
PCS-
M3 
4.05 ± 
3.12 
3.00 ± 
2.74 
1.70 ± 
1.95 
2.410 2, 43 .102 .101 
PCS-
H4 
9.53 ± 
6.26 
6.71 ± 
4.86 
3.80 ± 
5.85 
3.442 2, 43 .041* .138 
1. Pain Catastrophizing Scale Total, 2. Pain Catastrophizing Scale Rumination, 3. Pain Catastrophizing Scale Magnification, 4. Pain 
Catastrophizing Scale Helplessness; *p<.05; 
5.1.5. Personality 
Personality was assessed using the Eysenck Personality Questionnaire with four bipolar 
personality typings analysed (neuroticism, psychoticism, extraversion and lie). Looking 
at the normal distribution (Table 5.8), all the groups had scores that fell within a normal 
distribution for neuroticism, extraversion and lie; however, for psychoticism, the OA 
group appeared to be positively skewed and leptokurtotic. Levene’s F test also showed 
equality of variance in the population groups (Table 5.8). 
Table 5.8. Skewness and Kurtosis Z scores and Levene’s test for the Eysenck 
Personality Questionnaire between fibromyalgia, osteoarthritis and healthy controls 
 FMS 
Skew 
n=19 
FMS 
Kurt 
n=19 
OA 
Skew 
n=17 
OA 
Kurt 
n=17 
NHC 
Skew 
n=10 
NHC 
Kurt 
n=10 
Levene’s 
F, p 
EPQ-N1 -0.09 -0.94 -0.75 0.03 -0.68 -0.07 .94, n.s. 
EPQ-P2 1.81 1.13 2.53* 3.09* 1.49 -0.23 .22, n.s. 
EPQ-E3 -1.11 0.55 0.35 -0.96 0.22 -0.87 1.60, n.s. 
EPQ-L4 0.75 0.56 0.27 -0.66 1.10 0.38 .45, n.s. 
1. Eysenck Personality Scale Neuroticism, 2. Eysenck Personality Scale Psychoticism, 3. Eysenck Personality Scale Extraversion, 4. 
Eysenck Personality Scale Lie; *p<.05, *±1.96; 
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Firstly, looking at neuroticism, the FMS group appeared to have the greatest score on 
neuroticism, with OA being second highest and lowest in NHC. Analysis of variance also 
indicated a significant main effect within the groups (Table 5.9). Post-hoc analysis with 
Bonferroni corrections found the FMS group were significantly more neurotic than the 
healthy control group (Mdiff=6.44, p=.009). However, no differences were found between 
FMS and OA (Mdiff=2.27, p=n.s.) or OA and NHC (Mdiff=4.17, p=n.s.).  
 Psychoticism subscale showed no discernible differences in mean scores between 
the three groups, however the clinical groups had a lower psychoticism score than the 
NHC group. ANOVA did not show a significant main effect (Table 5.9). 
 For the extraversion subscale, the mean scores indicated a greater score for FMS 
patients, followed by OA and the lowest being NHC. However, no significant main effect 
was found.  
 Lastly for the lie scale, the clinical groups seemed to have a greater score than the 
NHC group. ANOVA showed a significant main effect (Table 5.9; p=.014). Post-hoc 
analysis with Bonferroni corrections found the clinical groups had a significantly greater 
score on the lie scale than the NHC group with a mean difference of 3.62 (p=.036) and 
4.12 (p=.016) for FMS and OA respectively. 
Table 5.9. Means and standard deviations of the Eysenck Personality Questionnaire 
in fibromyalgia, osteoarthritis and healthy control participants 
 FMS (M 
± SD) 
n=19 
OA (M 
± SD) 
n=17 
NHC (M 
± SD) 
n=10 
F df p η2 
EPQ-N1 15.74 ± 4.36 
13.47 ± 
5.80 
9.30 ± 
5.06 
5.258 2, 43 .009** .197 
EPQ-P2 4.47 ± 3.64 
3.88 ± 
2.47 
5.80 ± 
3.68 
1.094 2, 43 .344 .048 
EPQ-E3 12.16 ± 5.10 
11.71 ± 
6.08 
10.90 ± 
6.56 
.154 2, 43 .858 .007 
EPQ-L4 11.32 ± 4.18 
11.82 ± 
2.90 
7.70 ± 
3.13 
4.753 2, 43 .014* .181 
1. Eysenck Personality Scale Neuroticism, 2. Eysenck Personality Scale Psychoticism, 3. Eysenck Personality Scale Extraversion, 4. 
Eysenck Personality Scale Lie; *p<.05; **p<.01; 
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Tables 5.1-5.9 show the mean results of the psychometric assessments between 
fibromyalgia, osteoarthritis and healthy controls. Overall for most of the assessments, the 
clinical groups record higher values than the control. In addition, the fibromyalgia 
patients tend to have greater values than those in the osteoarthritis group. There were 
highly significant differences between the three groups for depression, state and trait 
anxiety, health locus of control (internal, external-doctor) and neuroticism. There were 
also significant differences between groups for pain catastrophizing and the EPQ-Lie 
scale. There were significant differences found between fibromyalgia and osteoarthritis 
in depression, there were similar differences found in anxiety measures.  
 There was a trend towards a lower health locus of control in fibromyalgia 
compared to osteoarthritis. For neuroticism the FMS patients were statistically significant 
for healthy controls but not for the osteoarthritis group.  
 Figures 5.1 to 5.5 depict graphically results of the psychological variables in the 
three different groups.  
 Figure 5.1. Bar graph comparing means scores of depression (CES-D), state, and trait anxiety (STAI) between 
fibromyalgia, osteoarthritis and healthy control participants. Standard error bars are also displayed. 
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Figure 5.2. Bar graph comparing means scores of the pain catastrophizing scale, depicting total, and subscores of 
rumination, magnification and helplessness, between fibromyalgia, osteoarthritis and healthy control participants. 
Standard error bars are also displayed. 
 
 
Figure 5.3. Bar graph comparing means scores of the Eysenck Personality Questionnaire in scores of extraversion, 
neuroticism, psychoticism and lying, between fibromyalgia, osteoarthritis and healthy control participants. Standard 
error bars are also displayed. 
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Figure 5.4. Bar graph comparing means scores of health locus of control depicting scores of internal, external-doctor, 
external-other and chance, between fibromyalgia, osteoarthritis and healthy control participants. Standard error bars 
are also displayed. 
 
 
Figure 5.5. Bar graph comparing means scores of the multidimensional scale of social support depicting the total social 
support score and subscores of familial, friend and significant other support. They are compared between fibromyalgia, 
osteoarthritis and healthy control participants. Standard error bars are also displayed. 
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6. General Discussion 
This is the first study to compare the electrophysiological sleep structure, subjective sleep 
experience, and psychological profiles of FMS patients with both non-FMS chronic pain 
patients, and healthy normal controls.  In recruiting the groups for this study considerable 
care was taken to ensure: 1) unambiguous and recent diagnoses of fibromyalgia syndrome 
in the FMS group; 2) similarities in age across the three groups;  3) the presence of 
significant pain-related sleep disturbance within the OA group (since, unlike FMS, sleep 
symptoms are not cardinal in arthritic pathology); and 4) in all groups, the appropriate 
control of extraneous factors likely to introduce confounds into the analyses (drug 
consumption, menopausal symptoms, comorbidities, etc.).  While both clinical (FMS & 
OA) groups showed PSQI scores in the ‘poor sleeper’ range of >5 (Buysse et al., 1989) 
and FSS scores indicative of daytime fatigue at screening, the NHC group showed a sleep 
profile consistent with their age and health status, with no significant sleep symptoms.   
Given, then, that the rigorous selection criteria were met by all participants, profiles for 
the resulting groups of 19 (FMS), 17 (OA) and 10 (HNC) support the view that these 
individuals are ‘representative’ of the intended clinical and non-clinical groupings, and 
provide the basis for robust tests of the study hypotheses.   
Fibromyalgia syndrome is a disorder characterised by chronic widespread pain 
and tenderness, sleep disturbance and fatigue. The aetiology of FMS is largely unknown, 
but there has been significant interest in the role of alpha wave intrusion in delta wave 
sleep which was first described by Moldofsky and colleagues (Moldofsky et al., 1975). 
However, the later findings of ‘alpha intrusions’ have been inconclusive. It has also 
remained unclear whether this a primary phenomenon or secondary to sleep disturbance 
from pain experience.  
In order to determine whether sleep abnormalities in the microstructure of sleep 
are present, and whether they are a result of pain or a secondary phenomenon, this thesis 
aimed to compare patients with fibromyalgia syndrome, osteoarthritis and healthy 
controls. They were compared on symptoms of sleep dysfunction (multiple aspects, 
including subjective and objective) and multiple psychosocial factors. It is understood 
from literature that patients with FMS, aside from being characterised by chronic 
widespread pain, also have sleep disturbance as a core symptom that exacerbates their 
symptomology and degrades quality of life. A comparator group that exhibited sleep 
dysfunction as a function of chronic pain was a necessity to determine whether sleep 
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disturbance was fundamental to the development of FMS or a consequence of FMS 
advancement, especially the well documented alpha-delta anomaly. 
Objective sleep was examined from both a macrostructure and microstructure 
perspective in order to understand the differences of sleep architecture in a more thorough 
approach. In addition to sleep disturbances, many psychological and psychosocial 
constructs have been found to be associated with this condition. Consequently, selected 
psychosocial variables were also measured in order to explore, and better define, the 
psychological phenotype in FMS. 
To reiterate the aims of the study, a series of controlled analyses were designed to 
address the following key research questions: 
1. When scored according to AASM criteria, does the polysomnographic sleep of 
FMS, OA, and healthy control participants show significant differences on 
measures of: total sleep time; sleep onset latency; sleep efficiency; wake after 
sleep onset; and the percentage of time spent in each stage of sleep? 
2. Through spectral analysis, do FMS patients exhibit a significantly greater 
frequency and power of alpha-delta sleep than OA patients or healthy controls? 
3. Through spectral analysis, do FMS patients exhibit significant differences in the 
microstructure of sleep across the standard frequency range for sleep PSG than 
OA patients or healthy controls?  
4. Do FMS, OA, or healthy control participants show significant differences on 
objective (PSG and Actigraphy) and subjective (PSQI, ESS and FSS) measures 
of sleep disturbance and quality? 
5. Do measures of total sleep time, sleep onset latency, wake after sleep onset and 
sleep efficiency correlate between polysomnography and actigraphy across the 
groups? 
6. In comparisons of mean values, do FMS, OA and healthy control participants 
show differences on psychometric assessments of: pain, depression, anxiety, 
‘perceived social support’, ‘health locus of control’, ‘pain catastrophizing’ and 
personality? 
6.1.  Participant Selection 
A vital part of this study was to obtain appropriately constituted and, on key variables 
(e.g. pain), comparable patient groups. From the outset, all the patients and participants 
were age and sex matched. In terms of age, all three of the groups did not exhibit any 
differences or variability. In order to exclude any inter-gender variation in sleep, all the 
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cohort selected were female. We had also measured height and weight to determine body 
mass index. Although the OA group had a significantly greater BMI than the NHC group, 
it was not deemed problematic; it is important for this study that sleep architecture is not 
disrupted due to factors other than pain experience, thus it was required to take into 
consideration risk factors for certain conditions that may occur such as sleep apnoea. In 
terms of a risk of obstructive sleep apnoea (OSA) in the patients, they were screened out 
for medically diagnosed sleeping problems, in addition the prevalence of obstructive 
sleep apnoea for example are found to be more common in males. Although there have 
been past studies that have found a relationship between greater BMI to an increase in 
OSA prevalence (Wall, Smith, & Hubbard, 2012), these have mostly been found in 
patients with a BMI greater than 30, whilst the patient set did not exceed these values. 
It was important that the FMS patients were newly diagnosed and originating from a 
single site. Newly diagnosed patients are less likely to have been subjected to 
pharmacological therapy prior to recruitment, and therefore their sleep architecture is less 
likely to have been altered due to drug therapy; as certain medications have been shown 
to affect sleep architecture such as tricyclic antidepressants and other opioids (e.g. 
Dimsdale, Norman, D, & Wallace, 2007). This paradigm allowed us to observe FMS 
patients from the onset of diagnosis to obtain a better valid representation and decreased 
the need to conduct ‘washout’ periods, although in some cases this was unavoidable.  
In addition to newly diagnosed patients, all the patients were diagnosed using the 
ACR 1990 criteria and their FIQ result indicated a similar severe level of daytime impact 
for the FMS patients. In terms of demographics, the majority of the participants were 
Caucasian, previous research has indicated inconclusive evidence in the differences in 
sleep architecture between ethnicities (e.g. Jean-Louis et al., 2001; Rao et al., 1999; 
Stepnowsky, Moore, & Dimsdale, 2003), although there may be scope to explore this 
further. 
The OA patients, were perhaps the most important for selection in this process. They 
were recruited from an orthopaedic waiting list and were awaiting surgery for knee, hip 
and shoulder operations. It was important that they exhibited a mainly localized chronic 
pain, but also were sleep disturbed due to pain. Thus the screening for these variables 
were highly stringent, and achieved by consultations with a rheumatologist for their pain 
condition and also rigorous screening using various sleep related questionnaires prior to 
recruiting the patient into the study. Additional to their pain, it was vital that they were 
free from pharmacological treatment that may affect their sleep; this point was also 
conducted smoothly via set agreed ‘washout’ periods.  
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It was important when recruiting these participants and analysing the results that they 
did not differ in certain areas. The clinical patients were required to exhibit similar levels 
of pain, although, because the two clinical groups had different diseases, it was not 
possible to control for pain; assessments using the BPI helped to ensure that both clinical 
groups were similar in terms of pain severity, pain interference and also on a basic visual 
analogue scale. We achieved this effectively, whilst the healthy control group were free 
from pain and pain interference using the same method. In terms of sleep quality as 
measured using the PSQI, we required that they exhibited clinical significance in terms 
of sleep disturbance. Both groups had scored highly on the global PSQI, which resulted 
in severely disturbed sleep, in contrast to a low sleep score obtained from the NHC group. 
Additionally, FMS patients were found to have a much greater level of fatigue and 
sleepiness than both the OA and NHC group; and there were similar statistically 
significant differences between OA and NHC; these large and significant differences 
between the three groups could perhaps be due to an alteration in terms of the 
micro/macrostructure of sleep.  
6.2.  Do FMS, OA and NHC participants show a difference on measures of 
objective sleep variables? 
PSG was recorded over two nights, however only the second night was used for all 
subsequent analyses for reliability purposes. They were scored according to the AASM 
guidelines. We failed to observe any differences between the three groups in TST, SOL, 
and WASO; they appeared to spend similar amounts of time sleeping, similar amounts of 
time getting to sleep and similar amounts of wake time during the night. However these 
findings do not replicate or reach a consensus with what is typically observed, whereby 
FMS patients characteristically have been found to sleep less, have prolonged sleep 
latencies and have increased night time awakenings (Roizenblatt et al., 2001). However, 
the mean trends for wake after sleep onset have found the greatest amount of wake time 
in the FMS patients, followed by the OA and the lowest being the healthy group, there 
was a greater standard deviation with the FMS group which may contribute to a non-
significant model, which highlights the greater range of variability in FMS patients, or 
the FM syndrome as a whole. 
Though the FMS patients did have a significantly lower sleep efficiency than the 
NHC group, but there were no differences between the clinical groups (FMS & OA) or 
between OA and NHC. This outcome agrees with what has been previously found (e.g. 
Wittig, Zorick, Blumer, Heilbronn, & Roth, 1982); although there were no differences 
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between the clinical groups nor between the OA and NHC groups, the mean values 
indicated a trend whereby FMS patients on average had a lower sleep efficiency than OA, 
however this was marginal (difference of 0.86) and non-significant, and the highest sleep 
efficiency with the healthy controls which was only significant between the FMS group. 
This implies that the FMS group had less variability in their sleep efficiency than the OA 
group. This result may also be possible due to a mediation effect of pain and sleep, since 
the FMS and OA groups’ exhibit two different diseases, a third mediating factor may be 
at play affecting the severity of sleep dysfunction which may relate to other physiological 
or psychological differences. 
Sleep was staged according to AASM guidelines; no differences were observed 
between the three groups in terms of the percentage amount of time spent in each stage 
of sleep. They appeared to be equal in the amounts of time spent in N1, N2, N3 and REM 
sleep, with their mean differences to be negligible. Typically, FMS patients have been 
found to have increases in N1 and N2 sleep and reductions in N3 (Harding, 1998) as 
compared to a healthy comparator group. However, this was not observed here. The 
present study has a methodologically robust research design, more so than previous 
research; employing a pain and healthy comparator group; conducting at-home recordings 
rather than in a lab; and evaluating psychometric factors. At this point, there may be 
indications that FMS irregularities in sleep dysfunction may be an abnormality of 
perception rather than reality. 
The question is now posed, whether these patients have greater amounts of 
awakenings or arousals? From the analyses, we did not find significant differences, they 
had similar amounts of awakenings and PSG arousals during the night, although the 
clinical groups did have greater mean numbers than the healthy controls for both 
awakenings and arousals, there was also a greater variability in the clinical groups, which 
further highlights the individual differences or even greater variability of sleep of the 
conditions as a whole. There was a trend however, where FMS patients had a greater, 
though not significant, amount of PSG arousals than the OA and NHC groups. 
Subjectively the FMS patients have already shown they are significantly more 
sleep disturbed, they are more fatigued and they have greater sleepiness than both the 
pain control group and the healthy control group, but they appear from the outset to have 
a similar sleep architecture on the macro level. In order to obtain a comprehensive picture, 
it was necessary to tease apart whether the sleep of the clinical groups was more 
fragmented than the NHC group. To do this we analysed the number of sleep stage 
transitions each participant group had; the greater the amount of sleep transitions, the 
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more fragmented we reasoned their sleep would be; sleep stage transitions are a measure 
of the frequency or number of transitions from one sleep stage to the next, an increase in 
the number of sleep stage transitions especially in a short period of time indicates a much 
poorer sleep quality. In addition to sleep stage transitions for the whole night, we also 
analysed the number of transitions per hour of sleep. The results showed that indeed the 
clinical groups exhibited a significantly greater amount of sleep stage transitions than did 
the healthy controls, both for the whole night of sleep and also particularly during each 
hour of sleep. However, we did not observe a difference between FMS and OA. This may 
help clarify the differences in subjective differences between the clinical groups and the 
healthy control group, perhaps it is not surprising that patients will develop symptoms of 
fatigue and sleepiness, if pain causes interruption in the pattern of sleep. However, the 
FMS patients still had significantly worse perceived sleep quality, perceived fatigue and 
perceived sleepiness than the pain control group (OA group). 
Having also run actigraphy for two weeks, the idea was to obtain a general 
measure of their sleep across a small period of time. The results of the actigraphy analysis 
also indicated that there were no differences in sleep quality between any of the three 
groups. The use of actigraphy is perhaps a secondary measure to aide in validation of the 
objective sleep or PSG recordings. The question that should be asked now, is why patients 
with FMS and OA have a greater subjective impairment in sleep quality with increased 
fatigue and sleepiness when their objective measures of PSG and actigraphy appear to be 
similar to a healthy comparator group? What then is driving this perceived sleep 
impairment? 
6.3.  Do sleep variables for polysomnography and actigraphy correlate across 
the groups? 
Actigraphy was included as an additional measure of objective sleep, both due to the need 
for a general picture of an individual’s sleep, but also as an exploration into the 
comparisons between one night of PSG and a measurement of sleep over a longer period. 
Pearson correlations between actigraphy and polysomnography on measures of TST, 
SOL, WASO and SE were conducted on all the groups together. Measures of SOL, 
WASO and SE, were all significantly correlated with each other. However, for TST, a 
weaker non-significant correlation resulted. It was reasoned that the more accurate and 
highly specific measure of PSG in determining sleep and wake times may have a part to 
play in a weaker relationship.  
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Due to the nature of actigraphy by use of preset algorithms on motion data for 
detecting sleep-wake status, there have been studies which have shown a lower specificity 
for this methodology. Studies have shown that actigraphy tends to overestimate certain 
measures such as sleep latency, total sleep time and sleep efficiency and underestimating 
awakenings (de Souza et al., 2003; Marino et al., 2013). Looking at data trends of the 
present study, the mean values appear to show actigraphy underestimating TST, SOL and 
SE, opposite to what previous studies have described; and overestimating WASO and 
awakenings. The use of actigraphy in certain populations are still relatively unknown, 
especially in two different chronic pain groups, this may be of worth to note when 
conducting future studies using this technology with other population groups. 
6.4. Are there differences between subjective and objective measures of sleep 
for FMS, OA and NHC? 
From the PSQI component measures of TST, SOL and SE were obtained. These 
subjectively obtained values were compared with objectively obtained values from PSG 
for all three groups. We found that the clinical groups had significantly underestimated 
the amount of sleep they had, and in turn underestimated their sleep efficiency. In 
comparison, the healthy control group did not exhibit differences in their subjectively 
perceived sleep times and objectively measured sleep times. This further points to a fault 
in the perception of the amount of sleep reported by these participants. The same result 
was found for both clinical groups (FMS and OA). This agrees with previous research, 
which found common misperceptions of sleep in FMS patients (Okifuji & Hare, 2011b). 
However, both pain groups had an error in sleep estimation, which was further explored 
by calculating the magnitude of difference (TST and SE) for both FMS and OA groups 
and then comparing the differences in magnitude between the two groups. It was found 
that that FMS patients had a significantly greater magnitude of difference from subjective 
to objective, than did OA patients. This may imply pain perception has a role to play in 
sleep misperception; however, this irregularity is much greater in FMS patients, which 
concurs with past research. However, pain may not be the only factor in deciding this, 
due to a greater misperception in FMS patients, further factors may play a role in 
exacerbating this phenomenon, which may relate to physiological or psychological 
functions.  
6.5.  The Microstructure of Sleep 
The main focus/hypothesis of this study was to investigate the microstructure of sleep, 
and explore differences in various EEG frequencies during different stages of sleep and 
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during different times of the night between FMS, OA and NHC. This was to answer the 
general question of whether patients with FMS have differences/anomalies in their sleep 
EEG which may contribute to their symptomology and (relative to OA patients and a 
healthy control group). This was achieved through a thorough spectral analysis of the 
EEG channels of the PSG. Through this multiple points of note were found.  
6.5.1. The Alpha-Delta Anomaly 
One of the main focuses of this study was to evaluate the alpha-delta sleep anomaly. The 
patients with osteoarthritis were selected only if they had sleep that was disturbed by pain. 
Multiple studies have documented greater alpha-wave intrusions during slow wave sleep 
in patients with FMS. These studies have been inconsistent in their findings and none 
have utilised a well selected and screened pain control group. Spectral analysis was 
utilised to decompose the wave and investigate the alpha-wave anomaly in its entirety. 
Initially the alpha frequency was explored for N3 for the whole night of sleep. 
Additionally, analyses were also carried out for the first three cycles of sleep that 
consisted of N3; a cycle by cycle examination was conducted as the literature has 
consistently demonstrated the first cycles of sleep as having the strongest signal before 
stepping down after each cycle (Besteiro González et al., 2011).  
The findings demonstrated that between the three groups, no discernible 
differences were found for the power of the alpha frequency signal during N3 sleep. This 
may arise due to several reasons, the main one being that generally, not everybody 
exhibits the same amount of N3 sleep across the entire night, in some cases patients may 
only exhibit less than 5% of N3 across the whole night in the patient groups, where for a 
typical sleeper it is around 30%. However, these findings do not support the hypothesis 
that alpha-wave intrusion is a primary abnormality found in fibromyalgia. Moreover, the 
patient groups did not exhibit differences in pain measures, but the results showed a 
consistent trend towards an increase in alpha power in the FMS patients compared with 
OA, and both clinical groups had a numerically greater alpha power than the healthy 
controls that was consistent throughout the night. This may indicate that the present study 
could be lacking power in order to produce a significant finding; it should be noted that 
the study failed to recruit the necessary numbers (20 per group) produced by the power 
calculation specified earlier. The trend toward an increase in alpha-wave intrusion in the 
clinical groups, questions whether alpha-waves are a function of sleep disturbed by pain 
rather than specific to FMS, there is thus still scope to explore this further. 
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In addition to slow wave sleep, numerically on average, alpha power was 
generally stronger in FMS patients, with OA having the second greatest alpha power and 
lowest strength in the healthy control group. This has been observed to be true for both 
NREM and N2 separated, in addition to the first three cycles of sleep. The lack of 
significant findings is perhaps due to a greater variability in the FMS patients, as they 
consistently had greater standard deviations for alpha. This agrees with past research that 
have found inconsistent alpha power within FMS patient groups where some exhibit a 
greater amount than others. This highlights the greater variability in FMS patients and 
perhaps is mediated by psychosocial factors such as anxiety and depression. 
6.5.2. Specific findings in the micro-structure of sleep 
Although no differences were found in alpha power, some differences were observed in 
spectral power at other frequencies, which may bear some significance. The results of the 
spectral analysis demonstrated significant differences in the averaged power of the sigma-
2 frequency in NREM sleep merged, N2 and N3. The greatest numerically observed 
power was found in the FMS group, followed by OA, with the NHC group having the 
lowest averaged power. However, only the osteoarthritis group exhibited a significantly 
greater amount of sigma-2 power than the NHC group for all three sleep stage groupings. 
This was again due to greater inconsistencies in the results of the FMS patients, where 
they had a larger standard deviation than the other groups.  
Sigma related activity can be clarified as relating to sleep spindle activity, the 
greater power observed in the sigma range may indicate a greater amount of sleep spindle 
activity; spindle activity is typically described as sinusoidal oscillations that fall within 
the 11-16 Hz range. Moreover spectral analysis has been consistently shown to be the 
most robust and reliable method of ascertaining spindle rate (Knoblauch et al., 2003). The 
sigma-2 frequency sits at 14-16 Hz, and reflects the frequency of faster spindles (13-15 
Hz) than the typically slower spindles that occur in the 11-13 Hz range  (Mölle, 
Bergmann, Marshall, & Born, 2011). No differences were observed between the FMS 
group and healthy control group, which suggests they exhibited a similar level of spindle 
activity, however FMS patients have consistently shown numerically greater sigma-2 
power as opposed to NHC, previous research however has found inconclusive results 
where FMS patients may display decreased sleep spindles compared to controls (e.g. 
Landis et al., 2004) or they may have an increase in N2 sleep, which by default would see 
an increase in spindle activity, but these research studies have mainly used a manual 
method of computing the number of spindles, rather than investigating the spectral 
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component of spindle activity, which can be less reliable due to human error. 
Additionally, again much greater variability was observed in FMS patients, which lead to 
possible non-significant findings in this respect. Moreover, a greater sigma-2 power was 
observed in the OA pain control group as compared to the NHC group, which further 
proposes pain as a function of increased spindle activity. There is, however, research that 
indicates a possible link between ‘fast’ spindles and depressed mood (Plante et al., 2013), 
so there may be merit here for future areas of investigation. 
In addition to sigma-2 activity, some variations in slow wave sleep were also 
observed. The groups showed significant differences in extreme slow wave activity in the 
delta-1 range (0.1-1 Hz). The OA group were found to have significantly lower delta-1 
power than both FMS and NHC groups in N3 sleep, these results appeared consistent 
throughout the night, where the FMS and NHC group showed no differences in delta-1 
power. This is an interesting finding, and leads one to reason that FMS is not a typical 
chronic pain condition, where OA exhibits a modified sleep structure akin to that of a 
characteristic chronic pain group, FMS do not, at least not entirely. This observation 
however, does not support the findings from previous research which described FMS 
patients as having less slow wave sleep than healthy baseline controls (Drewes et al., 
1995), in fact in the present study they appeared to exhibit the same amount of slow wave 
activity as the healthy control group; however, delta power across these groups have not 
been frequently explored. 
Overall a general consensus for most of what was observed with the spectral 
analysis relates to the greater variability in FMS patients in terms of the microstructure 
of their sleep, as observations generally show greater power in the FMS patients but a 
greater deviation from the mean. This may imply that FMS patients are highly varied 
individuals, and two patients may exhibit very different symptom severities. This should 
be taken into account with future research directions. However, it must also be considered 
that these patients are newly diagnosed; long-term diagnoses may gradually lead FMS 
patients to develop or fall into typical sleep characteristics found in previous studies such 
as increased alpha-delta sleep or decreased slow wave sleep, these in turn may be 
moderated by a third factor, perhaps relating to their psychosocial profile. 
6.6.  Psychosocial Analysis 
Several psychosocial factors have previously been found to be different in fibromyalgia 
sufferers compared to healthy controls. Some of these include a greater level of 
depression and anxiety, decreased social support, a greater external health locus of 
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control, increased pain catastrophizing and a more prevalent neurotic personality type. 
These were all analysed in this study in an attempt to explore and build a possible 
psychosocial profile of these particular patients. 
Although there were little differences in demographic analysis and sleep 
parameters between patients with fibromyalgia and those with osteoarthritis, there were 
significant differences in a number of their psychological parameters. Between the three 
groups, both clinical groups were significantly more depressed than the healthy control 
group, however the difference between FMS and OA did not reach significance, although 
this was close at .057. It is already known that FMS patients are more depressed than a 
healthy control group (Thieme et al., 2004), however FMS patients appeared to be similar 
to a matched pain control group. Although there appeared to be a trend where FMS 
patients had a greater depression mean score. FMS patients also had a greater standard 
deviation in terms of depression than both OA and NHC, further reinforcing individual 
differences within an FMS population, moreover the p values were close to reaching 
significance, and as a point of note, prior to corrections for multiple comparisons the test 
reached clinical significance.  
Furthermore, the models for state and trait anxiety found significant group 
differences. The FMS patients had numerically the greatest state and trait anxiety mean 
scores, with the OA group having the second highest, and lowest being the NHC group. 
Nonetheless, the only significant difference observed for state anxiety was between FMS 
and NHC. This indicated a greater severity in state anxiety in the FMS patients compared 
with healthy controls. Conversely with trait (general) anxiety, FMS patients exhibited a 
significantly much greater level of trait anxiety than both OA and NHC; this supports 
previous research implying a greater anxiety in FMS patients than with healthy controls, 
however we have also found the same to be true for a comparative pain control group, 
which may point to this being specific to FMS and part of their psychosocial profile. 
FMS patients have been shown to exhibit a decrease in perceived social support 
in previous research (Shuster et al., 2009). In the current study using the Multidimensional 
Scale of Perceived Social Support, we did not find any differences either in the total score, 
or the sub-scales between any of the groups. This did not agree with previous findings; 
however, it may point to the increased likelihood of heterogeneity in FMS patients. The 
newly diagnosed nature of FMS patients in the present study could account for the 
heterogeneity of the patients; social support is not a constant, and over time it may 
decrease, perhaps even due to FMS patients gradually developing into a more typical 
FMS profile with higher anxiety and greater depression. Moreover, cultural influences 
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should be taken into account when looking at social support, as some cultures promote 
support better than others. 
Health locus of control is well studied in the past; it is an individuals’ belief that 
one’s health is dependent upon either internal or external factors. For FMS, they have 
previously been shown to be more externally located, in other words they expect their 
health to be outside of their own control (Gustafsson & Gaston-Johansson, 1996). 
However, they have not been directly compared to a pain control group (OA). The clinical 
groups were less internally located than the healthy control group, moreover, they were 
more externally located particularly in the doctor subscale; this means that their beliefs 
of their health outcome is in their doctors’ hands. This result not only supports previous 
findings, but it also extends previous findings by including a pain control group. The 
findings in this facet of psychology implies that external health locus of control beliefs 
may be more likely with clinical patients, and are not particularly specific to FMS.  
FMS sufferers have also been found to be greater pain catastrophizers than healthy 
control groups (Carol S Burckhardt et al., 1997; Hassett et al., 2000). The results showed 
a general trend towards a greater pain catastrophization total score and subscores in FMS 
patients, followed by OA and the lowest scores in the healthy control group. Though FMS 
patients were only found to be more significant pain catastrophizers in terms of 
helplessness in comparison to the NHC group, with no differences found in the other 
subscales of rumination or magnification. Additionally, no differences were observed 
between FMS and OA patients. Helplessness has been previously identified as a potential 
mediator of health status in FMS patients, partial mediation of pain and disability through 
depression, and full mediation of pain effects through self-reported pain behaviour 
(Nicassio, Schuman, Radojevic, & Weisman, 1999). In order to investigate this further, a 
larger participant sample size would be required to find possible mediators/moderators of 
FMS symptoms through psychosocial variables. 
The last psychological variable explored was the aspect of personality. FMS has 
been explored as a potential manifestation of neuroticism (Netter & Hennig, 1998). More 
recently however, personality traits were examined in FMS patients to seek associations 
with key psychological processes and clinical symptoms; a significant association 
between the level of neuroticism and pain, sleep, fatigue, depression, anxiety and stress. 
It was concluded personality was a significant modulator of clinical symptoms in FMS 
(Malin & Littlejohn, 2012). In the present study, the EPQ-R was used as a personality 
measure which was robust in terms of reliability and validity. The findings indicated a 
difference in neuroticism scores within the three groups, and trends showed the FMS 
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group had the highest score on neuroticism, with the OA group being second, and the 
NHC group the lowest scoring on the neuroticism sub-scale. Nonetheless, only the FMS 
group reached clinical significance when compared to the healthy controls. This factor 
supports previous research whereby FMS were found to have a more neurotic personality 
type than a healthy control group; however, compared to osteoarthritis, no differences 
were found. Concurring with Malin & Littlejohn (2012), there are perhaps unexplored 
relationships relating to neuroticism and factors such as pain, sleep, fatigue etc. which 
should be taken into consideration for future research. There is a need to explore how a 
neurotic personality type interacts with variables such as pain perception, depression, and 
anxiety etc. to understand whether FMS could be a manifestation of neuroticism or 
perhaps its main symptomology is mediated by neuroticism. 
Additional to neuroticism, the lie scale within the EPQ-R was also explore, the 
analyses indicated that the clinical groups had a greater lie personality score than the 
healthy counterpart. It could suggest a specific personality trait linked to chronic pain 
patients, and this area needs to be investigated further. 
6.7.  Fatigue and Sleepiness 
One of the more noteworthy results from this study is the differences in subjective sleep 
related measures. Objective sleep measures found little differences between the clinical 
groups, most of the objectively observed sleep variables were similar between FMS and 
OA patients. The question is thus raised as to why FMS patients feel significantly more 
fatigued and have greater amounts of sleepiness than the OA patients. FMS patients are 
expected to be more fatigued and sleepy than healthy groups, but they are also seemingly 
different from OA, with which they share similar objective sleep characteristics. It seems 
to point to a more psychosocial effect rather than physiological, which may in turn 
exacerbate FMS symptom severity. Investigating relationships between fatigue, sleep and 
other psychosocial constructs are essential to understand this problem. 
6.8.  Limitations 
This study was important in addressing unanswered question behind the alpha-delta sleep 
anomaly and FMS. Nevertheless, limitations in the methodology, and constraints on the 
analyses must be recognised.  The PSG methodology focussed only on the EEG, EOG 
and SMG signals adequate to investigate the proposed hypotheses. However, the 
opportunity was not exploited to simultaneously incorporate channels which measured 
oxygen saturation (which could have provided a more precise indication of possible sleep-
related respiratory disturbances), or further EMG channels for help in detecting possible 
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undiagnosed sleep related motor conditions like periodic limb movements. Although 
participants were screened for these conditions using symptom questionnaires, the 
possibility of undetected sleep pathology remains present. In mitigation, it should also be 
pointed out, however, that the selection and screening of the present sample equates with 
best practice in this research area and, in combination with the diagnostic standardisation 
utilised here, delivered a methodology superior to that reported in many reported studies. 
It should also be recognised that, in conducting domiciliary recordings, the comfort of the 
participants was a priority, and time constraints in setting up additional channels would 
have been difficult. 
Finally, it is recognised that the present analyses have focussed narrowly on those 
comparisons required by the research questions set out at the start of the study.  However, 
there are clearly some areas (only indirectly related to the stated research questions) that 
are certainly worth exploring within this dataset using additional multivariate analyses: 
1) to assess possible mediating or moderating factors influencing pain-sleep relationships; 
and 2) selected controlled comparisons of sleep variables within the existing groups using 
ANCOVA models to adjust for psychological status.  The present n-sizes were sufficient 
to deliver adequate power for the tests reported here; care would need to be exercised in 
developing more complex multivariate models.  Nevertheless, it is fully acknowledged 
that the potential of the present database has not been fully exploited in the present, 
focussed analyses.  
6.9. Future directions 
This research was a key study into FMS, not only did we incorporate a similarly matched 
pain control group and healthy baseline group; we also incorporated multiple subjective 
and objective measures of sleep dysfunction and quality additional to numerous 
psychosocial measures in order to understand the relationships between these variables.  
 Future directions of research would perhaps point to a more in-depth analyses of 
how psychosocial variables interact with sleep measures. In order to produce predictive 
models that explore these relationships, a much larger scale study would then be 
warranted.  
 Additionally, the hope to investigate aspects of heterogeneity in FMS patients 
would be beneficial, as previous research and the current study has shown, FMS patients 
may be less homogeneous than we first thought, both in terms of psychological and 
physiological characteristics.  
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6.10. Implications for future research 
The present study attempted to not only examine FMS in an entirely comprehensive 
manner, but also to categorically define FMS in a way that has not been done before. The 
research design aimed to conclusively examine sleep from all relevant aspects, using 
multiple measures and psychometric instruments; to both conclude several observations 
made by previous studies, but also to investigate possible avenues that may be relevant 
for FM syndrome.  
The hope for these findings is to lead future research directions in FMS. The 
direction that is implied from the findings is to explore psychosocial aspects in greater 
detail, but also to explore their relationships with physiological measures and how they 
may affect each other. In doing this, future therapies and treatments for FMS could be 
tailored to incorporate behavioral interventions in current treatments of FMS. 
Conclusion 
FMS is not a homogeneous diagnosis, but shows varying proportions of comorbid anxiety 
and depression dependent on psychosocial characteristics of the patients (Thieme et al., 
2004). Previous studies have rarely utilised newly diagnosed patients, conducted at home 
recordings, whilst conducting psychometric testing as well; these methodological 
differences may account for much of what was observed. These patients may be more 
heterogeneous, as long-term diagnosed FMS patients over time may gradually develop 
into a typical FMS sufferer, fitting a specific profile, with high anxiety, depression, 
modified sleep structure; whereby newly diagnosed patients are not yet at that stage. 
Additionally, differences or lack thereof found in psychosocial factors may be simply due 
to a factor of time; for example, perceived social support may decrease over time post-
diagnosis. 
The results of this study helped to identify the clinical features of fibromyalgia. 
Patients with fibromyalgia have pain which is more severe than patients with 
osteoarthritis requiring surgery, more psychological symptoms and worse subjective 
symptoms of sleep, fatigue and sleepiness. In comparison, disturbed sleep is evidenced 
by sleep stage transitions, which is similar to patients with osteoarthritis, but their total 
sleep time is similar to healthy controls. 
 Is the reduction in sleep quality in fibromyalgia, simply a function of their 
psychological phenotype? The results of this study, do suggest that there may be certain 
abnormalities of sleep that are different. Although, I have shown that alpha-wave 
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intrusion is not specific to fibromyalgia, the increase in sigma-2 which possibly relates to 
faster spindles (spindles of a higher frequency) may reflect some very subtle differences 
in sleep pathology that cannot be explained by sleep that is disturbed from pain. It is 
increasingly recognised that the pain in fibromyalgia, can be explained by abnormalities 
of neural connectivity, and it is interesting to hypothesise that an interaction between 
psychological phenotypes and sleep abnormality may lead to the development of neural 
networks to pain pathways. 
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